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Abstract 
 
MB49, an H2b+ murine bladder carcinoma cell line, naturally expresses the male-specific 
minor histocompatibility antigen, HY, which can be used as a proxy tumour associated 
antigen. The MB49 cell line, together with two HY-specific TCR-transgenic mouse strains 
(as sources of tumour-specific CD4 and CD8 T cells), form a unique system in which anti-
tumour T cell responses can be manipulated and analysed. I have studied some basic but 
critical immunological aspects of MB49 cells, adoptively transferred T cells and an 
immunotherapeutic antibody.    
I confirmed that MB49 cells express all three defined HY genes (Dby, Uty and 
Smcy), and demonstrated that cultured and freshly isolated tumour cells display a distinct 
phenotype. I found that MB49 tumours are very aggressive even though they are clearly 
immunogenic. Female B6 mice are more efficient than males at controlling MB49 tumours, 
especially when inoculated with a low tumour dose, suggesting that HY-specific T cell 
responses make a significant contribution to immune control of MB49 tumours.  
I evaluated three different immunotherapies for treating MB49 tumours: Whole 
body irradiation followed by the adoptive transfer of Tumour Associated Antigen specific 
CD4 T cells, or IL-15 expressing CD8 T cells, were found to inhibit the growth of MB49 
tumours. Administration of anti-GITR mAbs was found to be very effective at eliminating 
established MB49 tumours. 
I observed a novel role for IL-2 in immunoregulation; by the suppression of the 
differentiation of IL-17-producing Th17 cells.  
Finally, I demonstrated that Transforming Growth Factor β is essential for the 
tumour-induced expansion of natural regulatory T cells.    
This study not only extends the current knowledge of the immunobiology of MB49 
tumours but also lays a foundation for further investigation with respect to designing 
rational T cell cancer immunotherapy using genetically manipulated, tumour-specific T 
cells. 
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Chapter 1 : Introduction 
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1.1 : Immunotherapy for Cancer 
 
Aetiology of human cancers is very varied with tumours arising in numerous tissues. The 
approximate number of deaths from cancer, worldwide, in 2008 was 7.6 million (M), the 
most common forms being lung cancer (1.3M), stomach cancer (0.8M) and colorectal 
cancer (0.639M)1.  Cancer represents an enormous challenge to health care systems and 
scientists across the globe; being a major cost to health care systems and a complex disease 
that scientists strive to understand and be able to modulate.  
 Over the last 20 years, a number of Tumour Associated Antigens (TAA) have been 
identified in murine and human tumours. TAAs are antigens derived from; aberrantly 
expressed non-mutated proteins; aberrantly expressed intronic sequences; alternative 
reading frames of normal genes and; cancer-specific mutated proteins 2-4. Whilst not all 
TAA are tumour-specific antigens they do represent a valid target for immunotherapy as 
they are more limited in their distribution, thus making any targeting therapies more 
specific than the systemic chemotherapy treatments most widely used in clinics.  The 
identification of TAAs and TAA-specific T cells in a range of different tumours, especially 
from melanoma patients, has meant that augmentation of adaptive immune responses to 
overcome tumours has become a clinical reality.  
There are three general strategies for cancer immunotherapy. The first uses 
monoclonal antibodies (mAb) to directly target tumour cells or modulate the immune 
system. The second uses various cancer vaccines including tumour-specific peptides, 
peptide-loaded DCs and/or novel adjuvants designed to activate endogenous DCs and T 
cells. The third utilises adoptive transfer of TAA-specific lymphocytes .  This latter 
approach, here-in called adoptive immunotherapy, has yielded encouraging clinical 
responses in melanoma patients5.   
Adoptive immunotherapy for the treatment of cancer was first realised in mice in 
the 1950s and 60s when it was demonstrated that the transfer of leukocytes, before tumour 
inoculation, could lead to tumour rejection6, 7. As the area developed, it was found that 
leukocytes from immunised mice, adoptively transferred to mice with established tumours, 
could cause regression8.   
Soon after these fundamental observations were made, the discovery of Interleukin-
2, an important cytokine required for the growth and survival of T cells, led to the ability to 
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generate large numbers of leukocytes in vitro9, 10. This capability has allowed the field of 
cancer immunology to develop rapidly.  One of the most significant findings being that the 
adoptive transfer of tumour infiltrating lymphocytes, isolated from tumour biopsies and 
expanded in vitro with IL-2 is effective at reducing tumour burden in mice11, 12. 
Rosenberg et al. have been pioneers in applying adoptive cell transfer of ex vivo expanded 
melanoma specific T cells to melanoma patients. In original trials, lymphocytes were 
harvested from freshly resected melanomas, subsequently expanded in vitro then 
adoptively transferred back to patients combined with high doses of IL-2. Results were 
promising with many patients showing an objective response13, 14. More recently, Dudley 
et al. have demonstrated that lympho-depletion, with cyclophosphamide and fludarabine, 
before adoptive cell transfer greatly improves objective responses15. Originally, adoptive 
immunotherapy was solely used in the treatment of metastatic melanoma, where the 
Melan-A/Mart-1 tumour antigen is well defined. However, recent trials have been 
extended to other forms of cancer including B cell lymphomas. Table 1, lists some of the 
most recent adoptive immunotherapy clinical trials.    
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Table 1. Clinical trials using adoptive transfer of T cells. 
Date Cell Type Treatment regimen Tum
our 
Responses Reference 
1988 In vitro expanded TIL High IL-2 MM 11/15 OR 13 
1994 In vitro expanded TIL Cyclo. High IL-2 TIL and IL-2 in 
two week cycles 
MM 24/86 PR 
5/86 CR 
16 
1990 In vitro expanded TIL High IL-2. TIL and IL-2 in two week 
cycles 
MM  17 
2002 In vitro expanded Mart-
1 or gp-100 T cells 
from PBMC 
Increasing doses of IL-2 s.c. MM 5/10 SD 
1/10 MR 
2/10 MiR 
18 
2002 In vitro expanded TIL 
(7.8 x 1010 cells i.v.) 
Cyclo and Flur for 7 days, cell 
transfer.  High IL-2.  
MM 6/13 OR 
4/13 MR 
 19 
2005 In vitro expanded TIL Cyclo (2d) then Flur (5d) transfer 
then high IL-2 
MM 15/35 PR 
3/35 CR 
20 
2006 PBMC transduced with 
Mart-1 specific TCR.  
Cyclo (2d) then Flur (5d) transfer 
then high IL-2 and Mart-1 vaccine 
MM 2/17 PR 
1/17 MR 
21 
2008 In vitro expanded NY-
ESO-1 specific CD4 
from PBL 
N/A MM 1/1 CR 22 
2008 Genetically modified T 
cells expressing CD20 
specific chimeric 
receptor 
Varied cytoreductive therapy before 
cell transfer then 14 days low IL-2 
Non-
HL 
MCL 
2/7 CR 
4/7 SD 
1/7 PR 
23 
2010 PBMC transduced with 
CD19 chimeric antigen 
receptor, 66% CD8, 
34% CD4. 
Cyclo, 2 days and Flur for 5 days. 
Then cell transfer followed by high 
IL-2 i.v. every 8hrs 
FL 1/1 PR 24 
Abbreviations:  CR; Complete response, Cyclo; Clycophosphamide, FL;  Follicular Lymphoma, Flur; 
Fludarabine, hrs; hours, i.v.; intra venous, MCL; Mantel cell lymphoma, MiR; Minor response, MM; 
Metastatic Melanoma, MR; Mixed response, NHL; Non-Hodgkin Lymphoma, OR; Objective response, PR; 
Partial response, s.c.; sub cutaneous,  SD; TIL; Tumour Infiltrating Lymphocyte.  Definitions: gp-100 T cells;  
High IL-2; High dose IL-2 (720,000 IU/kg), Low IL-2; 500,000 IU/m2.  
 
 Despite numerous trials, new protocols and encouraging reports of donor T cell 
persistence17, 18, 24 and infiltration into the tumour mass18, the full potential of adoptive 
immunotherapy has yet to be realised.   However, since Rosenberg et al. started their 
adoptive immunotherapy trials, many studies of murine models of cancer have taken place 
and a pantheon of new knowledge has been discovered about the mammalian immune 
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system, how it interacts with tumours and how it can be manipulated to enhance adoptive 
immunotherapy.    
 
1.2 : The Adaptive immune system 
 
Mammals have developed a complex immune system because of evolutionary pressure to 
protect the body from foreign substances including toxins and pathogenic micro-organisms. 
Evolution has required the immune system to develop a huge diversity of responses; this 
reflects the vast number of harmful chemicals, viruses and bacteria that are encountered in 
the environment. 
The immune system can be divided into two branches; the innate immune system 
and the adaptive immune system.  
  The innate immune system utilises the following four mechanisms to prevent toxins 
and pathogenic microbes from entering the body:  
1. Anatomical. Including the skin (epidermis and dermis) and mucous membranes 
2. Physiologic. Includes thermoregulation, PH (i.e. acidity in the stomach) and chemical 
mediators (i.e. lysozymes, interferons) 
3. Phagocytic/Endocytic. Neutrophils and macrophages can phagocytose micro-organisms 
4. Inflammatory.  Damage and infection cause leakage of vascular fluid into tissues which 
contains serum proteins, antibodies and phagocytic cells.  
 
The innate immune system exhibits limited specificity to toxins and pathogens whereas the 
adaptive immune system is characterised by its ability to discriminate between a huge 
variety of foreign and self-antigens. In addition, activation of the innate immune system 
does not lead to the development of memory responses whereas activation of the adaptive 
immune system does. 
The adaptive immune system comprises B cells that express B cell receptors (BCR) 
and generate antibodies and T cells that express T cell receptors (TCR) and produce 
cytokines and can in some cases, directly kill specific cells. Each B cell or T cell clone has 
a unique specificity for antigen; this specificity is generated by the rearrangement of a set 
of gene segments to generate antibodies (BCR shed from the surface of B cells), and TCR. 
T cells are only able to recognise specific peptide epitopes, derived from self or 
foreign proteins, when they are presented on the surface of a cell in association with a 
major histocompatibility complex (MHC) molecule. T cells only generate an effective 
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response when their TCR is engaged by MHC-peptide at the same time as they are co-
stimulated by ligands on an antigen presenting cell (APC) (Described in more detail in 
Section 1.2.13 :).  Engagement of the TCR alone leads to anergy, deletion or tolerance. Co-
stimulatory molecules can have positive or negative effect on the activation of T cells25.   
 
1.2.1 : The Major Histocompatibility Complex 
  
The major histocompatibility complex (MHC) was discovered in the 50s and 60s by Peter 
Gorer and George Snell when they identified a group of genes that were responsible for the 
rejection of transplantable tumours and other tissues in mice26. It was subsequently 
established, in both mice and humans, that MHC Class I genes encode glycoproteins that 
are expressed on all nucleated cells and present antigen to CD8 T cells and that the MHC 
class II genes encode glycoproteins that are expressed on APCs and present antigen to CD4 
T cells. 
 The MHC Class I and Class II genes are highly polymorphic with a huge number of 
different alleles at each locus which can differ in their DNA sequence from one human to 
another by 5 – 10%.  
MHC Class I proteins (MHC-I here-in) present peptides produced in the “MHC-I 
pathway”.  The MHC-I pathway processes intracellular proteins for presentation on the 
surface of most cells:  The assembly of MHC-I molecules occurs in the endoplasmic 
reticulum (ER) where the MHC-I heavy chain and β2- microglobulin (β2m; a non-
polymorphic, non-MHC encoded protein) proteins form dimers. Peptides generated, by 
proteosomes, from proteins in the cytosol are translocated into the ER by transporting 
proteins (TAP1 and TAP2). TAP proteins form a complex with MHC-I molecules and are 
essential for the loading of peptide and assembly of the MHC-I-peptide complex before it 
is released into the secretory pathway in the ER and subsequently transported to the cell 
surface for presentation of the loaded peptide27. 
MHC Class II proteins (MHC-II here-in) present peptides produced in the “MHC-II 
pathway”.  The MHC-II pathway primarily processes proteins, derived from extracellular 
sources, via the endosome/lysosome/phagosome compartments for presentation on the 
surface of professional APC. MHC-II molecules are heterodimers that assemble in the ER 
before being transported to the endocytic compartments. In these compartments, self and 
non-self peptides, that are derived from degraded larger proteins, are loaded onto the 
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MHC-II molecule before it is transported to the cell surface28 for presentation of the loaded 
peptide.   
 
1.2.2 : Antigen presenting cells 
 
All normal nucleated cells express MHC-I molecules. Once loaded with peptide, these 
complexes (pMHC-I) can potentially be recognised by CD8 T cells with the relevant TCR. 
MHC-II molecules loaded with peptide (pMHC-II) are only normally expressed by 
professional antigen presenting cells (pAPC), a group of cells which includes dendritic 
cells (DC), B cells and macrophages. pAPC can internalise antigen from their 
microenvironment by endocytosis or phagocytosis and process it, as described above, to be 
presented at the cell surface in combination with MHC-II.  
 
1.2.3 : B cells 
 
B cells are generated from lymphoid stem cells within the bone marrow. Progenitor B cells 
proliferate within the bone marrow and differentiate into precursor B cells. Development 
of immature B cells from precursor B cells, is dependent on the rearrangement of 
immunoglobulin DNA and is driven by IL-7. After a productive rearrangement and 
expression of a non-self reactive BCR with a particular antigen specificity, immature B 
cells are released into the blood stream and migrate thence to the periphery. An immature 
B cells is activated when the BCR recognises its cognate antigen, resulting in up-regulation 
of pMHCII which allows interaction with CD4 T cells. The B cell receives a co-
stimulatory signal from CD4 T cells through CD40-CD40L ligation (CD40 expressed on 
the CD4 cell and CD40L on the B cell) which leads to proliferation and generation of 
plasma cells and memory B cells29. Plasma cells secrete high levels of monoclonal 
antibody, the isotypes of which are dependent on the cytokine milieu.      
 
1.2.4 : Dendritic cells 
 
Dendritic cells (DC) are derived from bone marrow progenitor cells, found in different 
areas throughout the body and are classified according to their location. Langherhans cells 
are found in the epidermis and mucous membranes. Interstitial DC are found in most 
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organs. Interdigitating DC populate the secondary lymphoid organs and thymus. 
Circulating DC are found in the blood, lymph node and spleen. DC can be divided into two 
subsets, lymphoid DC are characterised by CD11c+CD8α+DEC205+CD11b- and myeloid 
DC by CD11c+CD8α-DEC205+CD11b+ 30, 31. Immature DC efficiently endocytose and 
phagocytose antigens in peripheral tissues, they subsequently degrade antigens and present 
the resultant peptides on their surface in combination with MHC-I and MHC-II.  
Inflammatory signals such as bacterial products (e.g. LPS and CpG etc), cytokines and 
chemokines (e.g. GMCSF and IL-4) cause the activation and maturation of DCs. Upon 
activation, DCs migrate to the lymphoid organs, up-regulate co-stimulatory molecules and 
MHC-I and MHC-II, secrete stimulatory cytokines (e.g. IL-12 and IL-6 etc) and present 
antigen to CD4 and CD8 T cells32, 33.     
      
1.2.5 : Monocytes/Macrophages 
 
Mononuclear cells which comprise monocytes circulating in the blood and macrophages in 
the periphery, are derived from granulocyte-monocyte progenitor cells in the bone marrow. 
Progenitor cells develop into pro-monocytes and enter the blood stream. Pro-monocytes 
migrate into peripheral tissues and mature into tissue specific macrophages. Macrophages 
express a restricted repertoire of phagocytic receptors that allows them to phagocytose 
dying cells, whole micro-organisms, activated clotting factors and cellular debris34. 
Macrophages can process antigen and present pMHC-I, pMHC-II and co-stimulatory 
molecules for T cell activation.         
  
1.2.6 : T cell development 
 
Negative and positive selection of the T cell repertoire during T cell development in the 
thymus determines the ability of the immune system to distinguish self from non-self.   
T cells originate in the bone marrow (BM) as haematopoietic stem cells (HSCs). 
HSC‟s differentiate into T lineage progenitors (TLP) which migrate into the blood stream 
and then into the thymus35. In the thymus T cell progenitors expand and differentiate 
through several distinct phases in the cortex and medulla of the thymus36. 
 TLP enter the thymus and progress into the inner cortex where they interact 
with cortical epithelial cells that are resident in the thymus. Early thymocytes are negative 
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for CD4 and CD8 and described as double negative (DN) thymocytes. Signalling through 
the Notch pathway commits TLP to the T cell lineage and they become DN cells37 
expressing the pre-TCR38. A positive signal through the pre-TCR ensures the thymocytes 
survival and they become CD4+CD8+ double positive (DP) thymocytes which express a 
mature TCR39.  Mature TCR molecules are dimers formed by the varying combination and 
interaction of the TCR proteins; TCR, , and .  The huge diversity of the TCR 
repertoire is generated by the rearrangement of the four genes (Tcra, Tcrb, Tcrd and Tcrg), 
that encode these proteins, during T cell development in the thymus40.  Rearrangement is 
driven by the Recombinase Activating Gene 1 and 2 (RAG1/2) proteins that create double 
stranded breaks at specific Recombination Signal Sequences (RSSs) that flank the TCR 
variable (V), diversity (D) and joining (J) gene segments. When the segments are rejoined 
they generate a TCR sequence41 that is translated into the TCR. Each T cell clone 
expresses a unique TCR on its cell surface.  
 DP thymocytes with a mature TCR interact with APCs, including thymic B cells, 
DCs, cortical thymic epithelial cells (cTECs) and medullary thymic epithelial cells 
(mTECs).  DP thymocytes are positively selected if they interact, with sufficient affinity, 
with self-peptide-MHC complexes on cTECs. At this point, DP thymocytes that interact 
with MHC-I restricted peptides are destined to become CD8 T cells and those that interact 
with MHC-II are destined to become CD4 T cells. Positively selected thymocytes migrate 
to the medulla and interact with mTECs. mTECs express MHC-I and -II and because of  
their promiscuous gene expression, under the influence of the autoimmune regulator 
(AIRE), can present virtually every possible self epitope to the TCR of DP thymocytes42. 
In the medulla, DP thymocytes that interact with self-peptide-MHC with very high affinity 
are negatively selected43.  
 The results of the thymic process of positive and negative selection is a repertoire 
of naïve CD4 and CD8 T cells that have a controlled affinity for self-peptide-MHC 
complexes. Crucially thymocytes that have a strong affinity for self-peptide MHC 
complexes are deleted and this prevents auto-immunity44.   It is this tolerance to self 
peptides that contributes to the persistence of tumours; most TAAs, which are derived from 
self proteins, are expressed by mTECs in the thymus during T cell selection and as a 
consequence, high avidity auto-reactive T cells, that could later recognise tumours 
expressing these TAAs, are deleted and a repertoire is created in which the remaining T 
cells have only a low to intermediate avidity for TAA, and thus minimal effector function 
upon TAA recognition45.   This is discussed in more detail in Section 1.4 : on page 31.  
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After release from the thymus, mature, naïve CD4 and CD8 T cells are found 
continually circling through the blood, peripheral tissues and lymph nodes. The effectors of 
the adaptive immune system are largely comprised of T cells that express TCRα and TCRβ, 
transcribed from the Tcra and Tcrb genes, and it is these αβ-T cells that will be discussed.     
Naïve CD4 and CD8 T cells are characterised by the low expression of CD44 and 
high expression of CD62L. CD62L (L-selectin) is a cell adhesion molecule that facilitates 
the entry of T cells into the secondary lymphoid organs.  
To become activated, T cells require at least two signals, one through the TCR and 
one through a co-stimulatory molecule, most commonly CD2846, to become activated (A 
more detailed description is given in Section 1.2.13 : T cell co-stimulation, below). 
Stimulation through the TCR alone, as happens in a tolerant situation when there are no 
additional signals from invading pathogens or damaged cells, leads to T cell anergy47 and 
tolerance48.  
Activated T cells have increased expression of CD44 and chemokine and homing 
receptors (e.g. CCR5/7) and reduced expression of CD62L; this expression profile 
facilitates their migration to the periphery and sites of inflammation and infection. The 
type of cytokines and cell surface markers that are expressed, by the T cells, after 
activation are influenced by the microenvironment,  the cytokines secreted by the APC and 
other cells in close proximity and the co-stimulatory signals received by the T cell from the 
APC.  
In addition to the expression of molecules that contribute to activation, activated T 
cells also begin to express inhibitory molecules such as Programmed Death-1 (PD-1) and 
Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) which, when bound to their cognate antigen 
on APC, causes the death and inactivation of activated T cells.  This feedback system 
regulates the strength and extent of the immune response ensuring that cytotoxic effects are 
limited to a small area and short time frame to minimise damage to healthy tissue.          
 
1.2.7 : CD4 T cells 
 
As mentioned above, DP thymocytes that recognise MHC-II restricted peptides, presented 
by cTECs during thymocyte development, are destined to become CD4 T cells; upon 
interaction with MHC-II in the thymus, they gradually down regulate CD8 and up regulate 
CD4 and migrate out of the thymus as mature naïve CD4 T cells. 
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 Activated CD4 T cells can develop cytotoxic functions49 but their primary 
function is to maintain and regulate B cell and CD8 T cell responses50.  Following antigen 
clearance,  a small proportion of activated CD4 T cells survive and persist in the blood 
stream and lymph nodes as memory CD4 T cells which are rapidly reactivated if the same 
antigen is presented again.     
CD4 T cells can be separated into four distinct subsets, Th1, Th2, Th17 and 
regulatory T cells (Treg) based on their function and cytokine profiles.    
 
1.2.8 : Th1 
 
A type 1 T helper response (Th1) is generated in response to intracellular pathogens such 
as bacteria and viruses. It is characterised by CD4 T cell secretion of Interferon gamma 
(IFNγ), IL-2 and Tumour Necrosis Factor alpha (TNF, activation of CD8 T cells and 
macrophages and the production of opsonising antibodies from B cells. IFNγ increases the 
production of IL-12 by DC and macrophages which in turn stimulates the secretion of 
IFNγ by Th1 cells thus providing a feedback loop that drives the Th1 response51.   
 
1.2.9 : Th2 
 
A type 2 T helper (Th2) response is generated against multi-cellular organisms and is 
typified by the activation of B cells and secretion of IL-4, 5, 6, 9 10 and 13 by CD4 T 
cells51. 
  
1.2.10 : Th17 
 
A distinct subset of CD4 T cells was recently identified as secreting IL-1752.  These cells 
have been termed Th17 cells. Th17 cells are found in inflammatory environments and are 
induced by TCR stimulation in the presence of Transforming Growth Factor- (TGFβ) and 
IL-653, 54. Th17 cells secrete IL-17A, IL-17F and IL-22 which induce a wide range of 
responses from surrounding tissue because of the ubiquitous expression of the IL-17 and 
IL-22 receptors55.    
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1.2.11 : Regulatory T cells 
 
CD4 regulatory T cells (Tregs) are characterised by the expression of the forkhead/winged 
helix transcription factor (FoxP3)56 and the α chain of IL-2 receptor (CD25)57. They 
suppress T cell responses by the secretion of suppressive cytokines IL-10 and TGFβ58 and 
by cell contact dependent mechanisms including perforin mediated cytotoxicity and 
membrane bound TGFβ and CTLA-4. Foxp3+ Tregs can be grouped into natural (nTregs) 
and induced Tregs (iTregs)59.  
nTreg differentiate and mature in the thymus; cells are committed to the Treg 
lineage when they recognise self-peptide-MHC with an avidity ranging between that 
required for positive and negative selection. Development in the thymus may not be 
consistent for all thymocytes and therefore it is possible that both conventional and 
regulatory T cells with the same or similar specificities can develop56.   
The primary function of nTregs is to control self-reactive peripheral T cells that 
escape thymic deletion, as suggested by early studies using neonatal thymectomy or 
depleting anti-CD25 antibodies57, 60, and verified by recent investigations using Foxp3DTR 
mice61.  
 iTregs are induced in the periphery and their primary function is similar to that of 
nTreg. However, iTreg differ from nTreg in that they can be induced in response to foreign 
antigen and can block other cells from producing IL-1762, suggesting that they have a 
distinct function from nTreg, possibly in mediating non-responsiveness to environmental 
antigens.  The development of iTregs needs a low dose of antigen presented by resting 
APC and engagement of CTLA-462-64. 
 
1.2.12 : CD8 T cells  
 
DP thymocytes that recognise MHC-I restricted peptides, presented by cTECs during 
thymocyte development, gradually down regulate CD4 and up regulate CD8 and migrate 
out of the thymus as mature CD8 T cells. CD8 T cells are then found in the blood, 
periphery and lymph nodes. Upon ligation of TCR with pMHC-I on APC and sufficient 
co-stimulation, CD8 T cells become activated and begin to proliferate. Upon activation 
CD8 T cells, also known as cytotoxic or killer T cells, secrete perforins, granzymes and up-
regulate Fas-Ligand (Fas-L) effecting the death of the target cell. CD8 T cell proliferation 
and activation is enhanced by IL-29, IL-765 and IL-1566. CD8 T cells spontaneously secrete 
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Th1 cytokines IFNγ and IL-2 but can be induced to secrete Th2 cytokines in the presence 
of IL-467.       
 Whether or not the source of antigen is cleared, CD8 T cells numbers fall 
dramatically during a phase of contraction. However, not all antigen specific CD8 T cells 
are lost and a small proportion survive and persist in the blood stream and lymph nodes as 
memory CD8 T cells which are rapidly reactivated if the same antigen is presented again68.   
 
1.2.13 : T cell co-stimulation 
 
Co-stimulation is required for optimal T cell activation, differentiation and survival. Co-
stimulatory molecules fall into two families, the immunoglobulin family, including CD28-
CD80/86 and the tumour necrosis factor receptor super-family, including OX40, GITR and 
4-1BB. A brief description of T cell costimulatory receptors is laid out in Table 2. 
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Table 2. Co-stimulatory molecules, the cells that express them, their ligands 
and the T cell response following ligation of the molecule. 
Receptor/Ligand  (T 
cell) 
Cognate 
Receptor/Ligand  
(Expressed by) 
Effect on T cell Ref. 
CD28  (CD4; CD8) CD80/86 (Bc;DC;Tc) Activation; Proliferation; 
Cytokine secretion 
69 
CTLA-4 (CD4; CD8; 
Treg) 
CD80/86  
(Bc;DC;Tc) 
Inhibition;  Tolerance 
Th1  
70 
ICOS (act CD4; act 
CD8; Treg) 
ICOS-L 
(Bc;DC) 
Increased IL-10.  Th2  71 
GITR (Treg; act CD4; 
act CD8) 
GITR-L (Bc; DC; Mθ)  Th1 or Th2 72 
CD40L (CD4) CD40 (Bc; Mθ)  Th2 73 
4-1-BB (CD8 more than 
CD4) 
4-1-BBL (Bc; DC; 
Mθ) 
Increased CD4/8 proliferation. 
Th1 or Th2. 
74 
OX-40 (mainly CD4; 
some CD8) 
OX-40L (Bc; DC; act 
Tc) 
Th2, but sustains Th1 
proliferation and survival 
74, 75 
PD-1 (act CD4; act 
CD8) 
PD-L1/PD-L2 (Bc; 
DC; Mθ; Tc) 
Negative regulation of PD-1 
expressing cell 
76, 77 
Abbreviations: 4-1-1BBL; 4-1-BB Ligand, act; activated, Bc; B cell, DC; Dendritic cell, 
GITR; Glucocorticoid Induced Tumor necrosis factor Receptor family related gene, ICOS; 
Inducible Costimulator,  GITR-L; GITR-Ligand, ICOS-L; ICOS-Ligand, Mθ; Macrophage, 
Tc; T cell.  Definitions:  Th1; induction of Th1 cytokines, Th2; induction of Th2 cytokines.  
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1.3 : Cytokines 
 
Cytokines are pluripotent mediators of the immune system, they are produced from many 
sources, including non-hematopoietic cells, under differential conditions. Cytokines are 
usually soluble although there are some that are membrane bound. They bind receptors on 
their target cell and induce various responses including migration, activation, proliferation, 
differentiation and inhibition. 
 Here follows a brief description of the cytokines that are important to this study.  
 
1.3.1 : IL-2 
 
IL-2 is secreted by CD4 and CD8 T cells after TCR stimulation and acts in an autocrine 
manner to enhance expansion, differentiation and cytolytic effector functions78. IL-2 is also 
required for the maintenance of Treg79. Indeed, CD25, the alpha chain of IL-2 receptor is 
expressed transiently on CD4 and CD8 T cells after activation but ubiquitously on nTreg 
cells. The ubiquitous expression of CD25 on nTreg may prevent autoimmunity by 
sequestering excess IL-2 in the local micronvironment80.   
    
1.3.2 : IL-10 
 
IL-10 is an anti-inflammatory cytokine that is secreted by monocytes and lymphocytes. IL-
10 can modulate T cell responses directly or indirectly via APC81. Importantly, IL-10 is a 
key cytokine controlling and driving the development and function of T regulatory type 1 
(Tr1) cells which are an independent regulatory T cell population (unlike Treg, Tr1 cells 
do not express Foxp382) that can inhibit CD4 responses83. 
    IL-10 inhibits cellular immune responses and antigen induced proliferation by 
down regulating MHC-II84 and co-stimulatory  CD80/86 molecules on DCs, monocytes 
and macrophages84-87 thus inhibiting the ability of APC to prime T cells88.  Furthermore, 
IL-10 inhibits cytokine production by macrophages89 and can directly inhibit IL-2 
production by CD4 T cells90.  
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1.3.3 : IL-15 
 
The role of IL-15 in the differentiation and survival of CD8 T cells is well established91, 92. 
The IL-15 receptor is one of the common γ chain cytokine receptors which includes IL-2R 
and IL-7R which are critical regulators of activated T cell proliferation, survival and 
memory generation. IL-15 is a pleiotropic cytokine that influences both the innate and 
adaptive immune responses; it promotes the survival and expansion of CD8 T cells66, 93 and 
stimulates CD8 T cell cytotoxity as well as playing an important role in the differentiation 
and survival of memory CD8 T cells and stimulating DC maturation94, 95.  
IL-15 has also been implicated in the de novo generation of iTreg whilst 
simultaneously abrogating the effect of Tregs on CD4 and CD8 T cell effector function. 
Together, these effects of IL-15 may allow rapid but transient responses against 
pathogens96. 
   
1.3.4 : IL-17A 
 
IL-17A is a pro-inflammatory cytokine that promotes cytotoxic T cells and angiogenesis 
and has been implicated in autoimmune diseases such as rheumatoid athritis55. The 
majority of IL-17A is produced by CD4 T cells but CD8 T cells can also produce some IL-
1797. The IL-17 receptor (IL-17R) is expressed ubiquitously52. Signalling through the IL-
17R causes the secretion of IL-6 and IL-8 from fibroblasts, keratinocytes and epithelial 
cells97.    
 
1.3.5 : IFNγ 
 
IFNγ, a signature cytokine released by CD4 and CD8 T cells after activation, causes the up 
regulation of MHC-I and -II molecules in numerous cell types98, 99. IFNγ promotes anti-
microbial and anti-tumour responses from macrophages; consistent with this, the 
neutralisation of IFNγ with the monoclonal antibody R46/A2 inhibits anti-viral and anti-
tumour responses100. IFNγ also regulates B cell functions including immunoglobulin 
production and class switching101.  
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1.3.6 : TGFβ 
 
TGFβ is an important mediator of suppression; it can cause apoptosis, inhibit proliferation, 
control inflammatory responses102 and can prevent the induction of CD8 mediated 
responses103. There are three TGF isotypes, TGFβ-1, TGFβ-2 and TGFβ-3.  TGFβ 
binds to TGFβ receptor II (TGFβRII) and the signal is propagated through the Smad 
pathway104. 
In addition, TGFβ can convert naïve CD4 T cells to Foxp3-expressing Treg cells105. 
TGF-β is secreted by numerous lung cancer cell lines in vitro and is produced by tumour 
cells and natural or induced Treg cells58. 
  
1.4 : Tumour immunology 
 
It is unclear what pushes a healthy cell towards becoming cancerous but it is known that 
genetic instability in cancer cells results in the rapid acquisition of mutations that enhance 
their survival and the development of tumours. Cancer cells provide their own growth 
signals, ignore inhibitory signals, avoid cell death, replicate uncontrollably, activate 
angiogenesis and in some cases, metastasise106. Cancer cells may also evade the immune 
system in a process termed immunoevasion.  Those that do evade the immune system, 
thrive and eventually represent the majority of cells within a tumour in a process termed 
immunoselection107,108. It is not clear whether immunoevasion is necessary for tumour 
development but it definitely enhances the process of tumour development.  
 There are several mechanisms associated with a tumours ability to evade immune 
responses. In brief, tumour cells can reduce the expression of MHC class I and co-
stimulatory molecules, thereby protecting them from immune recognition. Furthermore, 
tumour cells can actively suppress APC function by reducing expression of co-stimulatory 
molecules but increasing expression of inhibitory molecules. Tumour cells not only make 
suppressive factors themselves but also induce host immune cells to produce inhibitory 
factors. In addition, tumour cells express Fas-L which can induce apoptosis in Fas-
expressing T cells. Finally, tumour cells and/or tumour-derived factors can directly or 
indirectly down-regulate TCR expression, thus avoiding immune recognition by T cells. 
 Tumour growth and progression is also influenced by the normal function of the 
immune system; Tregs, whose function it is to prevent autoimmunity by suppressing self-
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specific immune responses, suppress immune responses to tumours whose TAAs are, for 
example, over-expressed or aberrantly expressed self antigens.  
I shall now describe the above factors, in more detail. 
   
1.4.1 : Tumour immune evasion 
 
Defects in antigen processing and presentation in tumour cells confers an advantage for 
tumour growth due to reduced recognition by T cells. The classical MHC-I pathway 
processes intracellular proteins for presentation on the cell surface. Deletion of MHC-I 
and/or accessory proteins required for antigen loading is common in tumours. For example, 
human ovarian carcinoma and colorectal carcinoma can down-regulate TAP1, TAP2  and 
β2m109, 110 which in turn reduces the cell surface expression of MHC-I molecules.  
As well as possibly having defects in antigen presentation, tumour cells are 
generally also poor stimulators of T cells, as they express limited T cell co-stimulatory 
molecules.  Evidence suggests that this is an important factor in immune evasion:  
Melanoma transfected with CD80 causes tumour rejection and concomitant immunity to 
challenge by the untransfected tumour111, suggesting that non-immunogenic tumours do 
not express CD80 and that enhancing T cell co-stimulation causes tumour rejection.  
Compounding the limited expression of positive costimulatory molecules, tumour 
cells can express abundant T cell inhibitory molecules, some of which are detailed below. 
PD-L1 expressed on DC and macrophages is able to bind PD-1 on T cells112-114. 
Ligation of PD-L1 by PD-1 on activated T cells inhibits T cell proliferation and cytokine 
production. Moreover, interaction of PD-L1 and PD-1 is essential for the induction of 
peripheral CD8 T cell tolerance76. Interestingly, tumour cells also express PD-L1 which 
can induce apoptosis in activated T cells expressing PD-1115. PD-L1 has been found to be 
expressed on human lung, ovarian and colon carcinomas and melanoma115.  
B7-H4 can be induced on human T cells, B cells, macrophages and DC. B7-H4 is 
also expressed on tumour cells, tumour infiltrating macrophages and tumour associated 
endothelial cells. IL6 and IL-10 increase B7-H4 expression whereas GMCSF and IL-4 
reduce B7-H4 expression. B7-H4 inhibits T cell responses116. B7-H4 was found to be 
expressed in ovarian carcinoma: in a study by Kryczek et al. ovarian carcinomas from 103 
patients were studied: B7-H4 expression on tumour-associated macrophages was found to 
be associated with increased numbers of Treg and a poorer prognosis when compared to 
expression of B7-H4 on tumour cells themselves117. 
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  The tumour microenvironment contains immunosuppressive factors that can be 
secreted directly from the tumour or from APC and T cells.  Indoleamine-2,3-dioxygenase 
(IDO) is an enzyme expressed by a subset of APC and some tumour cells. IDO catabolises 
tryptophan, decreased tryptophan and the presence of tryptophan metabolites inhibits T 
cells proliferation and induces apoptosis118, 119.  Tumour cells can induce IDO expression 
in DC in tumour draining LN, thus rendering them tolerogenic120. 
Immunosuppressive factors directly secreted from tumours include gangliosides, IL-10, 
prostaglandins, TGFβ and VEGF. IL-10 and TGFβ are the two best characterised 
suppressive cytokines in the tumour microenvironment (See also Sections 1.3.3 :, page 29 
and 1.3.6 :, page 31).  
IL-10 can modulate T cell responses directly or indirectly via APCs81. Importantly, 
IL-10 is a key cytokine controlling the development and function of Tr1 cells which is an 
independent regulatory T cell population, as Tr1 cells do not express Foxp382.  
 TGFβ can convert naïve CD4 T cells to Foxp3-expressing Treg cells105, it is 
secreted by numerous lung cancer cell lines in vitro and when secreted in high quantities 
(>109pg/ml), by tumours, it prevents the induction of CD8 mediated responses103.  
In summary, tumours can hi-jack many naturally occurring immuno-suppressive 
mechanisms to enhance their survival. Understanding these mechanisms at the cellular and 
molecular level is essential for us to rationally design new cancer immunotherapies. 
 
1.4.2 : Regulatory T cells and cancer 
 
CD4 and CD8 T cells, expressing TCR specific for TAA, are found in human melanoma121, 
ovarian carcinomas122, and colorectal cancer123 as well as in numerous murine tumours. 
However, tumours are rarely rejected by their hosts. One reason for the failure of anti-
tumour immunity is the presence of tumour-specific regulatory T cells which play a key 
role in suppressing anti-tumour responses:  As many TAAs are aberrantly expressed 
normal self-proteins124, the activity of self-reactive nTregs is proposed to mediate an 
inhibitory influence over the development of effective tumour specific T cell responses. 
Indeed, in vivo depletion of nTregs by anti-CD25 treatment leads to improved tumour 
immunosurveillance and inhibition of tumour growth125, 126.  Moreover, Treg cells, specific 
for TAA, can suppress anti-tumour immune responses127. Treg cells are found at elevated 
numbers in the PBL and tumours of patients with invasive breast or pancreatic cancer128. It 
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has been shown that tumour infiltrating Treg cells inhibit the effector functions of Th 
cells129 and CD8 CTL130.  
  
1.5 : Immunotherapy for tumour mediated immune suppression  
 
As has been described above, tumours have many and varied ways of suppressing active 
immune responses that inhibit early tumour development108.  However, the presence of T 
cell responses to TAA is heartening because it means that the immune system is trying to, 
and with a little help might eventually be able to, destroy tumours. 
 There are two key methods of targeting the pathways that tumours hijack to evade 
the immune system; antibody immunotherapy and adoptive immunotherapy.  
 
1.5.1 : Antibody immunotherapy 
 
Antibody immunotherapy can be broken down into two categories, immuno-targeting 
therapy and immuno-modulation therapy. Both therapies make use of monoclonal 
antibodies (mAb) specific for unique markers on the cell surface. 
 Immuno-targeting therapy uses mAb directed at TAAs on the surface of cancerous 
cells or, factors associated with the tumours growth. The binding of a mAb to tumour or 
tumour associated cells, leads to their death by antibody mediated immunity (AMI). An 
example of this group of antibodies is Alemtuzumab (aka, Campeth) which is a humanised 
rat anti-human CD52 mAb which destroys cells of chronic lymphocytic leukaemia by 
AMI131, 132.  Monoclonal antibodies can also be engineered to carry a toxin which kills the 
cell that the mAb binds for example MylotargTM which is an anti-CD33 mAb conjugated to 
an immunotoxin133.  
Immuno-modulation therapy uses mAbs that bind receptors and chemokines and 
influence the natural immune response to the tumour. For example, immuno-modulating 
mAbs can be used to block inhibitory pathways such as the PD-1/PDL-1/2 or activate 
stimulatory pathways for APC and/or T cells.  
 There are several promising immuno-modulating mAb in early clinical trials or 
murine trials that are of note.  These are described below.  
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1.5.2 : Anti-CTLA-4 (4F10) 
 
CTLA-4 is a potent immuno-modulatory receptor that is constitutively expressed on the 
surface of Treg134 and up-regulated after activation on conventional CD4 and CD8 T 
cells135. It competes with CD28 for binding to the co-stimulatory molecules CD80 and 
CD86. CD80/86-CTLA-4 signalling inhibits T cell proliferation and increases the 
activation threshold of the TCR70. 
 Blocking CTLA-4136 with the anti-CTLA4 mAb, 4F10, increases production of IL-
2 and IFNγ and enhances tumour rejection137, 138. Therapy with anti-CTLA4 has shown 
promising results in a Phase I trial for the treatment of prostate cancer139. 
   
1.5.3 : Anti-PD-L1  
 
As described earlier (Section 1.4.1 :, page 32), the PD-1/PD-L1 pathway is inhibitory, with 
ligation of PD-1 on T cells, by PD-L1 on APCs and tumour cells, resulting in down 
regulation of T cell responses.  Furthermore, it was noted that PD-L1 has been found to be 
expressed by various cancers 115. Therefore, blocking PD-1/PDL1 interactions has the 
potential to abrogate tumour mediated T cell tolerance and anergy. 
The anti-PD-L1 mAb140, increases CD8 T cell cytotoxicity and IFNγ secretion in 
vitro and inhibits the growth of the murine P815 tumour in vivo..  This response is specific 
as the anti-PD-L1 mAb did not have any significant effect on the growth of B16 
melanomas which do not express PD-L1141.  A separate study demonstrated that PD-1-/- T 
cells increased cytokine production, proliferation and cytolytic activity in response to PD-
L1 expressing tumour cell lines142.    
 A recent phase I clinical trial of a humanised anti-PD-L1 mAb in patients with 
mixed advanced metastatic cancers produced a durable complete response in1/39 patients 
and partial responses in 2/39 patients143.  
Together these reports suggest that blockade of PD-L1 is therapeutically 
advantageous.           
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1.5.4 : Anti-GITR (DTA-1)  
 
GITR is expressed at high levels on activated CD4 and CD8 T cells and Treg cells as well 
as at low levels on resting CD4 and CD8 T cells144, 145.  GITR-L is expressed on murine B 
cells, DC and macrophages146.   Ligation of GITR on Treg cells with DTA-1, an agonistic 
anti-GITR mAb, abrogates suppressive function of Treg cells147. Whereas, interestingly, 
engagement of GITR with DTA-1 mAbs or its natural ligand (GITR-L) activates resting T 
cells and causes up-regulation of CD25, CD69 and expression of IFNγ, IL-2, IL-4 and high 
amounts of IL-10148.  
 Administration of DTA-1 mAbs to mice eliminates established tumours, although it 
is unclear if DTA-1 abrogates Treg suppression or activates CD4 and CD8 effector cells126. 
Further experiments with the B16 model showed that DTA-1 enhances vaccine-induced 
CD8 T cell responses149. 
The suppressive effects of Treg cells are contact-dependent and activated at the site 
of antigen presentation, which in cancer patients is predominantly the tumour site. The 
local reversal of suppression, therefore, is a promising target for the treatment of 
established tumours. The potential ability of DTA-1 to reverse suppression and 
concomitantly activate CD4 and CD8 T cells147 make DTA-1 a promising mAb to develop 
for the treatment of cancer126, 147, 149, 150.  
 
1.5.5 : Adoptive Immunotherapy 
 
As described at the beginning of this Introduction, the clinical application of adoptive 
immunotherapy has met with limited success, probably because of immuno-suppressive 
mechanisms in the tumour microenvironment. To try and improve the clinical application 
of adoptive immunotherapy, numerous murine models have been developed that have 
offered some useful insights. 
 
1.5.6 : T cells engineered to express an antigen specific TCR 
 
In tumour-bearing hosts, the induction of CD8 T cell tolerance and anergy is very common, 
representing one of the major challenges to successful adoptive immunotherapy151. A 
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promising strategy to optimise adoptive immunotherapy is to use antigen-specific CD8 T 
cells genetically modified to counteract tumour mediated suppresion152. 
 Three independent pre-clinical animal studies using T cells with genetically 
modified TCRs have demonstrated that this methodology can cause tumour rejection. 
Abad et al. used T cells expressing a genetically engineered TCR, designated 
pmel1, that recognises the gp10025-33 peptide (expressed by the B16 melanoma) presented 
in the context of  H2Db153. The adoptive transfer of these modified T cells, into mice with 
B16 melanomas, successfully reduced the growth of tumours in a dose dependent manner. 
When unmodified lymphocytes were added concurrently with the pmel1 cells they 
abrogated tumour inhibition154.  
These results were repeated and confirmed by DeWitte et al., who demonstrated 
that an increasing number of unmodified lymphocytes inhibits the anti-tumour function of 
co-transferred genetically engineered OT-1 T cells that recognise the RIP-OVA antigen 
expressed on B16-OVA cell line155. In the same set of experiments, irradiation was found 
to boost the anti-tumour response more efficiently than vaccination. DeWitte et al. also 
demonstrated that a small increase in the efficiency of transduction, leading to better 
expression of the TCR, resulted in a significantly better anti-tumour response156. A 
complementary study by Wrzesinki et al. confirmed the importance of myeloablation by 
irradiation before adoptive T cells transfer157.  
 Both of these experiments used immunogenic transplantable tumours which may 
not correlate with the clinical situation where tumours are naturally arising and express 
normal self antigens. However similar results have been obtained in a system with a 
„spontaneously‟ arising tumour:  De Witte et al. generated Transgenic Adenocarcinoma of 
Mouse Prostate (TRAMP) mice which express the transforming SV40 large T antigen 
under the control of the prostate specific probasin promoter. In these mice the SV40 
antigen is expressed as self so the TRAMP mice are tolerant to it.  Subsequently, male 
TRAMP mice develop „naturally‟ arising prostatic neoplasia between 8 and 12 weeks of 
age. Autologous T cells isolated and transduced with a TCR specific for an epitope from 
the SV40 antigen were able to cause tumour remission upon adoptive transfer to the 
TRAMP mice. Genetically modified T cells alone reduced tumour progression however, 
for long term tumour remission vaccination was also required158. 
 Together these experiments demonstrate that it is highly feasible to expect tumour 
regression after therapy using genetically modified T cells expressing a tumour-specific 
TCR, even in animals tolerant to the antigen. They also suggest that preconditioning with 
radiotherapy and boosting with vaccination are essential for effective tumour remission.  
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These observations are repeated in numerous studies of adoptive T cell transfer that 
have used sub-lethal irradiation of between 4 – 8Gy to boost anti-tumour responses159-161. 
Irradiation enhances T cell adoptive transfer because it reduces the number of suppressive 
Treg, increases antigen shedding from tumours and increases the amount of „space‟ and 
cytokine availability by depleting competing T cells, all of which combined mean that 
adoptively transferred T cells have better anti-tumour potential162.          
  
1.5.7 : Gene transfer to T cells aimed at enhancing co-stimulation and 
migration to tumour tissues 
 
Tumours secrete suppressive cytokines and express low levels of pMHC-I and 
costimulatory molecules. One approach to overcome this form of suppression is to create 
genetically modified T cells that express high levels of costimulatory molecules such as 
CD28.  For example, Haynes et al. generated a chimeric receptor by fusing the antigen 
binding fragment of the anti-erbB mAb to the hinge region of CD8 and the transgenic and 
intracellular signalling domains of the human TCR-δ chain (scFv-antierbB2-δ).  They 
compared this chimeric receptor with a similar receptor that has the addition of the 
transmembrane region and cytoplasmic region of CD28 (scFv-antierbB2-δ-CD28). The 
adoptive transfer of the engineered T cells into SCID mice with Colo 205 tumours led to 
complete eradication of the tumours from 7 out of 10 mice. The anti-tumour response was 
even evident when  tumours that had been established for 3 days were treated163.   
 Weakly immunogenic tumours may not cause sufficient inflammation and cytokine 
release to attract tumour antigen-specific T cells, thus modifying T cells to increase their 
sensitivity or enhance their responses to mitogens could increase anti-tumour responses 
after adoptive therapy.  For example, IL-8 (CXCL8) is a chemokine that acts as an 
autocrine factor for melanoma, liver and pancreatic tumours and it is expressed by 
melanoma cells164. Genetically modified T cells that can migrate in response to 
chemokines may be able to infiltrate the tumour and exhibit beneficial anti-tumour effects. 
Indeed, Kershaw et al. identified a cytokine designated Gro-α (the receptor for which is 
CXCR2) that is secreted from melanoma cells. When they transduced T cells with CXCR2 
the T cells were able to preferentially migrate towards the chemokine and it also stimulated 
them to produce IFNγ. Although the group were not able to directly show that the modified 
T cells had enhanced anti-tumour properties they demonstrated a unique way of modifying 
T cells that may have potential applications in adoptive immunotherapy165.    
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1.5.8 : Genetic T cell modification by over-expressing exogenous 
cytokines 
 
Following activation, T cells respond to cytokines that can reduce their activation threshold, 
enhance their cytoxicity and prevent activation induced cell death. In the clinical trials 
previously described, IL-2 is the cytokine of choice to enhance adoptive T cell therapy. 
However, because of the requirement of IL-2 for Treg suppression as well as conventional 
CD4 and CD8 proliferation, it may also have deleterious effects on anti-tumour responses. 
IL-15 represents a rational alternative to IL-2 because it elicits similar responses from 
conventional T cells, i.e. prolonged survival, without enhancing suppressive Treg 
capacities92.  
Overwijk et al. found that IL-2 administration, combined with peptide vaccination 
and adoptive transfer of pmel1 T cells (gp10025-33 peptide specific), led to long term 
remission in mice with established B16 melanomas. However, they did note that even this 
triple combination did not always completely cure mice153.   
 A study by Oelert et al. demonstrated that both preconditioning with irradiation and 
the presence of IL-15 are required to cause tumour rejection in mice adoptively transferred 
with antigen specific TCR transgenic T cells166. A result that is corroborated by a study 
from Klebanoff et al. in which pmel TCR transgenic mice were crossed with human IL-15 
transgenic mice to create tumour specific T cells that express hIL-15. These double 
transgenic T cells were efficient at inhibiting growth of B16 tumours. Moreover, pmel cells 
that were cultured in IL-15, before adoptive transfer, were significantly better at reducing 
tumour growth than those cultured with IL-2167.         
 
1.5.9 : Adoptive T cell therapy using in vitro activated CD8 T cells 
 
The studies using the Pmel1/B16 melanoma model also revealed that the anti-tumour 
efficiency of adoptively transferred CD8 T cells is critically dependent on their 
differentiation status, with progressive differentiation inversely correlated with in vivo anti-
tumour effectiveness162. CD8 T cells, that have been fully differentiated in vitro, show 
profoundly impaired anti-tumour activity in vivo168. A similar pattern is seen in the CD8 
memory compartment whereby tumour-specific central memory CD8 T cells (TCM) are 
 40 
superior to effector memory cells (TEM) for causing the regression of established B16 
melanomas169. This is because the fully differentiated T cells have reduced expression of 
lymphoid-homing and costimulatory molecules, lose the ability to produce IL-2 and to 
respond to homeostatic cytokines, and have decreased survival and proliferative capacity in 
vivo
162. It is therefore very important to consider the activation conditions and phenotype 
of T cells before their adoptive transfer. 
 
1.5.10 : Adoptive T cell therapy using CD4 T cells 
 
CD4 T cells are critical for anti-tumour responses against a variety of murine tumours170-173. 
The ability of CD4 T cells to cause tumour rejection is largely based on their ability to 
secrete IFNγ171, 174, 175. Despite the ability of CD4 T cells to cause tumour rejection alone 
or in combination with other treatments, the field of CD4 adoptive immunotherapy has not 
advanced very far. Basic168, 170, 176 and clinical studies13, 16, 19 have concentrated on the 
adoptive transfer of CD8 T cells alone or in some cases with CD4 T cells170, 173 or CD4 
peptide vaccines177. 
 Mumberg et al. demonstrated that CD4 T cells were able to clear MHC-II-/- 
tumours in vivo by a mechanism that was dependent on the indirect effects of IFNγ174.  
This result was confirmed by Perez-Diez et al. who compared the anti-tumour efficiency of 
TCR transgenic CD4 and CD8 T cells directed at the male HY antigen expressed by MB49 
tumours. This study suggested that CD4 T cells were better than CD8 T cells at causing 
tumour rejection178.  
CD4 T cells can de differentiated in vitro into Th17 cells. Th17 cells produce pro-
inflammatory cytokines including IL-17A, IL-6, and Granulocyte–Colony Stimulating 
Factor (G-CSF) which activate other immune cells including neutrophils leading to local 
inflammation 179. Muranski et al. demonstrated that tumour specific Th17 cells are more 
effective than Th1 cells at destroying established B16 melanomas180. 
It has become clear that a wide variety of factors influence the anti-tumour effects of 
adoptively transferred T cells and these factors need to be carefully considered before 
clinical adoptive immunotherapy can be successful.  
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1.6 : Hypothesis 
  
Fundamental to this thesis is the use of the MB49-HY murine tumour system; the same as 
that used by Perez-Diez et al.178.  This system was chosen because of the availability of 
CD4 (Marilyn) and CD8 (MataHari) T cells that respond to male HY antigen expressed on 
the MB49 tumour and male tissues (detailed in Chapter 3). Taking advantage of extensive 
experience of anti-HY T cell studies in this laboratory181-188, and the availability of CD4 
and CD8 tumour specific T cells, it has been possible to address some of the key issues 
relating to the development of successful adoptive T cell cancer immunotherapy.  
Previous studies have suggested that MB49 tumours are rejected in female mice 
when mice are inoculated s.c. with 1 x 105 cells but that tumours develop when the number 
of cells is increased189 to 7 x 105. This suggests that although female C57BL/6 mice are 
capable of eliciting an immune response to HY antigen derived from the MB49 tumour the 
response is suppressed when more MB49 cells are used. We hypothesised that MB49 
tumour cells were capable of immunoevasion. And so, to establish a mechanism by which 
immunoevasion may be happening we will test a panel of cell surface markers that have 
been implicated in tumour escape from the immune system including PDL-1 and PDL-2 as 
well as common co-stimulatory molecules CD80, CD86 and CD40. 
 Low numbers of HY+ MB49 cells are rejected by female mice suggesting that a T 
cell mediated antigen specific immune response is active in these mice and therefore we 
expect to be able to detect CD4 and CD8 tumour infiltrating lymphocytes (TIL). We will 
deplete CD4, CD8 and Treg cells from tumour bearing mice to evaluate the relative 
contributions of the various T cell subsets to tumour growth. We expect that depletion of 
CD4 and CD8 effector T cells will enhance, and depletion of regulatory T cells will inhibit, 
tumour growth.  
 Cytokines that enhance or inhibit the immune response to tumour can have a 
significant impact on tumour growth. We have the reagents to test the effect of IL-10, IL-
15, IL-17, IFNγ and TGFβ on the growth of the MB49 tumours in C57BL/6 mice.  
 MB49 tumours, growing in female C57BL/6 mice, induce tumour infiltrating cells 
to produce IL-10 which in turn inhibits Th1 responses and decreases the survival time of 
the mice when compared to IL-10KO C57BL/6 female mice190. We predict that using the 
same system, i.e. IL-10 knockout191 C57BL/6 mice with MB49 tumours we will reproduce 
the results of Halak et al190. To confirm these results we will also use an IL-10R blocking 
antibody (1B1.3a)192 to inhibit IL-10 signalling in MB49 tumour bearing mice. 
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 IL-15 causes the activation and differentiation of CD8 T cells which enhances anti-
viral immunity66, 93. Additionally, antigen specific T cells expressing transgenic IL-15 have 
been shown to inhibit the growth of B16 melanomas167. Taking advantage of the 
availability of hIL-15 transgenic (Tg) mice193, the kinetics of MB49 growth in WT versus 
Tg mice will be compared. We predict that the growth of MB49 tumours will be inhibited 
in IL-15Tg mice when compared to WT mice.    
As described later, in section 3.1.3.5, there is a debate over whether IL-17A is pro-
tumour or anti-tumour194 because IL-17A enhances the function of cytotoxic T cells but 
also promotes angiogenesis and metastasis. IL-17A KO195 mice have previously been 
shown to be more resistant than wild type control mice to the MC38 tumour196 suggesting 
that IL17A is pro-tumour. We predict that IL-17A KO mice bearing MB49 tumours will 
react in a similar way. 
IFNγ, is a signature cytokine for Th1 cells and it plays a critical role in anti-tumour 
immunity197-199. Neutralisation of IFNγ with the mAb R46/A2 inhibits anti-viral and anti-
tumour responses100. We expect that IFNγ will be critical in the immune response to MB49 
tumours.     
 Glucocorticoid Induced TNFR related protein (GITR) is a member of the Tumour 
Necrosis Factor Receptor (TNFR) family that is expressed on T cells with the primary 
purpose of protecting them from activation-induced cell death. DTA-1, an antagonistic 
anti-GITR mAb, has been shown to cause tumour rejection in numerous murine models147, 
149, 200, 201 and has the potential to be an extremely effective treatment for a variety of 
different cancers. Although administration of DTA-1 can eliminate established tumours it 
is unclear whether DTA-1 abrogates Treg suppression or activates CD4 and CD8 effector 
cells126. We will, for the first time, evaluate the effect of DTA-1 in the MB49 tumour 
system. Additionally, we will investigate which T cell population is affected by the DTA-1 
mAb.      
 We surmised that the adoptive transfer of  Marilyn CD4 T cells would be more 
effective than the adoptive transfer of Matahari CD8 T cells at causing the rejection of 
MB49 tumours in immunodeficient (Rag-/-) and immunocompetant (Rag+) mice based on 
the study by Perez-Diez et al.178. CD8 T cells that are effective at killing tumour cells in 
vitro are not necessarily effective at killing the same tumour cells in vivo. However CD4 T 
cells are multi-potent cells that can directly kill tumour cells, in vitro and in vivo, activate 
antigen presenting cells and NK cells. To test this hypothesis HY-antigen specific, Marilyn 
CD4+ or Matahari CD8+ T cells will be adoptively transferred into MB49 tumour bearing 
mice and the growth of the tumour will be analysed. We will also study the effect of 
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combined therapies involving the use of T cell preconditioning and host irradiation to 
optimise the adoptive transfer of T cells. 
 Regulatory T cells represent a significant barrier to effective adoptive T cell 
immunotherapy for cancer as evidenced by reports that in vivo depletion of nTreg cells 
improves anti-tumour responses and enhances the efficiency of therapeutic cancer 
vaccines125, 126. We will design experiments using Marilyn Treg to study the expansion and 
distribution of antigen specific Treg cells in the MB49 system. We predict that antigen 
specific Treg will potently inhibit T cell responses to the MB49 tumour, potentially by 
direct cell-cell contact within the tumour.    
 
         
1.7 : Aims of this PhD project  
 
The aim of this study was to address some of the key questions that remain unanswered in 
the quest for an effective tumour immunotherapy.  These questions were: 
1.  What is the most effective cell type to transfer; CD4 or CD8?  
2.  Within the CD4 and CD8 compartments which is the more potent subset; naïve, 
activated, EM or CM, Th1 or Th17? 
3.  Does pre-conditioning with irradiation increase anti-tumour reactivity of 
adoptively transferred T cells?  
4.  Are tumour-specific CD8 T cells, that over-express IL-2 or hIL-15, better at 
clearing tumours that tumour-specific CD8 T cells not over-expressing these 
cytokines?  
5.  What are the roles played by Treg cells in anti-tumour immunity?  
6.  Can anti-GITR mAb (DTA-1) be used for cancer immunotherapy?    
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Chapter 2 : Materials and 
Methods 
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The materials and methods used in this project are detailed in this chapter. Firstly, buffers 
and chemical reagents are described, followed by the protocols used. The precise details 
(i.e. conjugated antibodies used for Fluorescence Activated Cell Sorting (FACS) and flow 
cytometry) of a protocol used for each section is described in the results.  
2.1 : Media 
Table 3. Media, use and composition 
Medium Use Composition 
Ammonium Sulphate Solution Purification of mAb from 
hybridomas 
4.1M (NH4)2SO4 in dH2O 
Blood Buffer Collection of blood PBS, 100U/ml Heparin, 2mM 
EDTA 
Complete culture medium Maintenance of hybridomas / 
tumour cell lines / in vitro 
cultures 
RPMI 1640 Medium, 
supplemented with 10% FCS, 
10mM HEPES, 100 IU/ml 
Penicillin, 100μg/ml 
Streptomycin, 2mM L-
glutamine and 2x105 M β2-
Mercaptoethanol*. 
Freezing Medium Storing cells in liquid nitrogen 8ml complete medium, 1ml 
DMSO, 1 ml 20% FCS 
MACS® buffer Washing of single cell 
suspensions before 
MACS/FACS  
PBS, 2mM EDTA, 1% FCS 
PBS Resuspending of cells/reagents 
for in vivo use 
NaCl, 137mmol/L; KCl, 
2.7mmol/L; Na2HPO4, 
8mmol/L; KH2HPO4, 
2mmol/L. pH 7.3. Oxoid, 
Hampshire, UK. 
RBC lysis buffer (Qiagen, 
Hilden, Germany).  
Depletion of red blood cells 
before counting/FACS 
Unspecified concentrations of 
NaCl, EDTA and Sodium 
Bicarbonate 
Abbreviations:  FACS; Fluorescence Activated Cell Sorting, PBS; Phosphate Buffered 
Saline, RBC; Red Blood Cell.  *Ingredients of complete culture medium (Invitrogen, 
Paisley, UK) except for FCS (Autogen Bioclear, Calne, UK).  
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2.2 : Mice 
 
The mice used in this project were housed under Special Pathogen-Free conditions in the 
Biological Services Unit, Clinical Sciences Centre, Hammersmith Hospital and used in 
accordance with Home Office guidelines as defined in the project licence. All the mice 
used in this project were on a C57BL/6 background.  
 
Table 4. Mice, strain, phenotype and primary reference 
Strain Phenotype Reference 
C57BL/6 Wild type, Thy1.2+ 202, 203 
C57BL/6 Thy1.1+ Wild type, Thy1.1+ 202 
Rag2-/- No TCR rearreangement and 
subsequently no B cells or T 
cells  
204 
Marilyn TCR transgenic for Dby-Ab 205 
MataHari TCR transgenic for Uty-Db 206 
hIL-15Tg Transgenic over-expressing 
human IL-15 
193 
dnTGFβIIR Transgneic for dominant 
negative TGFβ receptor type II  
207 
FoxP3-GFP Foxp3-reportor mice  208 
IL-10 KO IL-10KO  191 
IL-17 KO IL-17KO 195 
 
 
Thy-1.2+ Wild Type (WT) C57BL/6 (B6) mice are an inbred strain produced in 1921 by 
Clarence Little. The MHC haplotype of B6 is H-1c, H-2b, H-3a. B6 have a high total 
leukocyte count202 and a low incidence of spontaneous tumour development209 and are 
therefore an ideal strain for the study of immunology and tumour development. B6 were 
purchased from Harlan Laboratories (Bicester, UK). 
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    Thy-1.1+ C57BL/6  mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME). 
    Marilyn mice are HY-specific Rag2-deficient TCR-transgenic on a C57BL/6, H2b 
background kindly provided by Dr O. Lantz (Institut Curie, Paris, France). Marilyn mice 
express a transgenic Vβ6 T-cell receptor (TCR) isolated from a CD4 T cell that recognised 
the HY/Ab/Dby peptide (NAGFNSNRANSSRSS) presented by the class II molecule H2-
Ab205. Marilyn mice were originally on a Rag2-/- Thy-1.2+ background. Thy-1.2+, Thy-1.1+ 
and Thy1.1+1.2+ Marilyn mice on either a Rag2+/- or a Rag2-/- background were produced 
after crossing with Thy-1.1+ B6 mice. 
    MataHari mice are HY-specific Rag-deficient TCR-transgenic mouse lines on a 
C57BL/6, H2b background also provided by Dr O. Lantz (Institut Curie, Paris, France). 
MataHari mice express a transgenic Vβ8.3 TCR isolated from a CD8 T cell specific for the 
HY/Db/Uty peptide (WMHHNMDLI) restricted by the class I moleculeH2-Db206. 
MataHari mice were originally on a Rag1-/- Thy-1.2+ background. Thy-1.2+, Thy-1.1+ and 
Thy1.1+1.2+ MataHari mice on either a Rag1+/- or a Rag1-/- background were produced after 
crossing with Thy-1.1+ B6 mice. 
    Dominant-negative TGFβIIR (dnTGFβIIR) mice express a dominant negative form 
of TGFβIIR that has a truncated intracellular kinase domain. Despite being able to bind all 
three isoforms of TGFβ the receptor cannot mediate signal transduction207. The 
dnTGFβIIR mice on a C57BL/6 background were kindly provided by Richard Flavell 
(Yale University School of Medicine, New Haven, CT). dnTGFβIIR mice were mated with 
Rag2-/- Marilyn mice to produce F1 mice, from which double-transgenic naïve (CD4+ Vβ6+ 
CD25- dnTGFβIIR+) or nTreg (CD4+ Vβ6+ CD25+ dnTGFβIIR+) T cells were purified.   
    IL-15 transgenic (IL-15Tg) mice over-express human IL-15 (hIL-15). The IL-15Tg 
mice were generated on a C57BL/6 background and kindly provided by Thomas A. 
Waldmann et al. (National Cancer Istitute, Bethesda, MD)193. IL-15Tg mice were mated 
with Rag2-/- MataHari mice to produce F1 mice, from which double-transgenic (CD8+ 
Vβ8.3+ IL-15Tg) T cells were purified.   
    IL-10 knockout (IL-10-KO) mice do not produce IL-10 and were generated, on a 
C57BL/6 background using gene targeting, by Ralf Kuhn et al. (University of Cologne)191. 
IL-10-KO mice were purchased from the Jackson Laboratory (Bar Harbor, ME).  
    IL-17A knockout mice (IL-17A-KO) mice do not produce IL-17A and were 
generated, on a C57BL/6 background by Susumu Nakae et al. (Institute of Medical 
Science, Tokyo)195.  
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    Rag2-/- mice do not express recombination activating gene 2 (Rag2) which is 
essential for T and B cell development. Rag2-/- mice do not have T or B cells. Rag2-/- mice 
on a C57BL/6 background were originally produced by Fredirick Alt et al. (Columbia 
University, NY)204. A Colony of Rag2-/- mice were produced by us during the mating of 
Rag2-/- Marilyn females with WT B6 males. 
    Foxp3/green fluorescent protein (GFP) knock-in mice on a B6 background were 
generated and kindly provided by Dr B Malissen et al. (Centre d‟Immunologie de 
Marseille-Luminy, Marseille, France)208. FoxP3/GFP mice were mated with Rag2-/- 
Marilyn mice to produce F1 mice, from which double-transgenic nTreg cells (Mar-
nTregGFP+) were purified. 
  
2.3 :  Peptides 
 
The HY-Ab-Dby peptide, NAGFNSNRANSSRSS 186, and the HY-Db-Uty peptide, 
WMHHNMDLI185, were synthesised by the central research resource unit at the Clinical 
Sciences Centre (Hammersmith Hospital, London) using 9-fluorenylmethyloxycarbonyl-
protected amino acids and (2-(1-H-benzotriazol-2-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) activation chemistry.  
   
2.4 : Cell purification 
 
2.4.1 : Marilyn and MataHari T cells 
 
CD4+ Marilyn and CD8+ MataHari T cells were purified, from in vitro culture or from 
single cell suspensions of pooled spleen and lymph nodes, using MACS® cell purification 
kits (Miltenyi Biotec, Surrey, UK).  These kits use beads (MACS beads), linked to 
antibodies, and magnetic columns [MS (medium) or LS (large) columns were used in this 
study] to isolate cell populations from mixed cell suspensions.  Single cell suspensions 
were created using the end of a 1ml syringe plunger to force spleen and lymph nodes 
through a 70m nylon cell strainer (Becton Dickinson, Oxford, UK). Single cell 
suspensions were maintained in MACS buffer (PBS, 2mM EDTA, 1% FCS), pelleted by 
centrifugation at 400g for 5mins and washed once with MACS buffer. 
 49 
   Cells harvested from in vitro culture were washed once and re-suspended in MACS 
buffer. 20μl of anti-CD4- (for Marilyn T cells) or anti-CD8- (for MataHari T cells) MACS 
beads were added to the washed cells and incubated for 20mins at 4oC. Samples were 
washed once, re-suspended in 1ml MACS buffer and then added to an MS or LS MACS 
separation column. The column was washed three times with MACS buffer to remove the 
negative fraction. The positive fraction was isolated by removing the column from the 
magnet and flushing with at least 8ml MACS buffer. The positive fraction was washed 
twice in PBS before being re-suspended in PBS for i.v. injections or culture medium for in 
vitro work. 
     
2.4.2 : Regulatory T cells 
 
To purify CD4+CD25+ Treg cells, a single cell suspension was made with pooled spleen 
and lymph nodes from a Rag+/- female Marilyn mouse (as described in the last section). 1μl 
of anti-CD25-PE was added per sample and incubated for 15 mins at 4oC. Each sample 
was washed with MACS buffer then 20μl anti-PE microbeads were added for 20mins at 
4oC. Samples were each washed and re-suspended in 1ml MACS buffer and added to an 
MS or LS separation column. The column was washed three times with MACS buffer and 
the negative fraction collected and used to generate CD25 depleted conventional CD4 T 
cells. The positive fraction was isolated by removing the column from the magnet and 
flushing with at least 8ml MACS buffer.  
    To obtain a more pure population of Treg, the CD25+ fraction was stained with 1μl 
of anti-CD4-PE/Cy5, anti-Vβ6FITC and anti-CD25PE per sample.  Cells were then sent to the 
FACS facility at the Clinical Research Centre, Hammersmith Hospital for sorting.  
CD4+Vβ6+CD25+ Marilyn nTreg, GFP+CD4+Vβ6+CD25+ green Marilyn nTreg or 
CD4+CD25+ polyclonal Treg cells were purified to greater than 98% purity using a FACS 
Aria (Becton Dickinson). 
  
2.4.3 : Antigen presenting cells (APC)      
 
Spleen and/or lymph nodes were diced using a Size 22 scalpel and the resulting pulp was 
added to a 50ml Falcon tube. 2 mg/ml Collagenase XI and 10 μg/ml DNase in 1ml PBS 
with 2% FCS was added and incubated on a shaker at 37oc for 30mins. 100μl 0.1M EDTA 
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was added for a further 5 mins. Then 10μl/spleen anti-CD11c microbeads were added and 
incubated for 20mins at 40c. Labelled cells were washed twice in MACS buffer and 
separated on an LS column as previously described. The positive fraction was washed once 
in culture medium and used for culture. The negative fraction was incubated with anti-
CD11b microbeads and separated as described. The CD11b+ fraction was used for cell 
culture and the negative fraction was incubated with anti-B220 microbeads and B220+ cells 
were isolated and used for culture.   
 
2.5 : Proliferation assays 
 
2.5.1 : Peptide specific T cell proliferation assay 
 
Single cell suspensions from spleen and lymph nodes were cultured with complete medium 
with or without HY peptide and with or without cytokines. On day 3, 0.5μCi/well of 
tritiated thymidine (New England Nuclear) was added. 16 hours later cells were harvested 
onto a filter mat and analysed using a Wallac Trilux 1450 Microbeta liquid scintillation 
and luminescence counter (PerkinElmer, Beaconsfield, UK).  
 
2.5.2 : Mixed Lymphocyte Response Assay 
 
CD11c, CD11b or B220 APC were purified by MACS and plated at a defined 
concentration in 100μl in a 96 well U-bottomed tissue culture dish (Falcon) using a 200μl 
pipette Single cell suspensions of spleen and lymph nodes were cultured with complete 
medium with or without HY peptide and with or without cytokines. On day 3, 0.5μCi/well 
of tritiated thymidine (New England Nuclear) was added. 16 hours later cells were 
harvested onto a filter mat and analysed using a Wallac Trilux 1450 Microbeta liquid 
scintillation and luminescence counter (PerkinElmer). 
 
2.6 : Flow cytometry analysis 
 
Cells were prepared for Flow Cytometric analysis as follows: Cells were depleted of red 
blood cells using 2ml of red cell lysis (Qiagen) buffer incubated for 15mins at room 
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temperature. For the analysis of surface markers, cells were washed and incubated with 
conjugated antibodies (eBioscience, Hatfield, UK or R&D Systems, Abingdon, UK) for 
15mins at 40C in 100μl PBS. The amount of antibody used to detect each marker was 
determined in preliminary experiments.  Cells were washed once with MACS buffer and 
analysed using a FACS™ Calibur (Becton Dickinson). For tetramer staining, cells depleted 
of red blood cells were incubated with tetramer conjugated with PE for 15mins at 370C in 
100μl complete medium, followed by staining with anti-CD8PerCP at 40C.  Cells were 
washed once with PBS and analysed.  For intracellular cytokine staining, T cells were 
cultured in complete medium with 0.01μg/ml PMA and 0.05μg/ml Ionomycin, after 2hrs 
0.5μg/ml Brefeldin (BD Biosciences, Oxford, UK) was added for 2 hours (hrs).  At the end 
of the incubation, live cells were isolated by layering harvested cells on Ficoll and 
centrifuging for 20mins at 400g. Live cells were lifted from the top layer of Ficoll and 
washed once with PBS, before incubation with conjugated cell surface antibodies as 
described above. After staining the surface markers, cells were washed with MACS buffer.  
After washing, 0.3ml Fix/Perm (eBioscience) was added per sample and cells were 
incubated at 40C for 1hr. Cells were washed once with Perm buffer (eBioscience) prior to 
incubation with 0.5μl/sample conjugated anti-cytokine antibody for 15mins at 40C. Fixed 
and stained cells were washed once with Perm buffer to remove any excess intracellular 
antibody and then once with cold PBS before being analysed.  
 
2.7 : Carboxyfluorescein Succinimidyl Ester dilution assay   
 
To study proliferation, T cells were isolated from the spleen and lymph node or directly 
from culture. After purification, using MACS or FACS, as described above, cells were 
washed three times with PBS and then resuspended well, in 1ml PBS. 1 M of CFSE 
(Molecular Probes, Cambridge, UK) was added into cell suspension, and the cells were 
incubated for 10mins at room temperature.  At the end of the incubation cells were washed 
once with MACS buffer and twice with PBS before being re-suspended in complete 
medium for in vitro culture or in PBS for i.v. injection.  
    After in vitro culture or in vivo passage T cells were harvested and stained with 
antibodies against cell surface markers or intracellular cytokines as previously described. 
The dilution of CFSE and thus T cell division, was analysed using a FACS™ Calibur.   
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2.8 : Antibodies 
 
Monoclonal antibodies were purified from hybridomas that were grown in 500ml of 
complete medium in 1L roller bottles rotating at 0.02rpm at 370C for 10 days. Cells were 
removed from the supernatant by centrifugation (2000 r.p.m., 10 mins, RT). Cell free 
supernatant was then removed and slowly mixed 1:1 with saturated ammonium sulphate 
solution (VWR, Lutterworth, UK) then mixed with a magnetic stirrer at 40C overnight. The 
resultant precipitate was pelleted by centrifugation at 2000g for 30mins. The pellet was 
resuspended in 10ml PBS and put in dialysis tubing sealed at both ends. The dialysis 
tubing was floated in 4L PBS and stirred overnight at 40C. The PBS was replaced and 
stirred overnight again. Purified antibody was isolated from the dialysis tubing and 
centrifuged at 400g for 10mins, to remove any remaining cell particulates. The supernatant 
was filter sterilised and used i.p. in vivo or further purified using a protein AG column 
(ThermoFisherScientific, UK). 
To further purify antibodies, 10ml of supernatant was concentrated using a 
Centricon YM-10 centrifugal filter, as per manufacturers instructions (Millipore, 
Southampton, UK). Antibody was purified from 2ml of concentrated supernatant using a 
Protein A/G spin kit as per the manufacturers instructions (ThermoFisherScientific). The 
concentration of purified antibody was calculated using a BCATM Protein Assay Kit 
(ThermoFisherScientific).  
 
Table 5. Hybridomas. 
Antibody/Hybridoma Brief Description Reference 
DTA-1 Rat anti-mouse GITR, IgG2a 145 
1D11 Anti-TGFβ 210 
PC61 Anti-CD25 211 
1B1.3a Anti-IL-10R 192 
GL113 Anti-Galactosidase, control mAb  
YTS169.4 Anti-CD4 212 
YTS191 Anti-CD8 213 
R46A/2 Anti-IFNγ 100 
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2.9 : Skin grafting 
 
Skin grafting was conducted using a method previously described by Billingham and 
Medawar214 using tail skin grafted onto the lateral thorax.  
Donor tail skin was removed and cut into 1cm2 sections. Recipient mice were 
anaesthetised using Isoflurane (Halocarbon Products Corp.). When the mice reached a 
surgical plane of anaesthesia  0.26μg of Metacam (Boehringer Ingelheim GmbH )was 
injected s.c. Then the mice were stretched out, to ensure easy access to the surgical site, 
using elastic bands. The selected area was shaved, washed with 70% alcohol and sprayed 
with Opsite spray dressing. A piece of skin was removed from the right flank to create a 
graft bed, any excess blood was removed and a 1 cm2 tail skin graft was placed in the graft 
bed. The graft was covered with muslin soaked with Vaseline (VWR). A plaster was then 
wrapped around the midriff and graft. Mice were put in a warming chamber at 320C for the 
plaster to dry and for the mice to recover.         
Plasters were removed 7-10 days after grafting and grafts were inspected every other 
day.   
 
2.10 : Tumour cells 
 
2.10.1 : MB49 
 
MB49 is a murine bladder carcinoma that was generated in vitro by culturing explanted 
bladder from C57Bl/Icrf-at mice with 7,12-Dimethylbenz(a)anthracene (DMBA)215. 
MB49 cells were stored in liquid nitrogen until needed. When needed, one vial was rapidly 
thawed and washed in pre-warmed complete culture medium (Described in Section 2.1 :). 
MB49 cells in 10ml complete culture medium were cultured for 10 days. MB49 cells were 
maintained in culture and split every 3-4 days then used when needed. To harvest MB49 
cells, culture medium was removed and excess cells and protein were removed by washing 
3 times with PBS. 2ml of Trypsin solution (Invitrogen) was added to flasks and incubated 
at RT for 10mins. Cells were then removed from the flask and washed once with complete 
culture medium and then three times with PBS. For in vivo experiments MB49 cells were 
resuspended at 2.5 x 106 cells/ml in PBS and mice were injected, with an insulin needle, 
with 0.2ml (5 x 105 cells) s.c. to the dorso-lateral flank unless otherwise stated. The area of 
 54 
the tumour (mm2) (Length (mm) X Width (mm)) was measured at regular intervals using a 
pair of digital callipers. Data are presenetd as means +/- Standard deviations unless 
otherwise stated and group comparisons were done using the two-tailed Students t-test 
unless otherwise stated.    
 
2.10.2 : B16F10 
 
B16F10216 cells were thawed, maintained and injected in the same way as described for 
MB49 cells.    
  
2.11 : Polymerase Chain Reaction (PCR) 
 
I am indebted to Dr. Caroline Addey for completing this protocol. To examine the 
expression of HY genes in MB49 and B16-HY cells, RNA was isolated from MB49, B16-
HY, C57BL/6 male spleen or female spleen cells by phenol/chloroform extraction using 
Trizol (Invitrogen) according to the manufacturer‟s instructions. RNA from MB49 cells 
was quantitated and converted to complementary DNA (cDNA) by Reverse Transcription-
PCR (RT-PCR) using BRL Superscript Reverse Transcriptase (Invitrogen) according to the 
manufacturer‟s instructions.    cDNA was then used in PCRs with primers specific for the 
HY genes:  For PCR, in a final volume of 25 l, 2μl cDNA was mixed with 0.4 M 
forward primer, 0.4 M reverse primer, 1 U Taq Polymerase (Invitrogen), 1 X reaction 
buffer (supplied with Polymerase), 2 mM MgCl2 and 0.4 mM dNTPs.  The following 
specific primers were used (written 5‟-3‟): 
 Dby: Forward: CAGCAAGAGGTCTAGACA. Reverse: TCCTCTGTTGTGGCTACT 
Smcy: Forward: TGAGACATAAGAAGCCCC. Reverse: GGCTTAATCCTTGAACTC 
Uty: Forward: ACTTCGCCATATCCTCCT. Reverse: GTGCTTTCTGTCTCCTTC 
 The reaction mixture was incubated at 95oC for 5mins then cycled 30 times through 
the following programme: 95oC for 1min, 52.5oC for 1min, 72oC for 1mins, before a final 
extension step of 72oC for 7mins. PCR products were analysed by agarose gel 
electrophoresis on a 1% agarose gel containing Safeview (Invitrogen).     
 To check for the presence/absence of the dnTGFβRII gene in T cells from 
dnTGFRII transgenic mice, DNA was isolated from tail tips by incubation in 50mM Tris 
(pH8), 2mM NaCl, 10mM EDTA, 1% SDS and 1mg/ml proteinase K for 16hrs followed 
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by incubation at 100oC for 5mins. Extracts were then washed and diluted 1: 100 before 
addition to PCR. 
 2.5 μl was diluted in a final volume of 25 l with 0.4 M forward primer, 0.4 M 
reverse primer, 1 U Taq Polymerase (Invitrogen)1 X reaction buffer (supplied with 
Polymerase), 2 mM MgCl2 and 0.4 mM dNTPs.  The following primers were used (written 
5‟-3‟): 
Forward: CCCAACCAACAAGAGCTCAGG 
Reverse: TTGGGGTCATGGCAAACTGTCTC 
The reaction mixture was incubated at 95oC for 5mins then cycled 5 times through the 
following programme: 94oC for 1min, 60oC for 1min, 72oC for 1min, before a final 
extension step of 72oC for 10 mins. PCR products were analysed by agarose gel 
electrophoresis on a 1% agarose gel containing Safeview. The PCR product in 
dnTGFβIIR+ samples is 350bp.  
     
2.12 : IL-15 Transgenic Mouse Typing 
 
I am indebted to Dr. Caroline Addey for completing this protocol. IL-15 KO mice were 
typed using an IL-15 ELISA from R&D Systems following the manufacturer‟s instructions.  
 
2.13 : Lipofectamine transfection of Phoenix cells 
 
I am indebted to Dr. Caroline Addey for completing this protocol. To transfect MataHari 
cells with the IL-2 gene, MataHari cells from pooled spleen and lymph nodes were 
cultured at 2 x 105 cells/well in a 6 well plate with 0.3nM HYUty peptide for three days. 
Medium was removed 4 hours before tranfection, and cells were washed once with PBS.  
2ml medium [Complete culture medium, without penicillin (pen) and streptomycin (strep)], 
was added to each well. Two tubes were prepared:  Tube 1 contained 250μl OptiMEM 
(Serum-Free medium), 3g MigR1-IL-2, and 1g helper vector, pCL-Eco. Tube 2 
contained 10l Lipofectamine™ 2000 (Invitrogen) and 250l OptiMEM.  Tube 2 was 
vortexed and incubated for 5 minutes at 20-25oC. The two solutions were then gently 
mixed together and incubated for 20mins at 20-25oC. At the end of this incubation, 500μl 
of the resultant mixture was added to each well of cells and the cells were incubated at 
37oC, 5% CO2, overnight. The medium was then removed and replaced with 5ml of 
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Complete Culture Medium and cells were incubated for a further 24 hours at 37oC, 5% 
CO2. Cells were tested for successful transfection by flow cytometric analysis of GFP 
expression.       
 
2.14 : Immunofluorescence microscopy 
 
Lymph nodes, MB49 tumours and spleen were removed from MB49-bearing C57BL/6 
female mice. Tissues were fixed in 4% Paraformaldehyde and 10% Sucrose for 2 hrs. 
Tissues were then washed once in PBS before overnight incubation in OCT. Tissues 
immersed in OCT were flash frozen in cold propanol then transferred to liquid nitrogen 
and stored at -80oC until needed. For sections, tissues were removed from liquid nitrogen 
and warmed to -40 oC prior to cutting.  5μm sections were made using a cryostat. Sections 
were immediately mounted on poly-lysine coated microscope slides. Sections were stored 
at -20oC until needed. 
To analyse the location and number of T cells in the sections, sections were removed 
from the -20oC freezer and fixed in acetone for 20mins at -20oC. Sections were then 
washed twice with PBS and incubated with PBS containing 10% v/v FCS, for 20mins at 
4oC, to block Fc receptors and reduce non-specific binding. 50μg/ml anti-CD3 (BD) or 
Isotype antibody/sample was diluted in 100μl PBS and then added directly to the section.  
Sections were incubated with antibody at RT for 1hr. Sections were washed twice with 
PBS before a coverslip was mounted using vector shield containing DAPI (Invitrogen). 
Slides were dried for 1hr at RT before being analysed using a deconvolution microscope 
(Leica) and mmap software.   
 
2.15 : Analysis of adoptively transferred T cells 
 
Tumour dLNs, ndLNs, spleen and tumours were harvested from mice. The organs were 
cleaned of excessive fat and tissue before being forced through a cell strainer to create a 
single cell suspension. Cells to be analysed by flow cytometry were incubated with Red 
Blood Cell lysis buffer (Qiagen) at RT for 10 mins before being washed once with PBS 
and stained as described in section 2.6. Cells to be used for culture were washed once in 
culture medium and plated out at the desired concentrations for each experiment.     
 
 57 
 
Chapter 3 : Endogenous 
T cell responses against 
MB49 
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3.1 : Introduction 
 
3.1.1 : MB49 
 
Minor histocompatibility (H) antigens are the self-peptides derived from polymorphic 
genes and presented to the immune system via the MHC187. The molecular composition of 
minor H antigens share many similarities with that of tumour antigens; both types of 
antigen are comprised of a limited set of peptide epitopes which derive from variants of 
self-proteins. Expression of these antigens is often at a low level in normal tissue, resulting 
in limited cell surface density of pMHC complexes which may be insufficient to trigger T 
cell activation. T cell responses to both antigen classes are therefore, subject to the same 
controlling mechanisms and limits. Thus, data obtained from studies on minor H antigen 
immunity are relevant to tumour immunity. 
    The male-specific transplantation antigen, HY, is one of the best characterised 
minor H antigens. Three genes, identified on the Y-chromosome of H2b mice, encode 
proteins that give rise to the H2-Db- and H2-Ab- restricted peptide epitopes of HY; the 
H2-Db-restricted peptide epitopes are derived from the Smcy and Uty genes, while the H2-
Ab-restricted peptide epitope is derived from the Dby gene186, 217.  
    The MB49 tumour has been chosen for this study for a number of reasons:  It is a 
murine carcinoma cell line that was generated by incubating bladder tissue, from male 
C57BL/Icrf-at mice, with the carcinogen DMBA (7,12-Dimethylbenz(a)anthracene) 215. 
Therefore, MB49 is a chemically induced murine bladder carcinoma that, because it was 
generated from a C57BL/6 male, is H2b+ as well as being positive for the three genes that 
make up the male specific transplantation antigen, HY178, 189, 190.  
    In addition, unlike many current tumour models using tumours over-expressing 
„foreign‟ proteins such as cOVA218 or viral antigens130, the HY system employs self tissue-
proteins, HY, which are naturally expressed by MB49 cells at a physiological level, thus 
the results obtained from the HY system are more likely to reflect immune responses 
against TAA which are largely non-mutated self-proteins. Although MB49 has been shown 
to express other tumour specific markers for bladder carcinoma, such as the human bladder 
cancer marker, BCLA-4, the Prostate Cancer Stem Cell Antigen (PSCA) and Six-
Transmembrane Epithelial Antigen of the Prostate (STEAP)189, the primary immune 
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response in female C57BL/6 mice is against the HY antigen. Additional evidence for the 
specificity of the female response to the HY antigen, in this system, comes from previous 
studies that demonstrated that male C57BL/6 mice fail to reject MB49 tumours; suggesting 
that there are no syngeneic immunogenic antigens expressed by MB49219. 
    Cultured tumour cell lines may change their phenotypes after developing into 
tumours in vivo as variants are selected, by immuno-editing mechanisms (or under pressure 
of immunosurveillance), that can divide faster, live longer and evade the immune system.   
As discussed in the Introduction, there are several mechanisms utilised by tumours to 
suppress immune responses: Generally, tumour cells are poor antigen presenting cells 
(APC), as they express limited amounts of MHC-I and T cell co-stimulatory molecules. 
However, tumour cells can express abundant T cell inhibitory molecules including PD-L1 
115 and B7-H4 116 117. The tumour microenvironment also contains immuno-suppressive 
factors that can be secreted directly from the tumour or from APC and T cells. Immuno-
suppressive factors directly secreted from tumours include gangliosides, GM-CSF, IDO120, 
IL-6, IL-10, prostaglandins, TGFβ and VEGF220. IL-10 and TGFβ are the two best 
characterised suppressive cytokines in the tumour microenvironment, as described in 
Section 1.3 of this thesis. 
    Currently there is limited published data reporting the expression of MHC-I, MHC-
II, co-stimulatory and inhibitory ligands on the surface of the MB49 cell line and the ex 
vivo MB49 tumour. Therefore, together with evaluating the expression of HY antigens by 
the MB49 cell line and ex vivo tumour, it was important to also test the expression of MHC 
proteins, common tumour-associated cell surface proteins and immuno-suppressive 
cytokines. The results to these experiments are shown later in Section 3.2.1. 
 
3.1.2 : T cell responses to MB49/HY 
 
Growth of MB49 in vivo in C57BL/6 female mice has been tested by intravenous (i.v.), 
intraperitoneal (i.p.) and subcutaneous (s.c.) injection. Inoculation of MB49 i.v. or i.p. 
creates metastatic tumours that are not easily quantified and lead to rapid morbidity and 
mortality189, 221.  When administered s.c. to female C57BL/6 mice MB49 is an 
immunogenic tumour but inoculation of MB49 cells at doses of 7x105 and 1x106 produces 
a progressive solid tumour in female C57BL/6 mice189 and thus demonstrates that the 
immunogenicity of the tumour is not sufficient for it to be rejected when these high doses 
of MB49 cells are administered. Consistent with these results, another study showed that 
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female C57BL/6 mice reject low doses of MB49 (1 x 104) but not high doses (1 x 106)219. 
Moreover, when T cells from female C57BL/6 with large tumours were adoptively 
transferred to athymic mice those mice were able to reject male skin grafts suggesting that 
tumour bearing mice do generate a functional immune response to HY antigen from MB49 
tumours 219. Together these results demonstrate that MB49 is highly immunogenic.  
 Some reports have shown that female C57BL/6 mice do not generate detectable 
CD8+ T cell responses in vivo against the Db-Smcy and Db-Uty antigens despite being able 
to secrete IFNγ in response to both MHC-I antigens and Ab-Dby in vitro219. However, 
other reports suggest that female C57BL/6 mice can generate CD8 T cell responses 
detectable by tetramers178. This lab is experienced in using tetramers to detect CD8 T cells 
responses185 and the reagents are available to test tetramer responses.   
    Studies in mice have demonstrated that in vivo Treg depletion enhances tumour 
rejection in multiple murine tumour modesl125, 147, 222. The efficacy of mAb PC61, specific 
for CD25, is dependent on when it is administered with the best therapeutic results coming 
from administration 4 days before tumour administration. The effects of PC61 are 
dependent on a replete immune system with both CD4 and CD8 T cells222. 
    In the study described in this thesis, the growth of MB49 tumours was measured 
and T cell responses, to the tumours, were analysed using tetramers.  To investigate the 
contribution of CD4 and CD8 T cells to the growth of MB49, the CD4 and CD8 subsets of 
T cells were depleted, individually or in combination, using antibodies (the mAb YTS 
191213 is effective at depleting at CD8 cells and the YTS 169212 antibody can be used to 
deplete CD4 T cells).  To investigate the contribution of Treg to the growth of MB49 
female C57BL/6 mice were injected i.p. with CD25 depleting antibody, PC61211, to 
remove CD25+ T cells.  The results of these studies are shown in Section 3.2.2.4.  
 
3.1.3 : Tumour-related Cytokines 
 
Cytokines play a major role in the progression or rejection of tumours and many tumours 
have been shown to secrete tumourogenic cytokines or to induce surrounding cells to 
secrete them.  A number of knockout mice, transgenic mice or cytokine depleting 
antibodies are available to study the contribution of IL-10, TGFβ , IFNγ, IL-15 and IL-17A 
to the growth of MB49 tumours.  
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3.1.3.1  IL-10 
 
IL-10 can modulate T cell responses directly or indirectly via APC81. Importantly, IL-10 is 
a key cytokine controlling the development and function of Tr1 cells which are an 
independent regulatory T cell population, as Tr1 cells do not express Foxp382. IL-10 has 
been associated with several different forms of cancer including human melanoma223-225, 
small cell lung cancer226 and renal cell carcinoma227. 
    The role of IL-10 in tumour progression has been fiercely debated. There are 
conflicting reports, some claiming IL-10 inhibits tumour growth228-230 whilst others claim it 
promotes tumour growth190, 231-233. Indeed, IL-10 can both inhibit and stimulate CD8 T 
cells, inhibiting antigen-specific responses in the presence of APC but stimulating 
responses when combined with IL-2234.   
    IL-10 inhibits cellular immune responses and antigen induced proliferation by 
down regulating MHC- II84 and co-stimulatory CD80/86 molecules on monocytes and 
macrophages84-87. IL-10 inhibits cytokine production by macrophages89 as well as 
inhibiting the ability of APC to prime T cells88. IL-10 can also directly inhibit IL-2 
production by CD4 T cells90. In addition, IL-10 drives the differentiation of the regulatory 
Tr1 subset of CD4 T cells which in turn inhibit CD4 responses83. However, IL-10 is also 
pro-inflammatory and may lead to extravasation of T cells and increased numbers of 
tumour infiltrating lymphocytes. 
 It has been demonstrated that MB49 tumours, growing in female C57BL/6 mice, 
induce tumour infiltrating cells to produce IL-10 which in turn inhibits Th1 responses190. 
Consistent with this, IL-10 KO mice had prolonged survival after administration of 1 x 106 
MB49 cells 190.   
    Together these studies suggest that IL-10 is a potent cytokine whose involvement in 
tumour rejection needs to be properly established in relation to adoptive immunotherapy. 
    To examine the MB49 responses to IL-10, this study used IL-10 knockout mice191, 
that do not produce any IL-10, and an IL-10R blocking antibody (1B1.3a)192.  The 
experiments and results are described in Section 3.2.3.1.  
 
3.1.3.2 TGFβ 
 
TGFβ is an important mediator of suppression which is produced by tumour cells and 
natural or induced Treg cells58. TGFβ can convert naïve CD4 T cells to Foxp3-expressing 
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Treg cells105. TGF-β is secreted by numerous lung cancer cell lines in vitro and can 
prevent the induction of CD8 mediated responses103.  
    To study the effects of TGFβ, a transgenic mouse was created by L. Gorelik et 
al.207 , using a gene encoding a dominant negative (dn) form of the TGFβRII235. T cells 
from dnTGFβRII are defective in TGFβ signalling130 and suppression of CD4 and CD8 T 
cells by TGFβ-1, upon stimulation by CD3 and CD28, is abrogated207. Studies in which 
dnTGFβRII transgenic mice were inoculated i.v. with the poorly immunogenic D5-
B16BL/6 melanoma demonstrated that TGFβ is critical for the creation of tumour-
associated induced Treg which in turn suppress anti-tumour T cell function236. 
    A mAb that neutralises TGFβ (1D11) 210 has shown some effectiveness in 
enhancing anti-tumour responses which are further augmented by the addition of IL-2237. 
However, anti-TGFβ antibody alone does not inhibit the growth of the BL-6 derived lung 
epithelial cell line but anti-TGFβ does enhance tumour vaccination with a combination of 
antigen, hepatitis B virus core class II helper peptide, GMCSF and incomplete freunds 
adjuvant238 indicating that TGFβ is involved in the suppression of the immune responses 
needed for anti-tumour responses. 
    Both dnTGFβRII transgenic mice and 1D11 mAb were used in this study to test the 
importance of TGFβ for the growth of MB49 tumours.   The results of these experiments 
are shown in Section 3.2.3.5.  
 
3.1.3.3 IFNγ 
  
IFNγ, a signature cytokine for Th1 cells, plays a critical role in anti-tumour immunity197-199; 
Neutralisation of IFNγ with the mAb R46/A2 inhibits anti-viral and anti-tumour 
responses100. The R46/A2 antibody was used in this study to test the importance of IFNγ in 
the progress of MB49 tumours.   Results are shown in Section 3.2.3.2 
 
3.1.3.4 IL-15 
 
IL-15 is a pleiotropic cytokine that influences both the innate and adaptive immune 
response. IL-15 plays an important role in the differentiation and survival of NK cells and 
memory CD8 T cells. IL-15 stimulates DC maturation and NK and CD8 T cell cytotoxity94, 
95. IL-15 promotes the survival and expansion of CD8 T cells66, 93 and has been implicated 
in enhancing the efficacy of adoptively transferred CD8 T cells167, 169.  IL-15 has also been 
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implicated in the de novo generation of Treg whilst simultaneously abrogating the effect of 
Treg on CD4 and CD8 T cell effector function. Together these effects of IL-15 may allow 
rapid but transient responses against pathogens96.   
    Taking advantage of the availability of human IL-15 (hIL-15) transgenic (Tg) 
mice193 this study investigated the effect of exogenous IL-15 on the development of the 
MB49 tumour. The results of these investigations are shown in Section 3.2.3.3.   
 
3.1.3.5 IL-17 
 
There is intense debate over whether IL-17 is pro- or anti-tumour, as reviewed by Gopal 
Murugaiyan and Bhaskar Saha194: IL-17 promotes cytotoxic T cells which leads to tumour 
regression, however, IL-17 also promotes angiogenesis and metastasis which leads to 
tumour growth. Tumour growth leads to hypoxia within the tumour and this stimulates 
increased angiogenesis which in turn supplies more oxygen and nutrients to the tumour. 
The enlarged intra-tumour vasculature leads to increased metastasis of tumour cells out of 
the tumour but it also allows immune cells to infiltrate into the tumour which may enhance 
tumour rejection. 
    The majority of IL-17 is derived from Th17 CD4 T cells that secrete IL-17 under 
the influence of the transcription factor Rorγt239 and are generated by the combined actions 
of TGFβ and IL-6240.   The frequency of Th17 T cells is increased in several different 
forms of cancer241, 242 and indeed the tumour microenvironment is a source of cytokines, 
including IL-6, IL-21, IL-23, and TGFβ243, 244, that drive Th17 differentiation. 
    IL-17A KO195 mice (on a C57BL/6 background) were used, in this study, to 
understand whether or not IL-17 is important to the growth of the MB49 tumour in vivo. 
IL-17A KO mice have previously been shown to be more resistant than wild type control 
to the MC38 tumour196.  
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3.2 : Results 
 
3.2.1 :  MB49 
 
    Since a prolonged in vitro culture of MB49 cells could lead to loss of the Y 
chromosome, these cells were examined, for the expression of HY genes, by RT-PCR:  HY 
gene expression was tested by isolating RNA from either MB49 cells or freshly isolated 
female B6 splenocytes (as internal negative controls). RNA was amplified by RT-PCR 
using primers specific for Uty, Smcy, Dby and HPRT genes. As shown in Figure 1A, Uty, 
Smcy and Dby genes were clearly present in MB49 cells but not in female B6 spleen cells, 
indicating that MB49 cells constitutively express all three HY genes encoding the T cell 
epitopes of interest.  
    As mentioned in the introduction to this chapter, it has been suggested that 
cultured tumour cell lines may change their phenotypes after developing into tumours in 
vivo, therefore it was necessary to determine whether the phenotype of MB49 changes in 
vivo. To this end, in vitro long term cultured MB49 cells and the cells from an MB49 
tumour, freshly isolated from a female C57BL/6 mouse, were analysed for cell surface 
expression of MHC-I (Db and Kb), -II (Ab), CD40, CD80 and CD86 molecules. 
    In vitro cultured MB49 cells expressed a high level of MHC-I, Db and Kb, but little, 
if any, MHC-II, Ab, they were positive for CD40 but negative for CD80 and CD86 (Figure 
1B). 
    Ex vivo MB49 cells were isolated from one female mouse 30 days after s.c. 
inoculation of 5x105 MB49 cells. Tumours were dissected and digested with collagenase 
before staining with antibodies. As shown in Figure 1C, the freshly isolated MB49 cells 
were found to up-regulate Ab but down-regulate Db and Kb molecules, in comparison to 
cultured MB49 cells. Furthermore, fresh isolated MB49 cells had increased CD40, CD80 
and CD86 expression (Figure 1C) compared to cultured MB49 cells. 
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Figure 1. Characterization of the phenotype of MB49 cells 
A) Expression of HY genes by cultured MB49 cells. RNA was isolated from cultured 
MB49 cells and female B6 splenocytes and was amplified by RT- PCR using primers 
specific for Uty, Smcy, Dby and HPRT genes. PCR products were analysed on a 1% 
Agarose gel. B and C) Analysis of expression of MHC and co-stimulatory molecules by 
fresh and cultured MB49 cells. Cultured (B) or ex-vivo(C) MB49 cells were stained with 
PE- or FITC- conjugated antibodies ( ) or isotype controls ( ) and analysed by 
FACS for the expression of MHC Class I (Db and Kb), Class II (Ab), co-stimulatory 
molecules (CD40, CD80 and CD86). 
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Two years after the experiments presented in Figure 1C were conducted,  the phenotype of 
ex vivo MB49 was analysed again with two modifications:  Firstly, CD45 was introduced 
as a marker to distinguish tumour cells from tumour-infiltrating lymphocytes; CD45, a 
lymphocyte common antigen245, is not expressed by MB49 cells which are of epithelial 
origin215. Secondly, more markers were analysed because other co-stimulatory molecules 
and chemokine receptors had become of interest to this study.  
    As shown in Figure 2, the freshly isolated MB49 cells were found to be positive for 
Db and Kb. Ex vivo MB49 expressed a significantly higher level of CCR9 compared to the 
four other chemokine receptors tested, which were expressed at only very low levels. In 
addition, ex vivo MB49 tumour cells expressed PD-L1 and PD-L2 but a higher level of PD-
L1 than PD-L2. 4-1-BB was not expressed, CD86 was expressed at very low levels and 
levels of GITR-L were low and varied between the two tumour cells analysed.  
 
Figure 2. Ex vivo MB49 Cell surface markers. 
MB49 cells (5x105) were s.c. injected to two C57BL/6 female mice. 20 days later, MB49 
cells from two tumours were isolated and digested with collagenase before staining with 
anti-CD45FITC and PE-conjugated antibodies against respective cell surface markers. 
CD45-negative and -intermediated cells were gated and analysed for cell surface marker 
expression. Isotype control tumour 1 ( ) and tumour 2 ( ), PE-conjugated stained 
tumour 1 ( ) and tumour 2 ( ). Inserted numbers in each histogram represent mean 
fluorescent intensity (MFI). 
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3.2.2 :  T cell responses to MB49/HY 
 
3.2.2.1 Growth of MB49 tumour in C57BL/6 mice 
 
It has been previously described that s.c. inoculation of MB49 cells at doses of 7x105 and 
1x106 produced a progressive solid tumour in female C57BL/6 mice 189. To establish a 
dose of MB49 cells that would be relevant to this study we titrated the dose of MB49 cells. 
To this end,  1x105, 3x105, 6x105 or 1x106 MB49 cells were injected s.c. to the right lateral 
flank of female C57BL/6. Tumours became visible as small lumps after 3-5 days and after 
that were measured every other day, where possible, until the mouse had to be culled for 
ethical reasons as stipulated by the project licence. With a low dose of MB49 cells (1x105 
cells/mouse), 60% mice developed tumours which were smaller and grew relatively slowly 
(Figure 3A). With an intermediate dose of MB49 cells (3x105 cells/mouse), up to 80% 
mice developed tumours which were bigger and grew faster (Figure 3B). With a high dose 
of MB49 cells (6x105 and 1x106 cells/mouse), 100% mice rapidly developed tumours 
which were very aggressive, some tumour-bearing mice had to be culled at an early stage 
due to tumour ulceration, which is one of the end-points of the experiments under our 
licence (Figure 3C and D). 
 68 
 
Figure 3. Investigation of growth characteristics of MB49 tumours in 
C57BL/6 female mice.   
Female B6 mice were injected s.c. with 1x105(A), 3x105(B), 6x105(C) or 1x106(D) MB49 
cells. Tumour area was measured at regular intervals, each line represents an individual 
mouse.  
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 Although HY has been used as a surrogate tumour antigen on MB49 cells, they 
may also express other unknown tumour antigens. To determine the relative importance 
and contribution of HY antigens to anti-MB49 T cell responses, the growth characteristics 
of MB49 tumours in B6 female and male mice was compared. Due to central and 
peripheral self-tolerance mechanisms, T cells with HY specificity are absent in the male 
recipients of MB49 cells, although T cell responses against other unknown MB49 antigens 
are present. In contrast, female mice harbour normal T cell repertoires against HY and 
other unidentified tumour antigens expressed by MB49 tumours. 
    To test the immunogenicity of the MB49 tumours, 1x105 and 6x105 MB49 cells 
were injected s.c. to male and female C57BL/6 mice, respectively. As shown in Figure 4, 
at a dose of 6x105, MB49 tumours grew faster which led to an earlier mortality in male 
(mean survival time =12.7d) when compared to female (mean survival time = 22.8d) mice. 
When the dose of MB49 cells was reduced to 1x105, the difference in terms of mean 
survival time (MST) between female and male groups appears to become smaller (20.3 vs. 
29.3) (Figure 4B).  
    The correlation between the presence of HY-specific T cells and prolonged survival 
of tumour-bearing mice indicated that anti-HY T cell responses contribute to control of 
MB49 tumour in vivo.  
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Figure 4. Testing immunogenicity of MB49 cells 
A and C) Female ( , n = 3) or male C57BL/6 mice ( , n = 4) were injected s.c. with 
1x105 MB49 cells. B and D) Female ( , n = 6) or male C57BL/6 mice ( , n = 3) were 
injected s.c. with 6x105 MB49 cells. Tumour area was measured at regular intervals. 
Results are presented as tumour growth (A and B) and percent survival (C and D).  
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3.2.2.2 Antigen presenting cells associated with MB49 tumours 
 
It has been indicated that tumour-derived antigens are persistent in tumour-dLN however, 
the relative contribution by DC, B cells and macrophages, three individual APC subsets, to 
antigen presentation has not previously been explored in great detail. To test antigen 
presentation by DC, B cells and macrophages in the tumour-dLN during the course of 
tumour growth, three groups of B6 females (two mice/group) were injected s.c. with 5 x 
105 MB49 on days -24, -17 or -10. A group of naïve female C57BL/6 was used as a control.  
On day 0, CD11c+ DCs were purified by MACS from tumour-dLN (See Materials and 
Methods for more details). Purified DCs were then incubated with resting Marilyn CD4+ T 
cells (4x105/well), purified from Rag-/- Marilyn females by MACS positive selection. Co-
cultures were incubated for four days and proliferation was measured using a tritiated 
thymidine incorporation assay.  
    Marilyn CD4 T cells did not produce a significant response against DCs from 
control mice, however they responded vigorously to DCs isolated from MB49-bearing 
mice. A peak CD4 response was seen against DCs isolated from tumour-dLN 17 days after 
tumour inoculation (Figure 5A).  
    To directly compare antigen presentation abilities of B cells, macrophages and DCs, 
individual APC populations were isolated from MB49-dLN of female C57BL/6 mice that 
had been given 5 x 105 MB49 cells s.c. 17 days previously. 1 x 105 purified B cells, 
macrophages or DC were cultured with Marilyn CD4+ T cells, as described in Figure 6A.  
    CD11c+ DCs were significantly more potent at stimulating Marilyn T cells 
(p<0.0005) than either macrophages or B cells (Figure 5B), suggesting that they are the 
most effective APC in the tumour dLNs of MB49 bearing mice.  
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Figure 5. MB49-Dby-Ab antigen presentation by APC subsets  
A) On day 0, CD11c+ cells were isolated from the tumour draining LN of three groups of 
female C57BL/6 mice that were given 5 x 105 MB49 cells s.c. on day -24, -17 or -10. 
CD11c+ cells (1x105/well) were then co-cultured with purified Marilyn CD4+ T cells 
(4x105/well) for 3 days in a 96 well U-bottomed plate. Tritiated thymidine (0.5  μCi/well) 
was added on day 3 and proliferation was evaluated 24 hours later as counts per minute 
(CPM). The results are presented as mean ±SD.  
B) CD11c+( ), CD11b+( ) or B220+( ) APC were isolated from female C57BL/6  that 
were given 5 x 105 MB49 cells s.c. on day -17 and cultured with Marilyn CD4+ T cells as 
described above. The results are presented as mean ±SD. CD11b+( ) vs. CD11c+( ),   
** (p<0.0005). CD11c+( ) vs. B220+( )  *** (p<0.0005).  
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3.2.2.3 Role of CD4 and CD8 effector T cells in MB49 rejection 
 
Previous studies have demonstrated that Marilyn CD4 and MataHari CD8 T cells recognise 
MB49-derived HY antigen in vivo but only Marilyn CD4 T cells can cause MB49 tumour 
rejection178. Generally, CD8 T cells are the major effector cells for killing tumour cells but 
they require help from CD4 T cells. To examine the relative importance of polyclonal CD4 
and CD8 T cells in B6 females, to the rejection of MB49 tumours, an in vivo T cell 
depletion strategy was developed:  Female C57BL/6 mice were depleted of CD4, or CD8, 
or both populations using a single i.p. injection of 1 mg of depleting monoclonal antibodies 
(clones YTS 191213 for CD8; YTS 169212 for CD4). These clones recognise the distinct 
epitopes of respective target molecules which results in an efficient and a long lasting 
depletion in vivo. Three days after T cell depletion, the mice were injected s.c. with 2x104 
MB49 cells, which represents a sub-optimal dose of inoculation (i.e., under this dose, the 
injected MB49 cells do not develop into tumours in naïve B6 females, but do in Rag-/- B6 
mice). Tumour area was then measured at regular intervals.  
The depletion of CD4 or CD8 T cells abrogates the immune resistance to MB49 
tumours and results in faster tumour growth and earlier mortality in comparison to control 
mice which received no mAb (Figure 6). However, there is no significant difference in 
terms of MST between anti-CD4-treated (MST=34 days) and anti-CD8-treated groups 
(MST=33.8 days), suggesting that both cell types play an equally important role in 
controlling tumour growth. Depletion of both CD4 and CD8 T cells had a synergistic effect, 
resulting in faster MB49 growth and reduced survival (MST= 29.3 days) than either CD4 
or CD8 depletion alone (Figure 6).    
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Figure 6. Effect of in vivo depletion of T cell subsets in MB49-bearing mice  
A) 2 x 104 MB49 cells were injected s.c. to four groups of female C57BL/6 mice that had 
been treated with anti-CD4 ( , n=7), anti-CD8 ( , n=7), or both antibodies ( , n=6) i.p. 
on day -3 or untreated ( , n=6). A) Tumour area was measured, results are presented as 
mean ± SEM.***p<0.0001. 
B) MB49 progression was presented as % survival. The s.c. inoculation of B6 mice with 
MB49 cells does not lead to death. But the mice are recoded as death once they reach one 
of following end points of experiment. One is the maximum of sixe 14 mm x 14mm, the 
other is the development of severe ulceration by tumour. The mean survival time (MST) of 
individual groups was also indicated. 
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 Depletion of CD4 or CD8 T cells abrogates anti-tumour responses which reiterates 
their critical role in the endogenous immune response by female C57BL/6 mice against 
HY expressing MB49 tumours. To further explore cellular events during the course of 
endogenous T cell responses, tumour dLN and non-draining lymph nodes (ndLN) from 
C57BL/6 mice with 7, 13 or 21 day-old tumours, or control LN from naïve female 
C57BL/6 mice were harvested and counted using a haemocytometer.  In addition, for flow 
cytometric analysis, single cell suspensions were stained with anti-CD4FITC and anti-TCRPE 
for CD4+ T cells, anti-CD8PerCP and anti-TCRPE for CD8+ T cells, and anti-CD4PE and anti-
FoxP3FITC for regulatory T cells (Treg). The number of each cell type was calculated by 
multiplying the number of cells counted and the percentage of cells in the FSC:SSC 
lymphocyte gate and the percentage of cells in the CD4, CD8 or Treg populations. 
    The total number of lymphocytes was significantly higher in tumour-dLN than that 
in tumour-ndLN and control LN (p = 0.05) from naive mice at all three time points tested.  
On day 7 the number of lymphocytes in the tumour dLN was three times higher than in 
non-draining lymph nodes (6.1 x 106 for dLN compared to 2.1 x 106 for ndLN), suggesting 
that there is local tumour-antigen dependent T cell expansion (Figure 7A). 
  On day 7 the numbers of CD4 and CD8 T cells were increased in tumour dLN compared 
to non-draining and naïve lymph nodes. The number of CD4 T cells increased by at least 
1.4 times, from 600 x 103 in naïve lymph nodes and 677 x 103 in non-draining lymph 
nodes to 930 x 103 in tumour dLN (Figure 7B). 
 The number of CD8 T cells increased by more than 1.4 times from 475 x 103 in 
naïve lymph nodes and 672 x 103 in non draining lymph nodes to 968 x 103 in tumour-dLN 
(Figure 7C).   
   Regulatory T cell numbers were also increased in tumour dLN, on day 7, by at least 1.4 
fold, from 72 x 103 in naïve lymph nodes and 108 x 103 in non draining lymph nodes to150 
x 103 in tumour dLN (Figure 7D). 
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Figure 7. Representation of T cell subsets in the dLN of MB49 bearing female 
C57BL/6 
Female C57BL/6 were injected s.c. with 5 x 105 MB49 cells on day 0. On day 7 ( , n=2), day 13 ( , n=2) 
and day 21 ( , n=2) peripheral lymph nodes from naïve mice and tumour draining lymph nodes (dLN) or 
non-draining lymph nodes (ndLN) from MB49 bearing mice were isolated and the number of cells/lymph 
node were counted. Cells were then stained and analysed by FACS. 
A) Total lymphocyte number was calculated by multiplying the number of cells counted by the percentage of 
cells in the lymphocyte gate. Results are presented as mean (± SD). Day 7 naïve vs. day 7 dLN * p = 0.05  
B) LN were stained with anti-CD4FITC and anti-TCRPE. The number of CD4+ T cells was calculated by 
multiplying the number of cells, the percentage of cells in the lymphocyte gate and the percentage of cells in 
the CD4+TCR+ population. Results are presented as mean (± SD)   
C) LN were stained with anti-CD8PerCP and anti-TCRPE. The number of CD8+ T cells was calculated by 
multiplying the number of cells, the percentage of cells in the lymphocyte gate and the percentage of cells in 
the CD8+TCR+ population. Results are presented as mean (± SD)   
D) LN were stained with anti-CD4PE then fixed and permeabilised and stained with anti-FoxP3FITC. The 
number of Treg was calculated by multiplying the number of cells, the percentage of cells in the lymphocyte 
gate and the percentage of cells in the CD4+FoxP3+ population. Results are presented as mean (± SD) 
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 The analysis of T cell infiltration into the tumour mass requires the ability to 
distinguish host cells from tumour cells. We decided to take advantage of the availability 
of enhanced Yellow Fluorescent Protein (eYFP)-transgenic C57BL/6 mice, which 
constitutively express YFP in all cells, allowing “yellow” host cells to be distinguished 
from MB49 tumour cells by flow cytometry and by fluorescent microscopy. 5 x 105 MB49 
cells were injected s.c. into female eYFP-transgenic C57BL/6 mice. 15 days later, tumours 
were isolated and single cell suspensions were stained for anti-TCRPE and anti-CD4PerCP or 
anti-CD8PerCP. Tumour-infiltrating CD4 and CD8 T cells were detected by gating on YFP+ 
lymphocytes then analysing the proportions of CD4+TCR+ and CD8+TCR+ T cells. CD4+ T 
cells accounted for 6% and CD8+ T cells accounted for 5% of the total number of cells in 
the tumour (Figure 8A).   
    To verify the above results, tissue sections from the same tumour were stained with 
DAPI and anti-CD3PE before being analysed by deconvolution microscopy. As shown in 
Figure 8B, DAPI+YFP+ cells represented the host cells within the tumour whereas MB49 
tumour cells were DAPI+YFP-. CD3+ T cells were present at high numbers in the 
surrounding host tissue but at lower numbers within centre of the tumour, indicating that 
there is a limited infiltration. 
 
 
 78 
 
Figure 8. Detection of tumour-infiltrating CD4 and CD8 T cells by FACS and 
microscopy 
A) 5 x 105 MB49 cells were injected s.c. to 4 YFP+ female C57BL/6 mice. 15 days later, 
tumour was isolated and stained with anti-TCRPE and either anti-CD4PerCP or anti-CD8PerCP. 
The proportion of TCR+CD4+ or TCR+CD8+ T cells as the percentage of all tumour-
infiltrating cells was determined by FACS analysis.     
B and C) 5 x 105 MB49 cells were injected s.c. to a YFP+ female C57BL/6 mouse. 15 days 
later, whole tumour was isolated and embedded in OCT then flash frozen in liquid nitrogen. 
Sections were cut and stained with DAPI and anti-CD3PE (B) or isotype control (C) The 
host CD3+ T cells are stained red, the non-T lymphocyte host cells green and tumour cells 
blue. 
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 As MB49 tumours naturally express male antigens178, 189 it was of interest to test if 
tumour rejection is dominated by anti-HY T cell responses, which can be measured by 
HY-specific tetramers185. To detect tetramer+CD8+ T cell responses, female C57BL/6 mice 
were injected s.c. with 5 x 105 MB49 cells. Tumour-dLN were then harvested at day 6, 10, 
19 and 24. Single cell suspensions were stained with Db-UtyPE and Db-SmcyAPC tetramers 
and anti-CD8PerCP and analysed by flow cytometry. No detectable levels of tetramer+CD8+ 
T cells were found at any of the time points tested (Figure 9), indicating that systemic HY 
specific CD8 cell activation did not occur during the course of the primary response to the 
tumour. 
 
 
Figure 9. The failure of the induction of HY-specific tetramer+ cells in MB49-
bearing mice 
Draining lymph nodes were harvested from female C57BL/6 mice that had been injected 
s.c. with 5 x 105 MB49 cells and stained with Db-SmcyPE, anti-CD8PerCP and Db-UtyAPC 
then analysed by FACS. Representative dot plots shown were from three independent 
experiments. Smcy tetramer data not shown.   
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3.2.2.4 Role of regulatory T cells in MB49 rejection 
 
Studies in mice have demonstrated that in vivo Treg depletion, using PC61 (an anti-CD25 
antibody), enhances tumour rejection 125, 147, 222. To test whether this is the case in the 
MB49 system, female C57BL/6 mice were depleted of CD4+ or CD25+ T cells 3 days 
before being inoculated s.c. with a sub-optimal dose of MB49 (2 x 104 MB49 cells). 
Tumour size and survival were measured.   
   Untreated mice quickly rejected tumours.  Mice depleted of CD4+ T cells 
developed tumours more rapidly and had a shorter mean survival time, than mice depleted 
of CD25+ T cells; 34 days vs. 37.3 days respectively (Figure 10). Contrary to published 
results and predictions, depletion of CD25+ T cells caused increased tumour growth and 
decreased survival compared to untreated controls. 
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Figure 10. The impact of depletion of Tregs to MB49 growth in vivo 
2 x 104 MB49 cells were injected s.c. to female C57BL/6 mice that had been treated with 
anti-CD4 ( , n=7) or anti-CD25 ( , n=7) i.p. on day -3 or untreated ( , n=6). 
A) Tumour area was measured, results are presented as mean ± SEM. ( , anti-CD4 vs. , 
untreated; *** p < 0.001, , anti-CD25 vs. , untreated; ** p < 0.001). 
B) MB49 progression was presented as % survival. The s.c. inoculation of B6 mice with 
MB49 cells does not lead to death. But the mice are recorded as dead once they reach one 
of following end points of experiment. One is the maximum of sixe 14 mm x 14mm, the 
other is the development of severe ulceration by tumour. The mean survival time (MST) of 
individual groups was also indicated.  
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3.2.3 : Role of immuno-regulatory cytokines in MB49 rejection 
 
3.2.3.1 IL-10 
To test the role of IL-10 in the MB49 system, two strategies were employed. Firstly, IL-10 
KO or wild type (WT) female C57BL/6 mice were injected s.c. with 5 x 105 MB49 cells 
and the kinetics of tumour growth compared. Secondly, anti-IL-10R mAb (1B1) was 
injected i.p. to one group of tumour-bearing WT mice and tumour growth was compared to 
untreated controls.  
    Wild type mice were significantly better at controlling tumour growth when 
compared to IL-10 KO mice (p = 0.04) (Figure 11A). Moreover untreated WT female 
C57BL/6 mice were significantly better at controlling MB49 tumours than mice treated 
with an IL-10R blocking antibody (p = 0.01) (Figure 11B).  
    Together these results agree with the reports (described earlier) that suggest that IL-
10 is important for tumour rejection however, the exact causes for the anti-tumour effect of 
IL-10 in this system have not been tested.  
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Figure 11. Contribution of IL-10 to MB49 growth in vivo. 
 A) Wild type ( , n=4) or IL-10 KO ( , n=4) female B6 mice were injected s.c. with 
5x105 MB49 cells. Tumour area was measured at regular intervals, results are presented as 
mean ±SD. * p=0.04.  
 B) Wild type female B6 were injected s.c. with 5x105 MB49 cells then one group was 
injected i.p. with anti-IL-10R ( , n=3) and the other left untreated ( , n=4). Tumour 
area was measured at regular intervals, results are presented as mean ±SD. ** p=0.01 
 
 
 
 84 
3.2.3.2 IFNγ  
 
To test the influence of IFNγ on the growth of MB49, C57BL/6 female mice were divided 
into two groups of six mice; on day 0, a suboptimal dose of 5 x 104 MB49 cells was 
injected s.c. to both groups, one group was then given no further treatment whilst the other 
group was injected i.p. with R46/A2 (an anti-IFN antibody that neutralises IFN-100). on 
days -5, -3, 0, 7, 11, 14 and 18. Tumour progress was monitored by measurement of 
tumour size and mortality.  
    As shown in Figure 13, in vivo neutralisation of IFNγ led to significantly faster 
tumour growth in WT female C57BL/6 mice compared to untreated females (p = <0.001) 
(Figure 12A). Accelerated tumour growth in R46/A2 treated mice correlates with earlier 
mortality (Figure 12B). It was therefore concluded that IFNγ is a critical cytokine in anti-
MB49 immunity.  
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Figure 12. Contribution of IFNγ to MB49 growth 
6 female C57BL/6 mice were treated i.p. with anti-IFNγ ( , n=6) on days -5, -3, 0, 7, 11, 
14 and 18 and 6 mice were untreated ( , n=6). On day 0 all 12 mice were given 5 x 104 
MB49 cells by s.c. inoculation.  
A)Tumour area was measured at regular intervals and results are presented as mean ±SEM. 
*** p<0.001. 
B) MB49 progression was presented as % survival. The s.c. inoculation of B6 mice with 
MB49 cells does not lead to death. But the mice are recoded as death once they reach one 
of following end points of experiment. One is the maximum of sixe 14 mm x 14mm, the 
other is the development of severe ulceration by tumour. The mean survival time (MST) of 
individual groups was also indicated. 
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3.2.3.3 IL-15 
 
The role of IL-15 in the activation and differentiation of CD8 T cells in viral infection is 
well established66, 93. However, less information is available in terms of the role of IL-15 in 
the context of tumour immunity. Taking advantage of the availability of hIL-15 transgenic 
(Tg) mice, the kinetics of MB49 growth in WT versus Tg mice was compared. IL-15-Tg 
and WT mice were injected s.c. with 1 x 105 MB49 cells and tumour size was measured at 
regular intervals. No significant difference was seen between the IL-15-Tg and WT group 
(Figure 13).  
 
Figure 13. Comparison MB49 growth between WT and IL-15 transgenic mice 
IL-15-Tg ( , n=3) or wild type ( , n = 4) female C57BL/6 mice were given 1 x 105 
MB49 cells s.c. Tumour area was measured at regular intervals and results are presented as 
mean ±SD. One representative of three independent experiments is shown.  
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3.2.3.4 IL-17A 
 
To test the effect of IL-17A on the growth of MB49 tumours, we injected 5 x 105 MB49 
cells s.c. to IL-17A KO195 or WT female C57BL/6 mice and measured the growth of the 
tumour. IL-17A KO mice showed a small but still significant acceleration in tumour 
growth (p = 0.038) when compared to wild type mice, suggesting that IL-17 inhibits 
tumour growth.   
 
 
Figure 14. MB49 growth in IL-17A KO mice 
Wild type ( , n=8) or IL-17A KO ( , n=6) female C57BL/6 mice were inoculated s.c. 
with 5x105 MB49 cells. Tumour area was measured and results are presented as mean ±SD  
* p=0.038.   
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3.2.3.5 TGFβ 
 
To examine the role of TGFβ in the MB49 system, two different approaches were 
employed. The first approach was to use the dnTGFRII-Tg mice which express a 
dominate negative form of the TGFβ receptor type II (dnTGFRII) on all T cells. T cells 
from these Tg mice are therefore defective in TGF signalling130. When dnTGFRII-Tg 
mice were challenged with a low dose of MB49 cells (1 x 105), no tumour development 
was seen, although the inoculation of WT mice with the same dose of MB49 cells led to 
tumour growth (Figure 16B), suggesting that dnTGFRII-Tg mice are completely resistant 
to low dose MB49 challenge. 
    On the other hand, dnTGFRII-Tg mice developed tumours at the same rate as WT 
mice when a higher dose (1 x 106) of MB49 cells was injected (Figure 15A).  
    The second approach used to look at the role of TGF in the MB49 system was to 
neutralise TGFβ in vivo. C57BL/6 female mice were injected with 1 x 106 MB49 cells s.c. 
and then, on day 1, 2, 7, 10, 14 and 18, anti-TGFβ neutralising mAb, 1D11210, was injected 
i.p.. Tumour growth in this group was compared to untreated controls. In vivo 
neutralisation of TGFβ had no effect on MB49 growth (Figure 15C).    
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Figure 15. Effect of TGFβ on MB49 growth in vivo 
A) dnTGFβRII-Tg ( , n=7) or wt ( , n=3)  female B6 mice were injected s.c. with 1x106 MB49 
cells. Tumour area was measured, results are presented as mean ± SD. 
B) dnTGFβRII-Tg  ( , n=3) or wt ( , n=6)  female B6 mice were injected s.c. with 1x105 MB49 
cells. Tumour area was measured, results are presented as mean ± SD. ***p=<0.001 
C) Female C57BL/6 mice were injected s.c. with 1x106 MB49 cells on day 0, and then treated i.p. 
with anti-TGFβ ( , n=3) on day 1, 2, 7, 10, 14 and 18 or untreated ( , n=6) Tumour area was 
measured, results are presented as mean ± SD. 
 90 
3.3 : Discussion 
 
MB49 is a chemically induced murine bladder carcinoma that naturally expresses HY 
antigens. Since a prolonged in vitro culture could lead to loss of the Y chromosome, MB49 
cells were examined for the expression of HY genes by RT-PCR. Dby, Smcy and Uty genes 
were readily detectable in MB49 cells (Figure 1A.), thus confirming the published 
results178, 189, 190, 215. In agreement with other reports MB49 expresses class I MHC 
molecules Db and Kb, MB49 doesn‟t express class II MHC, Ab in vitro 178, 246(Figure 1B).  
    It was interesting to discover that MB49 cells down regulate MHC I and up 
regulate MHC II after being passaged in vivo. Studies have suggested that MB49 cells up 
regulate Ab after exposure to IFNγ in vitro and in vivo178, 246 but there have been no reports 
demonstrating the down regulation of Db and Kb. In fact exposure to IFNγ has been shown 
to up regulate Db and Kb on MB49 cells178. It is possible that this is an immuno-regulatory 
mechanism and that MHC Class I- cells are selected because of an on going immune 
response to the tumour. 
    There are no published results examining the expression of co-stimulatory receptors 
on MB49 cells ex vivo and so it was of great interest to demonstrate the expression of 
PDL-1 and PDL-2 on the surface of MB49 cells (Figure 2). MB49 can be added to the list 
of murine tumours and cell lines that express PDL-1142 and may be useful in studying the 
effects of the PDL-1/PD-1 signalling pathway to tumour progression141.   
  The growth of MB49 tumours after inoculation with varying cell numbers closely 
resembled what has already been published189, 190, with 6 x 105 and 1 x 106 MB49 cells 
causing a progressively growing tumour. Whereas 3 x 105 and 1 x 105 MB49 cells caused 
tumours in only 20% and 40% of female C57BL/6 mice respectively (Figure 3). 
    The growth of MB49 tumours was inhibited in female C57BL/6 but not male 
C57BL/6 suggesting that previous reports demonstrating a immune response to the HY 
antigen are correct178, 190, 219 (Figure 4).   
    CD11c+ cells in tumour dLN display major histocompatibility/HY peptide 
complexes and therefore are likely to be the primary APC subset involved in antigen-
derived expansion of T cells. Although tumour antigens persist in the dLN of tumour-
bearing mice247 it has not been investigated which population of APC are involved in 
antigen presentation. 
 This study provides direct evidence for the role of CD11c+ cells (Figure 5) in the 
presentation of tumour antigen in the tumour dLN. Although the MB49 cell line does not 
express H2Ab in vitro it has shown that freshly isolated MB49 tumour cells do178.  This 
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raises the possibility of direct antigen presentation by tumour cells to CD4 T cells. 
Whether freshly isolated MB49 tumour cells would be able to stimulate Marilyn CD4 T 
cells in the presence of interleukin-2 in vitro has not been investigated.   
    Depletion of CD4 and CD8 T cells caused an increase in the growth of MB49 
tumours as well as leading to a related reduction in survival (Figure 6). There was no 
significant difference between the effects of depleting CD4, CD8 or both subsets of T cells 
suggesting that they are equally important in controlling the MB49 tumour. 
    The numbers of Lymphocytes, CD4 and CD8 T cells are elevated in the tumour 
dLN of MB49 bearing mice. The numbers of all cells peaks at day 7.  
    The number of FoxP3+ regulatory T cells (Treg) is higher in the MB49 dLN than in 
the ndLN and pLN of control mice. Unlike other T cells, Treg numbers did not decrease 
over time and were as high on day 21 as they were on day 7 (Figure 7).  
This result is consistent with previous reports demonstrating increased Treg 
frequency in the tumour dLN of mice248 and humans128. The consistent number of Treg 
over the course of 21 days may suggests that dying cells or cells that are moving out of the 
dLN are being replaced by fresh natural Treg or the conversion of conventional CD4 T 
cells to induced Treg. It has been demonstrated that cytokines (e.g. TGFβ) and inhibitory 
molecules in the tumour microenvironment cause iTreg conversion249.  
    To analyse whether T cells were not only expanded in the tumour dLN but were 
also infiltrating into the tumour itself we made use of YFP+ C57BL/6 female mice which 
constitutively expresses the YFP protein in all cells. By staining MB49 tumour sections 
with anti-CD3PE and DAPI it was possible to distinguish between tumour tissue, host tissue 
and lymphocytes. MB49 tumour tissue was found to be infiltrated by CD3+ T cells (Figure 
8B). These results were confirmed by FACS that showed that CD4 and CD8 T cells 
represented 6% and 5% of the total number of cells in the tumour respectively (Figure 8A).  
    Despite having increased levels of CD8 T cells in the tumour dLN and showing 
signs of tumour infiltrating T cells the tumour dLN and peripheral blood did not contain 
any tetramer positive CD8 T cells (Figure 9). This result is in agreement with a previous 
study that also found low to undetectable frequencies of Uty-tetramer+ CD8 T cells in 
MB49 bearing mice219. 
 Together the observations, that there are CD4 and CD8 T cells infiltrating the 
tumour and that there is T cell expansion in the tumour dLN, but no systemic CD8 HY 
response or tumour rejection, leads to the conclusion that tumour derived factors are 
causing T cell suppression. Indeed, it has been shown that suppressive CD4 and CD8 T 
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cells can be induced by the tumour microenvironment to secrete TGFβ and IL-10 which 
promotes tumour growth250.  
    Depletion of CD25+ T cells 3 days before MB49 inoculation using the PC61 
antibody leads to increased tumour growth in the depleted mice compared to the controls. 
This result is at odds with the current literature125, 147, 222 and may be an anomaly, depletion 
with PC61 was attempted again in Chapter 4.  
    The contribution of IL-10, IL-15, IL-17, IFNγ and TGFβ to the growth of MB49 
tumours was studied. 
    MB49 tumours in IL-10 KO191 mice were larger and grew faster than in control 
mice (Figure 11), a result that was confirmed when IL-10 signalling was blocked using an 
IL-10R mAb192. Together these results confirm reports that IL-10 inhibits tumour 
growth228-230 but is contradictory to studies using IL-10 KO mice191 and even the IL-10 
blocking mAb192. Although I am confident with the results we have observed I am unsure 
how to explain the apparent contradiction with the results from Halak et al. who also used 
the MB49 tumour and IL-10 KO mice. 
    Neutralisation of IFNγ with the mAb R46/A2100 led to large rapidly growing MB49 
tumours in all mice tested (Figure 12) confirming numerous reports that IFNγ is critical in 
anti-tumour responses197-199. 
    There was no difference in the growth of MB49 in hIL-15 transgenic (Tg) mice193 
which demonstrated that over expression if IL-15 alone is not sufficient to cause MB49 
tumour rejection (Figure 13). The ability of IL-15 Tg mice to reject MB49 tumours is 
discussed in chapter 6.  
    MB49 tumours grew more rapidly and to a larger size in IL-17 KO195 mice (Figure 
14). A result which, in agreement with a study by Kryczek et al.196 which investigated the 
growth of MC38 tumour in IL-17 KO mice, suggests that IL-17 inhibits tumour growth. 
However, this result contradicts a study by Wang et al.251 which shows that the growth of 
MB49 is inhibited in IL-17 KO mice when compared to WT mice, although they do not 
state the dose of MB49 used. It may be that the MB49 dose is critical to the growth of 
MB49 tumour in IL-17 KO mice. However, in support of IL-17 mediated MB49 rejection a 
study by Vokaer et al.252 showed delayed rejection of syngeneic C57BL/6 male skin grafts 
transplanted to female IL-17 KO mice. The debate about IL-17 being pro or anti tumour 
remains open194.   
    In vivo neutralisation of TGFβ did not effect the growth of MB49 tumours when 1 
x 106 MB49 cells were injected s.c. A result that is in agreement with previous reports that 
suggest additional help with IL-2 or vaccination and adjuvant therapy are required to cause 
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tumour rejection after TGFβ neutralisation237, 238. Moreover, dnTGFβRII-Tg mice207 could 
not control MB49 tumours at the same dose. However, dnTGFβRII-Tg mice did 
successfully control a lower dose of 1 x 105 MB49 cells. These results suggest that the 
growth of MB49 tumours is independent of TGFβ mediated immune suppression when 
MB49 is inoculated at high doses, possibly because other immuno-regulatory mechanisms 
become dominant (i.e. IL-10 suppression/PD-L1/2 expression). At low doses of MB49 
tumour, TGFβ signalling is critical to MB49 growth suggesting that the immune system is 
only able to control the tumour if Treg and conventional CD4 and CD8 T cells can respond 
to TGFβ.
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Chapter 4 : Treatment of 
MB49 tumours with 
immuno-modulatory 
monoclonal antibodies 
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4.1 : Introduction 
 
Immunomodulation using monoclonal antibody (mAb) therapy has emerged as a powerful 
tool to treat a variety of diseases, including cancer. The journey to the clinic for mAb 
therapy often starts in murine models. Recent studies in mice have revealed the potent anti-
tumour effect of a mAb against Glucocorticoid-Induced Tumour necrosis factor Receptor 
(GITR), DTA-1. 
GITR is a member of the Tumour Necrosis Factor Receptor (TNFR) family.  It is 
expressed on T lymphocytes with the primary purpose of protecting T cells from 
activation-induced cell death72, 144, 253. Engagement of GITR with DTA-1 mAbs or its 
natural ligand (GITR-L) activates resting T cells and causes up-regulation of CD25, CD69 
and expression of IFNγ, IL-2, IL-4 and high levels of IL-10148. GITR-L is expressed on 
murine B cells, DC and macrophages146. 
    Administration of DTA-1 to mice eliminates established tumours147, 149, 200, 201, 
although it is unclear whether DTA-1 abrogates Treg suppression or activates CD4 and 
CD8 effector cells126.  Under normal conditions, CD4+ CD25+ FoxP3+ regulatory T cells 
(Treg) constitutively express higher levels of GITR than conventional CD4 and CD8 T 
cells145, 254. The outcome of GITR signalling on Treg cells appears to be functional 
inactivation (i.e. abrogation of their inhibitory function)145, 255, whereas ligation of GITR 
on conventional T cells provides a co-stimulatory signal promoting activation148, 256-259.  
 Since ligation of GITR by DTA-1 may disable Treg as well as co-stimulating 
conventional T cells146, 260, DTA-1 is potentially an effective reagent for enhancing T cell 
immunity against tumours 126, 147, 149, 150, 261.   Indeed, the effectiveness of DTA-1 at 
enhancing tumour rejection in murine models is well established, however the mechanisms 
of action of DTA-1 are currently being debated. Studies arguing that DTA-1 abrogates the 
inhibitory ability of Treg cells are based largely on in vitro data145, 254 but, these 
conclusions have been challenged by a more recent study that suggests that the action of 
DTA-1 is to make CD25- T cells resistant to CD25+ Treg mediated inhibition259.    
 It is important to bear in mind that T cell behaviour in vivo cannot always be 
predicted by in vitro analysis, and few studies have addressed the impact of DTA-1 on 
Treg cells in vivo262. Inactivation145, 147, 262, expansion150, and depletion263, or inhibition of 
migration200 of Treg cells are three possible outcomes of GITR ligation by DTA-1 on Treg 
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cells in vivo. Although it has been proposed146 and indicated200, 263 that DTA-1 depletes 
Treg in vivo, this has not yet been formally demonstrated.  
    To investigate the effects of DTA-1 in vivo, several strategies were tested in this 
study.  The results are described below.  
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4.2 : Results 
 
As mentioned above, DTA-1 treatment stimulates resting T cells and may cause 
inactivation145, 147, 262, expansion150, depletion263 or inhibition of migration200 of Tregs. This 
study set out to investigate the mechanisms by which DTA-1 therapy causes tumour 
rejection in the MB49 model. After confirming that the MB49 tumour model could be used 
to analyse the mechanisms of DTA-1 action, the effect of DTA-1 on the proportions of T 
cell subsets, Treg activity and survival and CD8 T cell activity, was examined.  The results 
of these experiments are described below. 
 
4.2.1 : Treatment of established MB49 tumours with DTA-1  
     
 Although administration of DTA-1 monoclonal antibodies (mAb) alone is 
sufficient to cause the rejection of some types of experimental tumours (Meth A and Colon 
26147), this treatment appears to be less effective for other experimental tumours (B16 and 
RENCA147, 150) unless an additional manipulation, such as DNA vaccination149, is also 
included.  This suggests that the efficiency of DTA-1 therapy is dependent on the 
characteristics of the tumour cells used.  
    The efficiency of DTA-1 therapy has not previously been tested in the MB49 
tumour. To assess the susceptibility of MB49 tumours to DTA-1 treatment, 17 female 
C57BL/6 mice were injected s.c. with 5 x 105 MB49 cells on day 0.  These mice were then 
randomly assigned to three different groups which were given either 50μg of DTA-1 by a 
single  i.p. injection on day 3 (n = 4) or day 8 (n = 9) or were left untreated ( n = 4).    
    Growth of MB49 tumours in the untreated group was rapid, reaching an average 
size of greater than 100 mm2 by day 28. In contrast, DTA-1 treatment, on either day 3 or 
day 8, caused a significant reduction in tumour growth (Figure 16A, p < 0.004) and an 
increase in survival (Figure 16B) compared to untreated controls.  Of note, the timing of 
administration of DTA-1 may be important for the anti-tumour response:  mAb treatment 
given 8 days after tumour inoculation appeared to be more effective than mAb treatment 
given 3 days after inoculation; day 3 treated mice had larger tumours (Figure 16A, p = 0.04) 
and reduced survival (Figure 16B, MST; 47.5 days vs. 49.4 days) compared to the mice 
treated on day 8.    
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 These data confirmed that the DTA-1 antibody was able to effect rejection of 
MB49 tumours and thus this system could be used to further investigate the mechanisms of 
DTA-1 mediated tumour rejection. 
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Figure 16. DTA-1 effectively treats MB49 tumours 
 A) A total of 17 B6 female mice were injected with 5 x 105 MB49 cells s.c. Mice were randomly 
divided into three groups: one was treated with 50 μg of DTA-1 i.p. on day 3 ( , n = 4), one on 
day 8 ( , n = 9) the other group was not treated ( , n = 4). Tumour area was measured, the 
results are presented as the mean ± SD. *** p < 0.004 ( control,  vs. day 8, ), * p = 0.04 ( day 
3,   vs. day 8, ).  
 B) MB49 progression is presented as % survival. The s.c. inoculation of B6 mice with MB49 cells 
does not lead to death. But the mice are recoded as death once they reach one of following end 
points of experiment. One is the maximum of sixe 14 mm x 14mm, the other is the development of 
severe ulceration by tumour. The mean survival time (MST) of individual groups was also 
indicated. One representative of three independent experiments is shown. 
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4.2.2 : The effect of DTA-1 on the proportions of T cell subsets  
  
The proportions of T cell subsets were analysed, in mice treated with DTA-1, to see if 
DTA-1 caused any significant changes, in these populations, which could explain the anti-
tumour effect of DTA-1.  Naïve female C57BL/6 mice were injected i.p. with 50μg of 
DTA-1 or an isotype control antibody (GL113) and after 5 days, peripheral blood was 
collected from the lateral tail vein and depleted of RBCs, before staining with anti-
FoxP3FITC, anti-CD8PerCP and anti-CD4APC. The percentage of CD4+ CD8+, and 
CD4+FoxP3+ T cells in the peripheral blood lymphocytes (PBL) was analysed by flow 
cytometry. The second analysis was carried out on day 11 but peripheral LN cells, rather 
than PBL, were analysed.   
   The proportion of CD4, CD8 T cells and Treg cells did not change significantly in 
the peripheral LNs of mice treated with DTA-1 (Figure 17B),  however there was a 
noticeable, but not significant, reduction in the percentage of Treg (from 8% to 6%), in the 
blood of DTA-1 treated mice (Figure 17A).   
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Figure 17. Effect of DTA-1 treatment on T lymphocyte populations and 
subsets.   
 A) Female C57BL/6 mice (n=2) were injected with DTA-1 or GL113 i.p., 5 days later 
PBL was taken and depleted of red blood cells and stained with anti-FoxP3FITC, anti-
CD8PerCP and anti-CD4APC. The percentages of CD4+ ( ), CD8+ ( ) and CD4+Foxp3+ T 
cells ( ) as a fraction of the total lymphocyte population are presented.  
B) Peripheral lymph nodes (pLN) from the same mice as described in A, were taken 11 
days after DTA-1 or GL113 treatment and stained with anti-FoxP3FITC, anti-CD8PerCP and 
anti-CD4APC. The percentages of CD4+ T cells ( ), CD8+ T cells ( ) and Treg ( ) as a 
fraction of the total lymphocyte population are presented. 
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4.2.3 : The effect of DTA-1 on Treg activity 
 
DTA-1-mediated GITR signalling on Treg cells abrogates their suppressive activities in 
vitro
145, 254. However, because T cell behaviour in vivo cannot be predicted by analysing in 
vitro T cell co-cultures, we evaluated the inhibitory capacities of Treg cells isolated ex vivo 
from either untreated or DTA-1-treated mice, one day after DTA-1 administration. In a 
preliminary experiment we injected anti-GITRPE i.v. to a female GFP-FoxP3 C57BL/6 
mouse and were able to demonstrate that CD4+GFP+ Treg preferentially bound anti-GITR 
for up to 2 days264. In a standard in vitro suppression assay, Treg cells isolated from DTA-
1-treated mice were as potent as those from untreated mice at inhibiting the response of 
conventional CD4 T cells (isolated from untreated mice) to anti-CD3 stimulation (Figure 
18). Likewise, Treg cells from control antibody (GL113)-treated mice showed similar 
suppressive activity to those from untreated or DTA-1-treated mice (data not shown). Thus, 
activation of GITR signalling on Treg cells in vivo does not lead to their functional 
inactivation.  This suggests that there are additional interactions occurring in vivo, to 
maintain the Tregs suppressive activities or abrogate the inhibiting effect of DTA-1, that 
do not occur in the in vitro assays described in other studies145, 254. The results of this study 
are consistent with the findings of Ramirez-Montagut et al.150. 
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Figure 18. Normal suppressive function of Treg cells from DTA-1 treated 
mice. 
Two groups of B6 mice (3 mice/group) were untreated or treated with anti-GITR by i.p. 
injection of 50 μg of DTA-1. 24 h later, Treg (CD4+CD25+) and conventional CD4 T cells 
(CD4+CD25-) were purified from pooled LN and spleen cells by FACS sorting. 
Conventional CD4 T cells (1 x 105/well) from the untreated group were cultured with anti-
CD3 (0.05 μg/ml) and accessory cells (T cell-depleted and irradiated B6 spleen cells, 
2 x 105/well) in the absence ( ) or presence of two times serially diluted Treg (from 1 x 
105/well to 780 /well) from either untreated ( ) or DTA-1-treated mice ( ) in 96-round 
bottomed plates for 3 days. Tritiated thymidine (0.5  μCi/well) was added to each well for 
the last 12 h. One representative of two independent experiments is shown.  
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4.2.4 : The effect of DTA-1 on Treg survival 
 
Treg cells constitutively express higher levels of GITR than conventional T cells.  It is 
thought that this may make them susceptible to deletion. To determine the effect of DTA-1 
on Treg survival (something that has been suggested to be affected by DTA-1 and may 
contribute to the anti-tumour effect of DTA-1), intra-tumoural accumulation of Treg cells 
was analysed:  Single cell suspensions of MB49 tumours isolated from untreated and 
DTA-1-treated mice were stained with anti-CD4PerCP followed by intracellular staining 
with anti-Foxp3FITC. The percentage of CD4+Foxp3+ cells in MB49 tumours from 
individual mice is shown in Figure 19A. The percentage of Treg in MB49 tumours is 
significantly decreased by DTA-1 treatment, declining from 10% in untreated mice to 6% 
in DTA-1 treated mice (p=0.026)(Figure 19A), which is consistent with other reports200.  
Figure 19A also shows that the depletion of Treg cells by DTA-1 is more extensive in 
tumours than in the dLN.  
 It is also speculated that the environment of a growing MB49 tumour might 
preferentially increase GITR expression on tumour-infiltrating Treg cells, rendering them 
more susceptible to depletion. To test this, Foxp3/GFP mice were injected s.c. with 5 x 105 
MB49 cells, 8 days later the expression of GITR by Treg cells in the MB49 tumour was 
compared with those in dLN. As shown in Figure 19B, there was a 4-fold increase in GITR 
expression on MB49-infiltrating Treg cells (Mean fluorescent intensity increased from 590 
in tumour draining LN to 2182 in tumour; p < 0.0003), which is likely to increase 
sensitivity to DTA-1-induced depletion. 
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Figure 19. DTA-1 preferentially depletes GITRhi Treg in MB49 tumours. 
A) On day 0, C57BL/6 female mice (n=8) were s.c. inoculated with 5 x 105 MB49 cells. 
Half the mice were injected i.p. with DTA-1 on day 5 and 9, and half of them received no 
mAb treatment. On day 15, all mice were culled and MB49 tumours were isolated and 
stained with anti-CD4PerCP followed by intracellular staining with anti-Foxp3FITC. The 
percentage of lymphocytes that were CD4+FoxP3+ is presented (n=4). *p = 0.026 
B) Female FoxP3-GFP C57BL/6 mice (n=4) were injected with 5 x 105 MB49 s.c. On day 
8 tumour draining lymph nodes (dLN) and MB49 tumours (n=4) were isolated and stained 
with anti-GITRPE and anti-CD4PerCP and analysed by FACS. The mean fluorescent 
intensity (MFI) of GITR expressed by CD4+ FoxP3-GFP+ lymphocytes is presented.  ***p 
= 0.0003.    
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  If one of the actions of DTA-1 is to deplete Treg cells in vivo, it would be 
interesting to compare DTA-1 with PC61, a standard anti-CD25 depleting mAb. A single 
injection of PC61 was very effective in causing the regression of MB49 tumours with 
100% (5/5) of mice tumour-free by day 20, when it was administered to female C57BL/6 
mice 2 days before MB49 inoculation (Figure 20A, ). However, the same treatment 
protocol using DTA-1 had a limited impact on tumour growth (Figure 20A, ), with only 
25% (1/4) of mice tumour-free at day 20.  
    This difference could be explained by the observation that PC61 was more 
effective at depleting Treg than DTA-1 in vivo (data not shown). On the other hand, DTA-
1 treatment was very efficient at causing the rejection of established MB49 tumours 
(Figure 16 A and B) whereas PC61 therapy had no effect (Figure 20B, , 0% tumour-free 
mice). The anti-tumour activity of DTA-1 was completely lost if PC61 was co-injected 
with DTA-1 on day 8 (Figure 20B, , 0% tumour-free mice). 
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Figure 20. Comparison of DTA-1 and PC61 anti tumour efficacy  
A) Two groups of B6 female mice were treated with 50μg of PC61 ( , n=5) or DTA-1 
mAb ( , n=4) by i.p. injection. 2 days later, all mice were injected s.c. with 5 x 105 MB49 
cells. The growth of MB49 tumours was monitored by measuring tumour size. Data is 
presented as the mean  SD, **p = >> 0.0001 
B) A total of 16 B6 female mice were injected s.c. with 5 x 105 MB49 cells. 8 days later, 
the mice were randomly divided into three groups and treated with 50μg 
of DTA-1 ( , n=6), 50μg of PC61 ( , n=5), or 50μg of DTA-1 mixed with 50μg of 
PC61  ( , n=5) by i.p. injection. The growth of MB49 tumours was monitored by 
measuring tumour size every other day. Data is presented as the mean  SD ***p = >> 
0.0001. 
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4.2.5 : The effect of DTA-1 on CD8 T cell activity 
 
Another potential mechanism of DTA-1 mediated tumour rejection is the 
augmentation of CD8 T cell effector functions.  DTA-1-mediated GITR signalling has 
been shown to enhance vaccine-induced CD8 tetramer responses against B16F10 
melanomas149.  A basic measure of CD8 effector activity is their proliferation in response 
to stimuli.  To test the CD8 co-stimulatory potential of DTA-1 mAb in vitro, MataHari 
CD8 T cells were stimulated with cognate peptide in the absence or presence of DTA-1. As 
shown in (Figure 21), the presence of DTA-1 mAb failed to augment the proliferation of 
MataHari CD8 T cells in response to peptide, indicating that DTA-1 is not co-stimulatory 
to CD8 T cells. 
 
 
 
 
 
Figure 21. In vitro response of activated CD8 T cells stimulated with DTA-1  
A) 1 x 105 Spleen and LN from Rag-/- MataHari were cultured in a 96 well U bottom plate 
for 4 days with HYUty peptide in the absence  ( ) or presence of 1:300 DTA-1 ( ) or 
1:1000 DTA-1 ( ). Tritiated thymidine (0.5  μCi/well) was added on day 3 and 
proliferation was measured on day 4. 
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4.3 : Discussion 
 
Although DTA-1 has been proposed146 and indicated263 to deplete GITR expressing-Treg 
cells in vivo, a formal demonstration has never been made. This chapter provides evidence 
showing that DTA-1 is a depleting mAb causing a moderate reduction of endogenous 
polyclonal Treg in tumour free mice (Figure 17A) and a significant reduction in MB49 
tumours (Figure 19A).  
    In agreement with previously published results147 DTA-1 therapy is extremely 
effective at causing complete tumour rejection and prolonged tumour free survival (Figure 
16). These results suggest that MB49 can be added to the list of tumours that do respond to 
GITR therapy, which includes the B16 melanoma200 and MethA147, and it would be of 
interest to further study the phenotype of tumours that are susceptible to DTA-1 therapy. 
    Administration of DTA-1 i.p. to WT C57BL/6 female mice did not significantly 
change the ratio of B cells (data not shown) or T cells in either peripheral blood (Figure 
17A) or lymph nodes  (Figure 17B). However there was a noticeable albeit non-significant 
reduction in the percentages of Treg in the peripheral blood. GITR is only expressed on 
CD4 and CD8 T cells after activation but is constitutively expressed at higher levels on 
Treg145 and therefore it is possible that DTA-1 binds only to GITR on Treg cells in the 
naïve mouse. The reduction of Treg from 8% to 6% (Figure 17A) suggests that DTA-1 is 
not causing activation and expansion of Treg, or CD4 and CD8 T cells, but is instead 
causing depletion of Treg. It has also been shown that DTA-1 can activate Natural Killer T 
cells265 although we have not assessed their involvement in this study.       
    The small reduction of Treg demonstrated in Figure 17 may be caused by antibody 
mediated depletion or it could potentially be caused by deactivation of Treg. If DTA-1 
abrogated Treg function and led to a subsequent reduction in autocrine signalling via the 
TGFβ and IL-10 pathways then the generation of Treg would also be reduced. To test this 
hypothesis the ex vivo function of Treg was tested .  
    Tregs were isolated 24h after DTA-1 treatment to allow sufficient time for GITR 
binding and signal transduction. Isolated CD4+CD25+ T cells were found to be functional 
Treg cells with similar suppressive activity as those from untreated mice (Figure 18) which 
is consistent with other reports150, 200 and supports the hypothesis that DTA-1 does not 
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abrogate the suppressive function of Treg. These findings suggest that the reduction of 
Treg in the peripheral blood demonstrated in Figure 17 is not due to the abrogation of Treg 
function and may in fact be due to antibody mediated depletion. Having tested the effect of 
DTA-1 on naïve populations and on Treg function it was then of interest to look at the 
effect of DTA-1 therapy on Treg in the MB49 tumour.  
    Mice that had been treated twice with DTA-1, on day 5 and 9 after MB49 tumour 
showed significantly reduced ratios of tumour infiltrating Tregs when compared to control 
mice.  It is possible that the reduction in Treg within the tumour may be because of 
inhibition of Treg migration to the tumour or because of antibody mediated depletion. In 
support of antibody mediated depletion DTA-1 has an IgG2b isotype which is shared by a 
large number of in vivo depleting mAb including those with specificity for CD4 (GK1.550), 
CD8 (YTS169213) and Thy1.2 (30H12266). However, a recent study from (Cohen/Wolchok; 
2010) suggests that DTA-1 inhibits migration of Treg into B16 melanomas and leads to 
loss of FoxP3 expression, but not suppressive function.    
  CD8+ MataHari T cells cultured with their cognate peptide with or without two 
concentrations of DTA-1 did not show any difference in their proliferative capacity (Figure 
21). This result conflicts with previous results demonstrating that DTA-1 stimulates CD8+ 
T cells in vitro257. However the study by Ronchetti et al. incubated polyclonal T cells with 
CD3, CD28 and DTA-1 and not with cognate peptide. It is possible that the type of signal 
through the TCR is critical to the response to DTA-1.     
  Because one of the actions of DTA-1 is to deplete Treg cells in vivo, it was of 
interest to compare DTA-1 with PC61, a standard anti-CD25 depleting mAb. A single 
injection of PC61 has been shown to be effective at reducing tumour progression in several 
murine tumours80, 147, 222. In agreement with previous studies PC-61211 caused the rejection 
of tumours in 100% of  female C57BL/6 mice when it was administered i.p. 2 days before 
MB49 inoculation. Conversely DTA-1 treatment had limited impact on MB49 tumour 
growth (Figure 20A). This difference could be explained by the observation that PC61 was 
more potent than DTA-1 at depleting Treg in vivo (data not shown). On the other hand, 
DTA-1 treatment was very efficient at causing the rejection of established MB49 tumours 
that were 8 days old whereas PC61 therapy had no effect (Figure 20B). It is possible that 
CD25-expressing effector T cells with anti-MB49 activity are depleted by PC61 treatment. 
Moreover, in support of this, the anti-tumour activity of DTA-1 was completely lost if 
PC61 was injected with DTA-1 on day 8 (Figure 20B). 
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White, Prof. Julian Dyson and Dr. Jian-Guo Chai, for their help in the preparation of this 
chapter and the paper that we published together using these results.  The paper is 
published under the title „Depletion of regulatory T cells by the anti-GITR mAb as a novel 
mechanism for cancer immunotherapy‟ in the Journal of Cancer Immunology and 
Immunotherapy264, a copy of this paper is attached in Appendix A.  
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Chapter 5 : Adoptive 
Transfer of CD4
+
 T cells 
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5.1 : Introduction 
 
Adoptive cell transfer of ex vivo expanded lymphocytes promises to be a successful 
therapy for cancer. Nevertheless, because of the suppressive environment that surrounds 
tumours it is clear that additional methods, that will improve T cell activation, persistence 
in vivo following transfer and anti-tumour activity, are still needed. 
   CD4 T cells are critical for anti-tumour responses against a variety of murine 
tumours170-173. This study has shown that CD4 T cells are critical for MB49 tumour 
rejection, as CD4 depletion leads to larger tumours and increased mortality (Chapter 1).  
Several murine studies have suggested that CD4 T cells are effective at causing tumour 
rejection172, 174, 178. Moreover, two of these studies find that CD4 T cells are more effective 
than CD8 T cells at causing tumour rejection even when adoptively transferred into 
immuno-deficient mice and they suggest that CD4 T cells can directly kill MHC-II 
negative tumours172, 178.   The ability of CD4 T cells to contribute to tumour rejection is 
thought to be largely based on their ability to secrete IFNγ171, 174, 175.  
   Despite the ability of CD4 T cells to cause tumour rejection alone or in 
combination with other treatments, the field of CD4 adoptive immunotherapy has not 
advanced very far. Basic168, 170, 176 and clinical studies13, 16, 19 have concentrated on the 
adoptive transfer of CD8 T cells alone or in some cases with CD4 T cells170, 173 or CD4 
peptide vaccines177.  
In this study CD4 T cells from Marilyn mice were used for adoptive transfer 
experiments. Marilyn CD4 T cells express the Tg TCR, encoding the VJ segments TCRα 
(Vα1.1-Jα35) and TCRβ (Vβ6-Jβ2.3), which recognises the HY/Ab/Dby peptide 
(NAGFNSNRANSSRSS) presented in the context of the H2-Ab 267 MHC-II molecule. All 
T cells in the peripheral blood, spleen and lymph nodes of female Marilyn Rag-/- mice are 
Vβ6+ CD4+ transgenic T cells.  Marilyn CD4 T cells have been shown to be effective at 
causing the rejection of MB49 tumours in Rag-/- C57BL/6 mice178. To test how effective 
naïve and activated Marilyn T cells were in immuno-competent mice, and at what dose, 
experiments were carried out in this study in which Marilyn T cells were adoptively 
transferred to WT female C57BL/6 mice with MB49 tumours.  The results are discussed 
after the introduction. 
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The adoptive transfer of T cells is often confounded by the suppressive conditions 
surrounding the tumour, the presence of Treg and the lack of co-stimulatory cytokines. To 
enhance adoptive T cell transfer, many murine studies have used sub-lethal irradiation of 
between 4 – 8Gy159-161. Irradiation reduces the number of suppressive Tregs, increases 
antigen shedding from tumours and increases the amount of „space‟ and cytokine 
availability by depleting competing T cells, all of which combined mean that adoptively 
transferred T cells have better anti-tumour potential.       
As previously described in Chapter 3, IL-17A has the potential to mediate tumour 
rejection. One of the main sources of IL-17A is Th17 CD4+ T cells that secrete IL-17A 
under the influence of the transcription factor Rorγt239 and are generated by the combined 
actions of TGFβ and IL-6240. The frequency of Th17 T cells is increased in several 
different forms of human and murine cancer241, 242, 268 and indeed the tumour 
microenvironment is a source of cytokines that drive Th17 differentiation including IL-6, 
IL-21, IL-23, and TGFβ243, 244.  
Th17 cells produce pro-inflammatory cytokines including IL-17, IL-6, and G-CFS 
and have been associated with inducing experimental autoimmunity including autoimmune 
encephalitis179, 269 (EAE) and collagen induced arthritis. The importance of Th17 cells in 
tumour immunity has only recently been investigated, with one study demonstrating that 
tumour specific Th17 cells are more effective than Th1 cells at destroying established B16 
melanomas180. 
An in vitro culture protocol was designed, during this study, in order to generate 
large numbers of Th17 cells for adoptive transfer. Th17 cells generated, using this protocol, 
were then used in adoptive transfer experiments. The results of which are described later in 
this chapter.  
  
5.2 : Characterisation of Marilyn T cells 
 
To study the adoptive transfer of CD4+ T cells, Marilyn CD4+ T cells were utilised as 
tumour-specific effector cells for cancer immunotherapy.  
Before using Marilyn T cells in vivo it was necessary to investigate their phenotype 
and responsiveness to cognate peptides. For the experiments described in this chapter 
Marilyn cells were identified by flow cytometry using anti-Vβ6 and anti-CD4 and/or anti-
Thy1.1/1.2. Peripheral lymph node cells from a Rag2-/- Marilyn female mouse were stained 
with anti-V6PE, anti-CD4PerCP and anti-CD62LAPC for flow cytometric analysis. It was 
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found that virtually all T lymphocytes co-expressed CD4 and V6 (Figure 22A, left panel), 
indicating a monoclonal CD4 T cell population was present. The majority of gated 
CD4+Vβ6+ cells also expressed a high level of CD62L, suggesting that they are naïve T 
cells (Figure 22A, right panel). When spleen and pooled LN cells from a Rag2-/- Marilyn 
mouse were cultured with HY/Ab/Dby peptide, cells proliferated in a peptide dose-
dependent manner, demonstrating that Marilyn CD4 T cells express a functional transgenic 
TCR (Figure 22B). 
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Figure 22. Characterisation of Marilyn T cells and response to antigen 
 
A) Peripheral lymph node (LN) cells from a naïve Marilyn Rag2-/- female mouse were 
stained with anti-Vβ6PE, anti-CD4PerCP and anti-CD62LAPC and the FACS data presented as 
a density plot.   
B) Spleen and pooled peripheral LN cells (2x104/well) from a naïve Marilyn Rag2-/- female 
mouse were stimulated with the indicated concentrations of HY/Ab/Dby peptide. Tritiated 
thymidine was added at 48 hours (0.5 Ci/well) and results are expressed as the mean SD 
of the counts per minute (CPM) 
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5.3 : Treatment of MB49-bearing mice with adoptively transferred 
Marilyn CD4 T cells 
 
Marilyn CD4 T cells have previously been shown to be effective at causing the rejection of 
MB49 tumours178. However, those studies were exclusively performed using Rag-/- B6 
females as recipients of CD4 T cells. To test how effective naïve and activated Marilyn T 
cells are, at various doses, in a more physiological situation, naïve or activated Marilyn T 
cells were adoptively transferred to WT female C57BL/6 mice with MB49 tumours.   
Female C57BL/6 mice were injected i.v. with naïve 0.31 x 106 or 2.5 x 106 pooled 
spleen and lymph node cells from Rag-/-  Marilyn female mice, on the same day the mice 
were inoculated s.c. with 5 x 105 MB49 cells. Tumour growth in mice treated with 2.5 x 
106 adoptively transferred naïve Marilyn T cells, was significantly slower (tumours 
reaching an average of 39 ±14 mm2 by day 19) than in control mice (104 ± 26 mm2 at day 
19) (p = >0.01), or mice that had been treated with 0.31 x 106 Marilyn T cells (89 ± 15 
mm2 at day 19) (Figure 23A). Although the adoptive transfer of Marilyn T cells slowed 
tumour growth in a dose dependant manner, it did not cause complete tumour rejection in 
any of the treated mice even at a higher dose of 5 x 106 Marilyn cell/mouse (data not 
shown). 
In an attempt to increase the efficacy of adoptively transferred Marilyn T cells 
against MB49 tumours, T cells were activated in vitro before adoptive transfer. The spleen 
and lymph nodes from Rag+/- Marilyn female mice were isolated and cultured for three 
days with 100nM HY-Dby peptide. After three days cells were harvested, and the T cells 
purified.  T cells (0.5 x 106 or 2 x 106) were then adoptively transferred into female 
C57BL/6 mice which were then injected s.c. with 5 x 105 MB49 cells. The adoptive 
transfer of either 0.5 x 106 or 2 x 106 activated Marilyn T cells significantly reduced the 
growth of the MB49 tumour, within the time frame of this experiment (21 days), when 
compared to controls (p > 0.01), from 119 ± 50 mm2 in untreated mice, to 14 ± 12 mm2 
and 12 ± 12 mm2 in mice treated with 2 x 106 and 0.5 x 106 Marilyn T cells, respectively 
(Figure 23B). The adoptive transfer of activated Marilyn CD4 T cells caused tumour free 
survival up to day 31 in 1/3 mice treated with 2 x 106 T cells and 2/4 mice treated with 0.5 
x 106 T cells (data not shown).   
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Figure 23. Comparison of the effect of the adoptive transfer of naïve or 
activated Marilyn T cells on MB49 tumour growth 
A) Female C57BL/6 mice were not treated ( , n=3) or injected i.v. with 2.5 x 106 ( , 
n=4) or 0.31 x 106 ( , n=5) cells pooled from spleen and lymph nodes from Rag-/- Marilyn 
female mice. On the same day, 5 x 105 MB49 cells were injected s.c. to all mice. Tumour 
size was measured. Data is presented as mean ± SD.  *** p = <0.01 ( -control vs. -2.5 
x 106 Marilyn i.v.)  
B) Female C57BL/6 mice were not treated ( , n=3) or injected i.v. with 0.5 x 106 ( , n=4) 
or 2 x 106 ( , n=3) in vitro activated Marilyn CD4 T cells which were purified from 3 
days cultures containing Marilyn spleen cells and 100 nM HYDby peptide. On the same 
day of T cell transfer, 5 x 105 MB49 cells were injected s.c. to all mice. Tumour area was 
measured as Width x Length at regular intervals. Data is presented as mean ± SD. ** p = 
0.01( -control vs. -2 x 106 Marilyn i.v.) 
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To better understand the underlying cellular mechanisms responsible for this successful 
therapy, based on Marilyn CD4 transfer, we decided to monitor the fate of donor CD4 T 
cells in vivo. To this end, Thy1.1+ Marilyn CD4 T cells were labelled with CFSE and 
adoptively transferred into Thy1.2 C57BL/6 mice that had been inoculated, s.c. with 5 x 
105 MB49 cells, 7 days previously. Eight days after the adoptive transfer, the tumour dLN, 
ndLN and tumour were harvested and the expansion and proliferation of the adoptively 
transferred Marilyn T cells was analysed by flow cytometry.  
Donor Marilyn CD4 T cells were found to have accumulated in the tumour dLN as 
well as in ndLN. A small but significant proportion of donor T cells were also present in 
MB49 tumours. For example, donor CD4 T cells made up 0.6 ± 0.1 % in the tumour dLN, 
0.2 ± 0.02% in the ndLN and 0.03 ± 0.001 % in the tumour (Figure 24A and B). In mice 
adoptively transferred with Marilyn T cells but without MB49 tumours, the frequency of 
donor CD4 T cells in pLN was 0.1%.  
When the CFSE dilution profile of donor CD4 T cells was analysed, it was found 
that Marilyn T cells in the dLN divided faster than those in the ndLN or in pLN of control 
mice. Only 8 ± 3% of Marilyn T cells in the dLN were undivided compared to 39±13% in 
the ndLN, and 99% in pLN of control mice (Figure 24 C and D). 
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Figure 24. Representation of donor CD4 T cells in various tissues of tumour-bearing 
mice. 
On day 0, two Thy1.2 C57BL/6 female mice were s.c. inoculated with 5 x 105 MB49 cells. 7 days later 2 x 
106 CFSE labelled Thy1.1 Marilyn T cells were adoptively transferred to control mice (n=1) and MB49 
tumour bearing mice (n=2). 8 days later tumour dLN (( , n=2), ndLN ( , n=2), tumour ( , n=2) and 
control pLN ( , n=1) were harvested and prepared for FACS. 
A) The cells from different tissues were stained with anti-Thy1.1PerCP and anti-CD4APC. The cells were gated 
on the small lymphocyte gate and the percentage of CD4+Thy1.1+ cells were presented as the mean±SD from 
two individual mice.  
B) One representative density plot is shown.  
C) The cells from different tissues were stained anti-Thy1.1PerCP and anti-CD4APC. The cells were gated on 
the small lymphocyte gate and the donor cells were identified by being CD4+Thy1.1+. The percentage of 
donor cells that remained CFSEhi were designated undivided and are presented as the mean ± SD from two 
individual mice. D) One representative density plot is shown. 
From the previous experiments it was evident that Marilyn T cells were proliferating and 
expanding in response to MB49 tumour antigen however, the anti-tumour capacity was not 
enough to completely clear the tumour in 100% of mice. To define whether Marilyn T cells 
were being inhibited by tumour-related mechanisms, the capacity of Marilyn T cells to 
divide in response to tumour versus male skin grafts was compared. The hypothesis was 
that the tumour microenvironment is immuno-suppressive but that of the allograft is not. 
Thy1.2+ female C57BL/6 mice were transplanted with syngeneic male skin grafts 
or inoculated s.c. with MB49 cells and then injected i.v. with CFSE labelled Thy1.1+ 
Marilyn T cells. T cell expansion and CFSE dilution in graft dLN (gdLN) and tumour dLN 
(tdLN) was then compared by flow cytometry. 
The results of these experiments were that there were more donor T cells present in 
the gdLN (0.6% ± 0.3%) than in the tdLN (0.14% ± 0.08%) (Figure 25 A and B). A 
significantly higher proportion of the donor T cells was CD44high in the gdLN (90% ± 1%) 
compared to in the tdLN (69% ± 11%; p = 0.006) (Figure 25C and D). The frequency of 
undivided CFSEhigh T cells was significantly higher in the tdLN (10% ± 3.7%) than in the 
gdLN (3% ± 1%; p = 0.004) (Figure 25E and F).  These results were consistent with the 
hypothesis of the experiment.  
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Figure 25. Comparison of donor CD4 T cell response to male skin grafts and 
MB49 tumours. 
Thy1.2 female B6 mice were either not treated ( , n=4) or injected s.c. with 5 x 105 
MB49 cells on  both sides of flanks ( , n=6) or transplanted with syngeneic male skin 
grafts ( , n=3). 7 days later, 4.6 x 106 CFSE labelled CD4+ Marilyn T cells were injected 
i.v. 5 days later, peripheral lymph nodes, tumour or graft draining lymph nodes, MB49 
tumours and skin grafts were harvested and stained, anti-Vβ6PE, anti-Thy1.1PerCP and anti-
CD44APC and analysed by FACS.  
A) Percentage of donor T cells in pLN, tumour-dLN and graft-dLN lymph nodes are 
represented as mean ± SD. 
B) Density plots of one representative example are shown.   
C) Percentage of CD44high donor T cells in pLN, tumour-dLN and graft-dLN lymph nodes 
are represented as mean ± SD. ** p = 0.006.  
D) Density plots of one representative example are shown.   
E) Percentage of CFSEhi undivided donor T cells in pLN, tumour-dLN and graft-dLN 
lymph nodes are represented as mean ± SD. ** p = 0.004.  
F) Density plots of one representative example are shown. 
 
 124 
 
5.4 : A combination therapy using Marilyn CD4 T cells and pre-
conditioning of hosts.  
 
Adoptive T cell therapy using naïve and activated HY-specific Marilyn T cells slows the 
growth of the MB49 tumour in a dose dependent manner (Figure 23) however, the tumour 
does seem to exert some immunosuppressive effect (Figure 25) which may explain why 
Marilyn T cell therapy does not cause complete remission or prolonged tumour-free 
survival in 100% of mice treated. It is likely that additional manipulations are needed to 
boost the anti-tumour effects of Marilyn T cells to overcome tumour mediated suppression 
and cause complete tumour remission and prolonged survival in all animals treated. 
Sub-lethal irradiation has been shown to enhance the efficacy of adoptively 
transferred T cells by; reducing the number of Treg that can inhibit anti-tumour responses; 
increasing the availability of cytokines required for the proliferation and survival of 
adoptively transferred cells and; increased antigen presentation via antigen shedding from 
dying tumour cells159-161.  
To study the effect of irradiation on the adoptive transfer of Marilyn T cells to mice 
with established MB49 tumours, female C57BL/6 mice were injected s.c. with 5 x 105 
MB49 cells. Seven days after injection, established tumours, with an average area of 22 ± 9 
mm2, had developed. On day 7, mice were sub-lethally irradiated with 5Gy and then 1 x 
106 Marilyn T cells, from pooled spleen and lymph nodes of Rag-/- Marilyn female mice, 
were adoptively transferred by i.v. injection.  A control group were inoculated with MB49 
cells but were not irradiate and did not receive Marilyn T cells.  
Tumours, in the group that was irradiated and received Marilyn T cells, continued 
to grow to an average size of 43 ± 14 mm2 on day 15. But after day 15, MB49 tumours 
began to regress, and by day 27 were significantly smaller than tumours in the untreated 
group (Figure 26A, p = 0.004). At the end of the experiment (day 34) all mice (7/7) in the 
treated group were tumour free (data not shown). Treatment correlated with long term 
survival, with 100% of the treated group living until the end of the experiment compared to 
a mean survival time of just 18.8 days for the untreated group (Figure 26B).    
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Figure 26. Combinational therapy with irradiation and CD4 T cell transfer 
causes the complete rejection of established MB49 tumours.  
A) Female C57BL/6 mice were injected with 5 x 105 MB49 cells s.c. Seven days later mice 
were irradiated with 5Gy and then received 1 x 106 Marilyn CD4 T cells, purified from the 
pooled spleen and lymph nodes of Rag-/- Marilyn female mice, by i.v. injection ( , n=7) 
or were left untreated ( , n=4). Tumour area was measured at regular intervals. Data are 
presented as mean ± SD, ** p = 0.004. 
B) MB49 progression is presented as % survival. The s.c. inoculation of B6 mice with 
MB49 cells does not lead to death. But the mice are recoded as death once they reach one 
of following end points of the experiment. One is the maximum of tumour size with 14 
mm x 14 mm, the other is the development of severe ulceration by tumour. The mean 
survival time (MST) of individual groups is also indicated. 
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At the end of the irradiation-adoptive transfer experiment (day 34), MB49-dLN and spleen 
were harvested from three MB49-free, treated mice and the production of IFNγ and 
phenotype of the donor Marilyn T cells were analysed.  
 11% of donor Marilyn T cells in the MB49-dLN and 29% of donor Marilyn T cells 
in the spleen of treated mice, produced IFNγ following a short period in culture with PMA 
and Ionomycin (Figure 27A and B).  
 The analysis of the phenotype of adoptively transferred T cells revealed that 40% 
of gated donor CD4 T cells in MB49-dLN were Central Memory (CM) cells (CD62Lhi 
CD44hi) and 35% of donor CD4 T cells were Effector Memory (EM) cells (CD62Llo 
CD44hi )(Figure 28A and B). The expression of chemokine receptors by adoptively 
transferred T cells was also analysed; the only chemokine receptor that was up-regulated 
on the adoptively transferred T cells was CCR9 which was expressed on more than 12% of 
donor T cells (Figure 28C and D).    
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Figure 27.  Adoptively transferred Marilyn cells were differentiated to Th1-
like effectors in MB49-bearing mice after pre-conditioning with 5Gy 
irradiation. 
Thy1.2+ female C57BL/6 mice were inoculated s.c. with 5 x 105 MB49 cells. 7 days later, mice 
were irradiated with 5Gy and injected i.v. with 1 x 106 Thy1.1+ Marilyn CD4 T cells. At day 34, 
1x106 spleen or dLN cells from three individual tumour-free mice were cultured with 4x106 male 
Rag-/- spleen cells in 24-well plates. 5 days later, PMA (50 ng/ml), Ionomycin (500 ng/ml) and 
Brefaldin (1 g/ml) were added to 24-well plates. 4 hours later, the cells were harvested and the 
dead cells removed using Ficoll. After washing, the cells were surface stained with anti-Vβ6PE, 
anti-CD4FITC and anti-Thy1.1PerCP. Cells were then fixed and permeabilised before being stained 
with anti-IFNγAPC.   
A) The frequency of IFNγ-producing donor CD4 T cells recovered from MB49-dLN and spleen of 
rejected and control mice is shown.    
B) Density plots of one representative example are shown.    
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Figure 28. Phenotype of adoptively transferred Marilyn T cells following pre-
conditioning with 5Gy irradiation  
As described in Figure 5, Thy1.2+ female C57BL/6 were inoculated s.c. with 5 x 105 MB49 cells. 7 
days later, mice were irradiated with 5Gy and injected i.v. with 1 x 106 Thy1.1+ Marilyn CD4 T 
cells. dLN cells from three tumour-free mice were harvested and analysed individually on day 34. 
A) dLN cells were stained with anti-Vβ6FITC, anti-CD62LPE, anti-CD44APC and anti-Thy1.1PerCP. 
Proportions of naïve (CD62Lhi CD44lo), CM (CD62Lhi CD44hi), and EM (CD62Llo CD44hi) subsets 
within host T cells (Thy1.1-, ) or donor T cells (Thy1.1+, ) was analysed.  
B) Density plots of one representative example are shown. 
C) dLN cells were stained with anti-Vβ6FITC, IsotypePE or three individual PE-conjugated mAb 
including anti-CCR5, anti-CCR7 and anti-CCR9 and anti-Thy1.1PerCP. The percentage of donor T 
cells expressing respective CCR receptors is presented (n=3). 
D) Density plots of one representative example are shown. 
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5.5 : Differentiation of Th17 cells from naïve Marilyn CD4 T cells in 
vitro 
  
To explore the anti-tumour efficacy of Th17 cells in the MB49 model, a variety of in vitro 
conditions were tested in order to create an optimal culture system whereby a large number 
of tumour-specific Th17 cells could be produced for adoptive immunotherapy. Several 
conditions were tested, including neutralisation of IL-2 with mAb (S4B6)270 because IL-2 
has been shown to inhibit the development of Th17 cells268.       
We confirmed that neither IL-6 or TGFalone can induce Th17 cells from naïve 
Marilyn CD4 T cells after activation with HYDby peptide and that Th17 development 
requires a combination of both cytokines. In addition, IL-23 did not appear to expand 
differentiated Th17 cells. More importantly we demonstrated, by two different approaches, 
that IL-2 inhibits Th17 development. Firstly, the presence of neutralising anti-IL-2 mAb 
(clone S4B6) greatly enhanced Th17 development (Figure 29A and B) and secondly, 
addition of exogenous IL-2 into culture profoundly inhibited Th17 differentiation (data not 
shown).      
 
 130 
 
Figure 29. IL-2 inhibits in vitro Th17 differentiation from naive Marilyn CD4 T 
cells following peptide stimulation in the presence of IL-6 and TGFβ.  
A) Splenocytes and lymph node cells (2x105/well) from Rag2-/- Marilyn female mice were 
stimulated with HYDby peptide (150 nM) plus the cocktail of Th17- polarising cytokines 
(TGFβ, IL-6 or IL-23, 2ng/ml) in the presence  ( ) or absence of anti-IL-2 ( ) (clone 
S4B6, 1:100 dilution of hybridoma supernatant) in a 96 well plate for 6 days.  The cells 
were stimulated with PMA and Ionomycin in the presence of monensin for 4 hours. Dead 
cells were removed using Ficoll and viable cells were stained with anti-Vβ6FITC and anti-
CD4PerCP, fixed and permeabilised then stained with anti-IL-17PE and anti-IFNγAPC and 
analysed by FACS. Gated Vβ6+CD4+ cells were analysed for IL-17 and IFN production.  
B) Representative dot plots show the percentage of IL-17-producing and IFN-producing 
cells within gated Vβ6+CD4+ population. 
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5.6 : Adoptive therapy using in vitro polarised Th17-like Marilyn 
CD4 T cells. 
 
Using the in vitro Th17 and Th1 conditioning regimen described above, Th17-like Marilyn 
CD4 T cells were adoptively transferred into C57BL/6 mice that had established MB49 
tumours. Similar to HYDby-activated Marilyn CD4 T cells, in vitro differentiated “Th17-
like” Marilyn CD4 T cells were also capable of eliminating established MB49 tumours, 
with no difference in terms of kinetic of regression (Figure 30). Unfortunately, due to time 
constraints this was the only experiment of this type performed.  
 
 
  
 
 
Figure 30. Adoptive transfer of Th17 conditioned Marilyn T cells leads to the 
regression of established MB49 tumours. 
 A) Three groups of B6 female mice were injected s.c. with 5 x 105 MB49 cells. 4 days 
later the mice were split into three groups and adoptively transferred with 1.2 x 106 Th1 
( , n=5), Th17 ( , n=3) or naïve ( , n=5) Marilyn T cells  . The growth of MB49 
tumours was monitored by measuring tumour size. Data is presented as the mean  SD.   
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5.7 : Discussion 
 
As Marilyn CD4 T cells were adoptively transferred to treat MB49 tumours, it was of 
importance to characterize their phenotype and function. FACS analysis confirmed that 
Rag2-/- Marilyn female mice harbour monoclonal naïve CD4 T cells that express the 
transgenic TCR (Figure 22) and proliferate in vitro in response to Ab-Dby peptide with a 
peak response at 100-1000nM (Figure 22B) which confirms previous results178, 206.  
Adoptive transfer of naïve Marilyn cells inhibited the growth of MB49 tumours in a 
dose dependent manner. High doses (2.5 x 106) of Marilyn T cells inhibited the growth of 
the tumour in all mice tested, however treatment did not cause tumour rejection (Figure 
23A). Marilyn T cells that had been activated in vitro for 3 days before being adoptively 
transferred to female C57BL/6 mice were more effective at controlling subsequent tumour 
growth but, again, did not successfully clear the tumour (Figure 23B).  
Together these results suggest that Marilyn T cells are effective at reducing the 
growth of MB49 tumours in female C57BL/6 WT mice. However, whereas a previous 
study in Rag-/- female C57BL/6 mice demonstrated that 8 x 105 naïve Marilyn cells were 
sufficient to cause the rejection of 1 x105 MB49 cells injected s.c. one day previously178, 
these results suggest that a much higher number (5 x 106) is required in immuno-competent 
mice. Immunosupression by Treg, which are present in immuno-competent mice but not 
Rag-/- mice, is the likely reason. The interaction between Treg and the MB49 tumour are 
discussed in Chapter 7. 
Activating Marilyn T cells in vitro before adoptive transfer may increase 
infiltration into the tumour, a hypothesis that is corroborated by a study from O. Lantz et 
al.
271. Using Marilyn cells, they describe a direct relation between the strength of Marilyn 
cell priming in vivo and their subsequent ability to infiltrate into Dby expressing MCA-101 
tumours. Priming in vitro decreases the expression of CD62L and increases expression of 
chemokine receptors, a combination of changes that is required for infiltration of T cells 
into the periphery and into the tumour mass.      
Adoptively transferred naïve Marilyn cells proliferate and expand in MB49 tdLN 
and migrate into the tumour mass. Proliferation and accumulation in ndLN is less 
significant than in dLN (Figure 24). All Marilyn cells within the MB49 tumour had 
undergone more than 7 cell division, which is the limit for detection using CFSE. This 
result was in line with previous studies271.     
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To further investigate whether Marilyn cells were being inhibited by the MB49 
tumour, their response against MB49 tumour and syngeneic male skin grafts were 
compared. It was found that Marilyn T cells proliferate more robustly in response to male 
skin grafts than to MB49 tumours. The frequency of Marilyn cells in the gdLN was higher 
than in tdLN, these cells expressed higher levels of the activation marker CD44 and the 
number of undivided Marilyn cells was lower (Figure 25). Both MB49 tumour and male 
skin grafts express the HY antigen, although MB49 tumours, because they are larger than 
grafts, probably release more antigen. Despite this Marilyn T cells respond better to 
antigen in the gdLN. Together these results suggest that inhibition of the immune response 
by MB49 tumours extends to the tdLN as well as being directly associated with the tumour 
microenvironment. 
Marilyn T cell therapy does not cause complete remission of MB49 tumours. 
Preconditioning recipients with sub-lethal irradiation is a commonly used regimen to 
enhance adoptive transfer159-161. 5Gy of irradiation enhanced the therapeutic potential of 
Marilyn cells transferred to tumour bearing mice. So much so, that rather than 
administering Marilyn T cells then tumour on the same day, it was possible to inoculate 
C57BL/6 female mice with MB49 cells 7 days before treatment.   
In agreement with previously published results, established tumours were rejected 
in mice treated with 5Gy irradiation followed by adoptive transfer of Marilyn cells (Figure 
26). This experiment demonstrated the importance of pre-conditioning in eliciting 
therapeutic responses from adoptive transfer therapy. 
FACS analysis of the donor T cells in the dLN and spleen of treated mice revealed 
that up to 29% of the cells expressed IFNγ showing that they were Th1 T cells (Figure 
27B). Furthermore, up to 50% of donor T cells expressed a T cell effector phenotype, with 
up to 35% expressing a T central memory phenotype (Figure 28 A and B). 
Interestingly, when donor T cells were examined for the expression of chemokine 
receptors, only CCR9 was expressed at high levels (Figure 28 C and D). The ligand for 
CCR9 is CCL25 and CCR9 KO mice have reduced numbers of T cells in the lamina propia 
of the small intestine272, 273. CCR9 is critical for T cell migration to the small intestine and 
its expression on Marilyn T cells may be essential for their response to the murine bladder 
carcinoma. It would be interesting to study whether CCR9 KO Marilyn T cells are 
impaired for their ability to cause MB49 tumour rejection.       
In agreement with previous studies TGFβ and IL-6 are required but IL-2 is 
inhibitory for Th17 cell differentiation in vitro268, 274 (Figure 29).  Adoptively transferred 
Th17 polarised cells have been shown to be effective at destroying established B16 
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melanomas180. Using IL-6, TGFβ and anti-IL-2 represents a unique system to polarise 
Th17 cells for adoptive transfer. However subsequent adoptive transfer of Th17 T cells did 
not control tumours any better than naïve or Th1 T cells, in this experiment all mice treated 
with Marilyn cells rejected MB49 tumours (Figure 30).     
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Chapter 6 : Adoptive 
Transfer of CD8+ T cells 
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6.1 : Introduction     
 
Because of their powerful in vitro and in vivo killing activities, CD8+ T cells have been 
utilised in adoptive transfer experiments for treating murine tumours168, 176, 275. As 
described in Chapter 1, the successful treatment of established B16 tumours by adoptive 
transfer of TCR transgenic pmel1 (specific for the gp-10025-33 peptide) cells requires a 
combination of the following four essential elements153: 1) 5Gy irradiation (or 9Gy 
following bone marrow transplantation)157 prior to CD8 transfer; 2) adoptive transfer of 
pmel1 cells; 3) gp10025-33 vaccination after cell transfer, and 4) co-administration of IL-
2153, IL-15167 or IL-15 plus IL-21276. 
CD8 T cell responses against the H2Db-restricted HYUty peptide, expressed by 
MB49 cells, were studied using CD8 T cells from MataHari mice that express a Tg TCR 
specific for the HYUty peptide (WMHHNMDLI) and restricted by the H2-Db MHC-I 
molecule205 It has been previously described that MataHari CD8 T cells do not cause the 
rejection of MB49 tumours178 however, in that study, immuno-deficient Rag-/- B6 female 
mice were used as recipients of MataHari CD8 T cells. The behaviour of T cells in 
lymphopenic Rag-/- hosts is quite different to that in WT recipients277-279. Therefore, in this 
study, to evaluate their anti-tumour efficacy, MataHari T cells were adoptively transferred 
into MB49-bearing WT mice. 
In order to better understand the behaviour of adoptively transferred MataHari T 
cells in vivo, their phenotype and functionality was further characterised in vitro.  
To increase the activation and survival of adoptively transferred MataHari CD8 T 
cells, we pre-conditioned the host by using a low dose of irradiation (5Gy), and included 
vaccination strategies, as these additional manipulations appear to be essential for the 
success of CD8-based immunotherapy in the pmel-B16/F10 model153. 
In an attempt to further enhance the effectiveness of these CD8 cells, in vitro 
activated rather than resting MataHari CD8 T cells were utilised for adoptive transfer. In 
addition, MataHari CD8 T cells co-expressing Tg human-IL-15193, or MataHari CD8  T 
cells transduced with human IL-2, were also tested.  
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6.2 : Characterisation of MataHari T cells in vitro 
 
Before using MataHari T cells in vivo, it was necessary to investigate their phenotype and 
responsiveness to cognate peptides.  
When peripheral lymph node cells from a Rag2-/- MataHari female mouse were 
stained with anti-V8.3PE, anti-CD8PerCP and anti-CD62LAPC we found that there were two 
populations of T cells-expressing transgenic Vβ8.3. 5% of lymphocytes co-expressed CD8 
and V8.3 and 7% co-expressed CD4 and V8.3 (Figure 31A, left panel). The majority of 
gated CD8+Vβ8.3+ cells expressed a high level of CD62L, suggesting that they are naïve 
CD8 T cells (Figure 31A, right panel) whereas the majority of the CD4+Vβ8.3+ cells 
expressed low levels of CD62L suggesting that they are anergic T cells which may have 
cross reactivity with self/environmental antigen.   
When spleen and pooled LN cells from a Rag2-/- MataHari mouse were cultured 
with HYUty peptide, proliferation was observed in a peptide dose-dependent manner, 
demonstrating that the Tg TCR is functional (Figure 31B).  
To distinguish which population, (i.e, CD8+Vβ8.3+ or CD4+Vβ8.3+) was 
responsible for peptide-induced proliferation, we labelled spleen and pooled LN cells from 
a Rag2-/- MataHari mouse with CFSE before culturing them with HYUty peptide. We 
observed that the CD8+Vβ8.3+ cells (Figure 31C, bottom panel) but not the CD4+Vβ8.3+ 
cells (Figure 31C, top panel) proliferated, demonstrating that only CD8+Vβ8.3+ cells were 
able to recognise cognate peptide, thus representing functional MataHari T cells.    
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Figure 31. Characteristic of MataHari T cells in vitro. 
A) Peripheral LN cells from a naïve MataHari Rag2-/- female mouse were stained with 
anti-Vβ8.3FITC, anti-CD62LPE, anti-CD8PerCP and anti-CD4APC. CD4+Vβ8.3+ (middle panel) 
and CD8+Vβ8.3+ (right panel) T cells were gated and analysed for CD62L expression.   
B) Spleen and pooled peripheral LN cells (2x104/well) from a naïve MataHari Rag2-/- 
female mouse were stimulated with the indicated concentrations of HYUty peptide. 
Tritiated thymidine (0.5 Ci/well) was added at 48 hours and the cells were harvested 24 
hours later. Results are presented as the mean CPM ±SD.  
C) Spleen and LN from MataHari Rag2-/- female mouse were labelled with CFSE and then 
cultured with HYUty peptide for 3 days. Cells were harvested and stained with anti-
Vβ8.3PE, anti-CD8PerCP and anti-CD4APC. The dilution of CFSE was analysed after gating 
for CD8+Vβ8.3+ T cells (bottom panel) and CD4+Vβ8.3+ T cells (top panel). 
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6.3 : Adoptive therapy with MataHari T cells with or 
without additional manipulations 
 
To test whether or not adoptively transferred naïve MataHari T cells can cause MB49 
tumour rejection in WT female C57BL/6 mice, 2 x 106 CD8 T cells purified from pooled 
spleen and lymph nodes of MataHari Rag-/- female mice, were injected i.v. into female 
C57BL/6 mice which were subsequently inoculated s.c., two days later, with 3 x 105 MB49 
cells. No difference in tumour growth was observed between the MataHari treated group 
and the control group (no CD8 transfer) (Figure 32A).  
In an attempt to activate donor MataHari T cells in vivo, we introduced a 
vaccination protocol. WT B6 females were inoculated s.c. with MB49 cells 24 hours 
before i.v. injection of purified MataHari CD8 T cells and s.c. vaccination with HYUty 
peptide, with or without Complete Freunds Adjuvant (CFA). The combination of CD8 
transfer and vaccination with peptide plus CFA was more effective at inhibiting tumour 
growth than either no CD8 transfer (p = 0.002) or treatment with peptide without CFA (p = 
0.017)(Figure 32B). 
To test whether or not irradiation can be used to enhance the anti-tumour responses 
of MataHari T cells, female C57BL/6 mice were inoculated s.c. with 6 x 105 MB49 cells. 
Two days later one group was irradiated with 5Gy and adoptively transferred with 2 x 106 
CD8 MataHari T cells whilst the other (control) group just received the adoptively 
transferred CD8 MataHari T cells. There was no observable difference in tumour growth 
between the two groups (Figure 32C).        
 
 
 
 140 
 
 141 
Figure 32. Vaccination but not irradiation boosts anti-tumour responses 
mediated by adoptively transferred MataHari CD8 T cells.  
A) 8 Female C57BL/6 mice were given 2 x 106 CD8+ MataHari T cells i.v. ( , n=4) or 
were untreated ( , n=4).  Two days later, the mice in both groups were inoculated s.c. 
with 3 x 105 MB49 cells. Tumour area was measured as Width x Length at regular 
intervals. Data is presented as mean SD. 
B) At day 0, 16 Female C57BL/6 mice were given 5 x 105 MB49 cells s.c.. At day 1, the 
mice were then randomly split into three groups. Two groups of mice were adoptively 
transferred with 2.1 x 106 MataHari CD8+ T cells (  and ), and the third group ( ) of 
mice were not. At day 5, two groups of mice received CD8 T cells were either left 
unvaccinated ( , n=5) or vaccinated ( , n=5) with HYUty peptide plus CFA by s.c. 
injection. Vaccines were made by mixing 100 μl PBS containing 100 nM HYUty peptide 
with 100 μl CFA. The third group (no CD8 transfer) also received the same vaccination at 
day 5 ( , n=6). Tumour area was measured as Width x Length at regular intervals. Data 
are presented as mean  SEM. ( , peptide and CFA vs. , peptide, CFA and MataHari; * 
p = 0.017), ( , untreated vs. , peptide, CFA and MataHari; ** p = 0.002).  
C) 10 Female B6 were inoculated s.c. with 6 x 105 MB49 cells. Two days later the mice 
were split into two groups, one was irradiated with 5Gy ( , n=5) and the other was not 
( , n=5), then both groups were injected i.v. with 2 x 106 MataHari CD8+ T cells. Tumour 
area was measured as Width x Length at regular intervals. Data are presented as mean as 
mean SD. 
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6.4 : Adoptive therapy using in vitro activated MataHari T cells  
 
In an attempt to increase the efficacy of adoptively transferred CD8 T cells against MB49 
tumours, MataHari T cells were activated in vitro with 0.1 nM HYUty peptide in the 
presence or absence of exogenous IL-2, for 1 or 2 days.  These cells were subsequently 
purified before being adoptively transferred (1 x 106 cells or 3 x 106 cells) to female 
C57BL/6 mice which had been inoculated s.c., with 5 x 105 MB49 cells, 3 days earlier. 
There was no significant reduction in tumour growth irrespective of how the T cells were 
activated or how many were transferred.  
  
 
 143 
 
Figure 33. Adoptively transferred MataHari CD8 T cells which have been 
activated in vitro failed to control the growth of MB49 tumours. 
A) Rag1-/- MataHari spleen and LN cells were cultured with 0.1 nM HYUty for 1 or 2 days, 
CD8 T cells were purified and adoptively transferred to female B6 that were inoculated s.c. 
with 5 x 105 MB49 on the same day of T cell transfer. Two doses of purified CD8 T cells 
with different activation stages were used [1 x 106  from 1 day culture ( ), 3 x 106 from 2 
days culture ( )].  
B) Rag1-/- MataHari spleen and LN cells were cultured with 0.1 nM HYUty in the presence 
of different concentration of hIL-2 (10 or 50 U/ml) for 3 days, CD8 T cells were purified 
and adoptively transferred to female B6 that had been inoculated s.c. with 5 x 105 MB49 3 
days previously [(10U/ml, , n=2, 5x105 cells/mouse), (50 IU/ml, , n=3, 1x106 
cells/mouse), (50U/ml,  , n=4, 2x106 cells/mouse)]. 
 144 
 
6.5 : Adoptive therapy using hIL-15 Tg MataHari T cells  
 
In tumour-bearing hosts, the induction of CD8 T cell tolerance and anergy is very common, 
representing one of the major challenges to successful immunotherapy151. A promising 
strategy to optimise adoptive T cell immunotherapy is to use genetically modified, antigen-
specific CD8 T cells152. One genetic modification strategy is to genetically engineer T cells 
to express specific cytokines; in tumour models in which the genes encoding IL-211, 12, 280 
or IL-15167, 169 have been transferred into T cells, the T cell responses are significantly 
enhanced.   
To test whether the over-expression of Tg hIL-15 in MataHari CD8+ T cells would 
enhance their capacity to control MB49 tumours, we compared the anti-MB49 activities 
between CD8 T cells expressing MataHari TCR alone and those co-expressing MataHari 
TCR and the hIL-15 transgene. Double Tg mice were created by mating Rag2-/- MataHari 
females with hIL-15-Tg males to produce F1 mice. The expression of the MataHari TCR 
was screened, by analysis of Vβ8.3 in PBL, by flow cytometry, and the expression of hIL-
15 was examined by hIL-15 ELISA to determine the concentration of hIL-15 in mouse 
serum. From F1 females, Rag2+/- MataHari females with and without co-expressing IL-15-
Tg were selected as donor mice to provide single Tg or double Tg CD8 T cells.  
Before using double Tg CD8 T cells in vivo, we wanted to investigate whether the 
expression of hIL-15 gene would alter their phenotype and responsiveness to cognate 
peptides. We compared the expression of CD62L, Vβ8.3, CD8 and CD44 and the 
proliferation of PLN cells from a single Tg (MataHari) and a double Tg female B6 mouse 
in response to cognate HYUty peptide. When spleen and pooled LN cells were cultured 
with HYUty peptide, proliferation was observed in a peptide dose-dependent manner in 
both types of T cells. Proliferation was slightly but not significantly lower in double Tg T 
cells in response to a range from 0.1 to 100 nM HYUty peptide (Figure 34A). Although 
single and double Tg mice had similar proportions of Vβ8.3+ CD8+ T cells (data not 
shown), they displayed different frequencies of naïve, EM and CM T cells. In the single Tg 
mice, the vast majority (73%) of gated CD8+Vβ8.3+ T cells were naïve (CD44loCD62Lhi), 
with a minor fraction of CM (8%) and EM (7%) phenotype (Figure 34B, left panel). In 
contrast, in the double-Tg mice, the frequency of CM and EM cells was increased whereas 
that of naive cells was reduced (Figure 34B, right panel). Taken together, these results 
suggest that although single- and double-Tg MataHari CD8 T cells express a functional Tg 
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TCR capable of recognising cognate peptide, they harbour a different proportion of naïve, 
CM and EM subsets.    
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Figure 34. Comparison of peptide responses and phenotypes between 
MataHari and MataHari IL-15Tg CD8 T cells.    
A) Spleen and LN cells (2 x 105/well) from single-Tg ( ) or double-Tg mice ( ) were 
stimulated with HYUTY peptide at variable concentrations for 3 days. Tritiated thymidine 
(0.5 Ci/well) was added at 48 hrs, 24hrs later the cells were harvested and proliferation 
was measured. Data are presented as mean ±SD.  
B) Lymph nodes from single-Tg or double-Tg mice were stained with anti-CD62LFITC, 
anti-Vβ8.3PE, anti-CD8PerCP and anti-CD44APC. CD8+Vβ8.3+ MataHari T cells were gated 
and analysed for CD44 and CD62L expression. 
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To test whether or not double-Tg CD8 T cells would be more potent than single-Tg CD8 T 
cells at rejecting MB49 tumour, 10 x 106 purified CD8 T cells, from single-or double-Tg 
mice, were injected i.v. into female C57BL/6 mice which were then inoculated with 3 x 
105 MB49 cells s.c. on the same day as T cell transfer. Early tumour growth was 
significantly inhibited in mice adoptively transferred with double-Tg CD8 compared to 
mice with single-Tg CD8 (Day 11; p = 0.02). However, no long term difference in tumour 
growth, between the groups, was recorded (Figure 35A).  
In an attempt to increase the anti-MB49 efficacy of adoptively transferred double-
Tg CD8 T cells, we activated the T cells in vitro before transfer: The spleen and LN cells 
from double-Tg mice were stimulated with 0.3 nM HYUty peptide for 3 days before CD8 
T cells were purified and adoptively transferred to female C57BL/6 mice (which were then 
inoculated s.c. with 4 x 105 MB49 cells on the same day as T cell transfer). Early tumour 
growth was significantly inhibited in mice adoptively transferred with activated double-Tg 
CD8 compared to mice with activated single-Tg CD8 (Day 11; p = 0.04). However, 
activated double-Tg T cells, did not control long term tumour growth any better than 
single-Tg T cells (Figure 35B). 
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Figure 35. Adoptive therapy using resting or in vitro activated single-Tg or 
double-Tg CD8 T cells.   
A) 10 x 106 CD8+ cells purified from either single-Tg ( , n=3)  or double-Tg mice ( , 
n=3) were adoptively transferred to female C57BL/6 mice which were then inoculated s.c. 
with 3 x 105 MB49 cells on the same day of T cell transfer. Tumour area was measured as 
Width x Length at regular intervals. Data is presented as mean± SEM. Day 11; p = 0.02  
B) Spleen and LN cells of single- or double-Tg mice were stimulated with 0.3 nM HYUty 
peptide in 24 well plates. 3 days later, viable CD8+ T cells were purified by MACS and 5 x 
106 single-Tg CD8+ ( , n=2) or 10 x 106 double-Tg CD8 T cells ( , n=2) were 
adoptively transferred to female C57BL/6 which were then inoculated s.c. with 4 x 105 
MB49 cells. Tumour area was measured as Width x Length at regular intervals. Data is 
presented as mean ± SEM. Day 11; p = 0.04. 
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To follow the fate of donor MataHari CD8 cells in MB49-bearing mice, Thy1.1+ single- or 
double-Tg CD8 T cells were adoptively transferred to Thy1.2+ WT C57BL/6 mice that 
were s.c. inoculated with 5 x 105 MB49 cells. After 11 days the tdLN and tumour tissues 
were harvested and the frequency and absolute numbers of the adoptively transferred donor 
CD8 T cells was analysed. The absolute number of tumour-infiltrated double-Tg CD8 T 
cells was significantly higher than that of tumour-infiltrated single-Tg CD8 T cells  (Figure 
36 A and B, p = 0.025). However, the number of donor T cells recovered from draining 
lymph nodes of the two groups was similar (Figure 36 C and D).         
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Figure 36. For accumulation in MB49 tissues, double-Tg CD8 T cells are more 
potent than single-Tg CD8 T cells 
6 x106 naïve single- or double-Tg CD8 T cells (Thy1.1) were injected i.v. to female C57BL/6 mice (Thy1.2) 
which were inoculated s.c. with 5 x 105 MB49 cells on the same day of T cell transfer.11 days later, tumour 
and  tumour-dLN were harvested. The cells were counted and then stained with anti-Vβ8.3PE, anti-
Thy1.1PerCP and anti-CD44APC. The small lymphocyte gate used to gate lymphocytes was also applied to the 
MB49 tissues.  
A) The absolute number of double-Tg ( , n = 4) or single-Tg CD8 T cells ( , n = 4) recovered from the 
tumours was calculated by the total number cells/tumour x % Thy1.1+ Vβ8.3+ donor cells. Data are presented 
as mean ± SD. * p =0.025. 
B) The frequency of tumour-infiltrated donor CD8 T cells is shown by one representative density plot. 
C) The absolute number of double-Tg ( , n = 4) or single-Tg CD8 T cells ( , n = 4) recovered from 
tumour-dLN was calculated by the total number cells/tumour x % Thy1.1+ Vβ8.3+ donor cells. Data are 
presented as mean ± SD. 
D) The frequency of donor CD8 T cells in MB49-dLN is shown by one representative density plot. 
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6.6 : A combinational therapy using double-Tg CD8 T cell transfer 
and host preconditioning  
 
Despite the increased frequency and higher absolute number of tumour-infiltrated donor 
double-Tg CD8 T cells, MB49 tumours are not rejected. Therefore it is likely that 
additional manipulations are needed to boost the anti-tumour effects of double-Tg CD8 T 
cells. Sub-lethal irradiation has been shown to synergise with IL-15 to enhance the 
cytotoxicity and proliferation of adoptively transferred pmel CD8 T cells166. Moreover, we 
have shown in Chapter 5, that sub-lethal irradiation enhances the anti-tumour effects of 
adoptively transferred Marilyn cells. To study the effect of irradiation on the anti-MB49 
capacity of adoptively transferred double-Tg CD8 T cells, female C57BL/6 mice were 
irradiated with 5Gy before i.v. adoptive transfer of double-Tg CD8 T cells and s.c. MB49 
challenge.  
The results of two independent experiments are shown below.  In the first 
experiment, MB49 tumours in the control mice (irradiated but no CD8 transfer) grew faster 
than in mice that had been treated with double-Tg CD8 T cells.  Furthermore MB49 
tumours reached an average size of 64 ± 8 mm2 by day 18 in control mice compared to 
significantly smaller (p = 0.019) tumours (39±14 mm2 by day 18) in mice treated with 
double-Tg CD8 T cells (Figure 37A). A similar result was observed in the second 
experiment, MB49 tumours in the control group were larger and grew to 80±22 mm2 by 
day 17, whereas tumours in mice that had been treated with double-Tg CD8 T cells were 
significantly smaller (p = 0.013) reaching a size of 38±14 mm2 by day 17 (Figure 37B).  
 
     
    
. 
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Figure 37. Effective adoptive immunotherapy with double-Tg CD8 T cells 
requires pre-conditioning of host with 5Gy irradiation. 
A) 7 female C57BL/6 mice were irradiated with 5Gy, of which 4 mice ( , n=4) were given 3.7 x 
106 double-Tg CD8 T cells by i.v injection, the remaining 3 mice were not ( , n=3). Then all 
mice were inoculated s.c. with 4 x 105 MB49 cells on the same day of CD8 transfer. Tumour area 
was measured at regular intervals. Data are presented as mean ± SD. * p = 0.019.   
B) 7 female C57BL/6 mice were irradiated with 5Gy. Of which, 5 mice ( , n = 5) were treated 
with 6.6 x 106 double-Tg CD8 T cells i.v, two remaining mice were untreated ( , n = 2). Then all 
mice were inoculated s.c. with 4 x 105 MB49 cells. Tumour area was measured at regular intervals. 
Data are presented as mean ± SD. * p = 0.013 
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6.7 : The use of genetically modified MataHari CD8 T cells to treat 
MB49 tumour. 
    
Having found that antigen specificity of CD8 T cells is necessary but not sufficient for 
clearing tumours, we decided to use genetic modification approaches to enhance anti-
tumour CD8 responses. To this end, we engineered retroviral constructs encoding the 
human IL-2 gene (hIL-2). MataHari CD8 T cells were activated with HYUty peptide prior 
to transduction with the hIL-2 encoding retrovirus. The expression of human IL-2 by 
MataHari CD8 T cells was verified by co-expression of GFP from the viral vector.   
To test whether hIL-2-transduced MataHari CD8 T cells could cause MB49 tumour 
rejection, 10 x 106 hIL-2-transduced MataHari CD8 T cells were injected i.v. into female 
C57BL/6 mice that had been irradiated with 5Gy. One day after T cell transfer, the mice 
were inoculated s.c. with 5 x 105 MB49 cells. Control mice were irradiated and inoculated 
s.c. with 5 x 105 MB49 cells but were not injected with CD8 T cells. 
   MB49 tumours in the control mice were significantly larger, reaching an average size of 
60 ± 6 mm2 by day 13, than in treated mice (p > 0.0001) whose tumours measured an 
average of 6±6 mm2 (Figure 38A). 
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Figure 38. Irradiation followed by adoptive transfer of IL-2-transduced 
MataHari T cells efficiently controls MB49 tumours 
A total of 13 WT female C57BL/6 were irradiated with 5Gy. Twenty four hours later, five 
mice were injected i.v. with 10 x 106 IL-2-transduced MataHari T cells ( , n = 5), and 8 
mice were not ( , n=8). All mice were inoculated s.c. with 5 x 105 MB49 on the same day 
of CD8 transfer. Tumour area was measured as Width x Length at regular intervals. Data 
are presented as mean ± SD. p > 0.0001.   
 
 
6.8 : Discussion. 
 
As MataHari CD8 T cells would be utilised as effectors in treating MB49 tumours by 
adoptive transfer, it was of importance to characterize their phenotype and function. FACS 
analysis showed that Rag2-/- MataHari female mice have two populations of T cells-
expressing transgenic Vβ8.3, 5% of lymphocytes co-expressed CD8 and V8.3 and 7% co-
expressed CD4 and V8.3 (Figure 31A, left panel). This unexpected observation does not 
correlate with the originally derived transgenic MataHari which expressed a monoclonal 
population of CD8+V8.3+ T cells178, 205. However, the majority of gated CD8+Vβ8.3+ cells 
expressed a high level of CD62L, suggesting that they are naïve CD8 T cells (Figure 31A, 
right panel) whereas the majority of CD4+Vβ8.3+ cells expressed low levels of CD62L 
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suggesting that they are anergic T cells which may have cross reactivity with 
self/environmental antigen.   
When spleen and pooled LN cells from a Rag2-/- MataHari mouse were cultured 
with HYUty peptide, a strong proliferation was observed in a peptide dose-dependent 
manner, demonstrating that the transgenic TCR is functional (Figure 31B).  
    To distinguish which population, (i.e, CD8+Vβ8.3+ or CD4+Vβ8.3+) is responsible 
for peptide-induced proliferation, we labelled spleen and pooled LN cells from a Rag2-/- 
MataHari mouse with CFSE before culturing them with HYUty peptide. We observed that 
the CD8+Vβ8.3+ cells (Figure 31C, bottom panel) but not the CD4+Vβ8.3+ cells (Figure 
31C, top panel) showed CFSE dilution, demonstrating that only CD8+Vβ8.3+ cells are able 
to recognise cognate peptide, thus representing functional MataHari T cells.     
Adoptive transfer of naïve MataHari cells inhibited the growth of MB49 tumours 
when combined with a vaccine of complete freunds adjuvant mixed with HYUty peptide 
(Figure 32B). Naïve MataHari cells alone or after irradiation did not successfully clear the 
tumour (Figure 32A and C). MataHari T cells that had been activated in vitro before being 
adoptively transferred to female C57BL/6 mice did not successfully inhibit MB49 tumour 
growth (Figure 33A and B).  
Together these results suggest that MataHari cells are only effective at reducing the 
growth of MB49 tumours in female C57BL/6 WT mice when they are boosted by 
vaccination. This confirms results from a previous study in Rag-/- female C57BL/6 mice 
that demonstrated that 1 x 106 naïve MataHari cells did not cause the rejection of 1 x105 
MB49 cells injected s.c. one day previously178, these results suggest that additional help is 
required in immuno-deficient and immuno-competent mice. These results differ from those 
of many studies that have found that the adoptive transfer of tumour reactive CD8 T cells 
inhibits tumour growth168, 176, 275. MataHari T cells efficiently kill MB49 cells in vitro178 
but are ineffective in vivo. This may be because of tumour mediated suppression281, 
exhaustion by chronic antigen stimulation282, anergy283 or FAS/FAS-L mediated activation 
induced cell death284. 
To try and boost the anti-tumour capacity of MataHari T cells, MataHari mice were 
crossed with IL-15 transgenic mice193. IL-15 was chosen because it can abrogate the 
effects of AICD193, 285 and Treg mediated suppression on conventional CD4 and CD8 T 
cells96, it helps long term survival of CD8 memory cells 91, 92 and increases anti tumour 
activity167.     
MataHari IL-15 double transgenic CD8 T cells were used as effectors in treating 
MB49 tumours by adoptive transfer. FACS analysis showed that double-Tg female mice 
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had increased fractions of effector memory (EM) and central memory (CM) cells, whereas 
T cells in single transgenic mice were predominantly naïve cell (Figure 34B), which is in 
agreement with previously published results167. Proliferation in response to cognate peptide 
by both single and double transgenic was comparable (Figure 34A). 
Adoptive therapy using naïve (Figure 35A) and activated (Figure 35B) double 
transgenic T cells inhibited early growth of MB49 tumours when compared to single 
transgenic cells. However by the end of the experiment tumour sizes in both groups were 
similar, suggesting double transgenic T cells are marginally better at controlling MB49 
tumours than single transgenic cells. In vitro activation of single and double transgenic 
cells did not improve tumour therapy. 
When tumours from treated mice were analysed it was found that double transgenic 
cells were present at higher numbers than single transgenic cells (Figure 36A and B). 
However the proportions of single and double transgenic cells in the tdLN were very 
similar (Figure 36C and D), suggesting that double transgenic cells had an increased 
capacity to infiltrate into the tumour. In a similar study, Klebanoff et al. used pmel T cells 
crossed with IL-15 Tg mice to show that IL-15 reduced the growth of B16 melanomas. 
This study demonstrated that IL-15Tg T cells were better at controlling B16 melanomas 
than either pmel or pmel expressing IL-2167.   
Double transgenic T cell therapy does not cause complete remission of MB49 
tumours. Preconditioning recipients with sub-lethal irradiation is a commonly used 
regimen to enhance adoptive transfer. 5Gy of irradiation significantly enhanced the 
therapeutic potential of double transgenic cells transferred to tumour bearing mice (Figure 
37A and B). These results corroborate previous findings suggesting that pre-conditioning 
with irradiation synergises with IL-15 to abrogate CD8 T cell tolerence166.  
In a separate experiment, 5Gy of irradiation followed by adoptive transfer of hIL-2 
transduced Matahari CD8 T cells was even more effective at preventing the growth of 
MB49 tumours than double transgenic cells (Figure 38). This is in agreement with several 
experiments that have used IL-2 to augment in vivo anti-tumour responses167, 286, 287. 
Together the results in this chapter demonstrated that MataHari cells are incapable 
of causing tumour rejection alone despite being able to recognise tumour antigen. In this 
sense MataHari cells represent an anergic and tolerant CD8 T cell population similar to 
those found in tumour bearing patients. Therefore, the extra manipulations that are needed 
to activate MataHari cells to become tumour effector cells may well be representitive of 
those found in a clinical setting. Here we describe that a strong TCR signal by vaccination, 
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or a combination of pre-conditioning by irradiation followed by transfer of T cells 
expressing exogenous IL-2 or IL-15 are effective at causing tumour rejection.       
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Chapter 7 : Treg and 
MB49     
 159 
 
7.1 : Introduction 
 
The primary function of natural CD4+ CD25+ Foxp3+ regulatory T (nTreg) cells is to 
control self-reactive peripheral T cells that escape thymic deletion57, 60, 61.  As many tumour 
associated antigens are aberrantly expressed normal self-proteins288, the activity of self 
reactive nTreg cells is proposed to inhibit tumour-specific T-cell responses. Indeed, in vivo 
depletion of nTreg cells improves anti-tumour responses and enhances the efficiency of 
therapeutic cancer vaccines125, 126. Expansion of nTreg cells is often correlated with tumour 
growth151, 289  but several key questions regarding tumour-driven nTreg expansion remain 
unanswered.  
  Firstly, do tumour antigens, which are altered self-proteins, activate endogenous 
polyclonal nTreg cells? Furthermore, does tumour-derived transforming growth factor-β 
(TGF-β) expand activated Treg cells in an antigen-independent manner290? And do 
activated nTreg cells, which can suppress anti-tumour immunity non-specifically in vivo, 
become expanded by tumour?  
Secondly, do nTreg cells expand solely in response to the tumour and what is the 
relative contribution of antigen-specific and non-specific expansion to the overall pool of 
nTreg cells? In addition, is there a difference in the in vivo migration of nTreg cells 
expanded by these two distinct pathways? 
  Finally, do murine tumours, other than the non-immunogenic B16 tumours, expand 
polyclonal nTreg cells via a TGF-β-dependent mechanism and does290 this mechanism 
apply to other immunogenic tumours and to tumour-specific nTreg cells? 
    The responses of tumour-antigen specific nTreg in vivo has only been examined 
following vaccination to viral components291, 292 and little is known about nTreg expansion 
in response to the tumour.  
  To address these questions, tumour-specific nTreg cells purified from female 
Rag2+/- Marilyn mice or polyclonal nTregs purified from WT B6 by FACS sorting were 
injected intravenously (i.v.) into tumour-bearing wild-type (WT) B6 mice. WT C57BL/6 
mice were inoculated with MB49 (as described previously) or the HY-negative B16 
melanoma, or B16 melanoma that had been transfected with the Dby gene to produce an 
HY-positive variant (B16/HY). By comparing the nTreg reactions to all three tumours the 
relative contributions of non-specific and HY-specific nTreg-cell expansion by tumours 
can be investigated. 
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7.2 : Adoptive transfer of CD25 depleted Marilyn T cells 
 
CD25-depleted but not undepleted Marilyn CD4 T cells are potent responders in vivo. To 
compare in vivo anti-HY responses by Marilyn CD4 T cells with or without nTreg cells, 
CD4 cells purified from Rag 2+/- Thy-1.1+ Marilyn females were either depleted of CD25-
expressing cells or not. After CFSE labelling, CD25 replete and CD25 depleted Marilyn T 
cells were adoptively transferred into four groups of Thy-1.2+ C57BL/6 female mice. Next 
MB49 cells were injected subcutaneously into the right flank of two groups of recipients of 
each donor population.  
Five days after tumour inoculation, the representation of donor cells in various tissues of 
the individual mice in all four groups was analysed. 
  Donor cells in the group which received both CD25 depleted CD4 and MB49 cells 
mounted a robust response with an eight-fold expansion in the dLN, (0.545 ± 0.01% vs. 
0.065 ± 0.02% in the control group that received CD25 depleted CD4 alone, p < 0.01), and 
a significant accumulation in the tumour (3.55 ± 0.27%)(Figure 39A). In addition, 
proliferating donor cells (Thy-1.1+ Vβ6+) in dLN significantly increased CD44 expression 
after progressive cell divisions whereas those in peripheral LN (inguinal, pLN) of the 
tumour free control group did not (86.7 ± 0.3% vs. 5.98 ± 1.6%, p < 0.01)(Figure 39B, C 
and D, right panels). In contrast, the donor cells in the group given both CD25 intact CD4 
T cells and MB49 cells (Figure 39C) underwent a poor response with a limited 
accumulation in the dLN (0.01 ± 0.01% vs. 0.055 ± 0.01% in tumour-free control group, 
p > 0.05) and tumour (0.06 ± 0.01%) (Figure 39A) which could be the result of either 
failure of activation or accelerated activation-induced cell death in the presence of CD25+ 
nTreg cells. As > 90% of CD25 replete donor cells lost CFSE but up-regulated CD44 
(Figure 39C, right panel), it is likely that all donor cells were recruited into the anti-MB49 
response but most of them were eventually eliminated during the course of the response. 
Taken together, these results clearly indicate that CD25+ nTreg cells have a huge impact 
on determining whether a CD4 response would be successful, because a minor population 
of Marilyn nTreg cells co-transferred with a majority of conventional Marilyn CD4 T cells 
is associated with a substantially reduced response to MB49. 
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Figure 39.  Comparison of anti-MB49 responses by CD25-depleted and CD25 
intact Marilyn CD4 T cells.  
A) Four groups of Thy-1.2 B6 females (three or four mice/group) were adoptively transferred with 
1.5 x 106 CFSE-labelled CD25-depleted ( ) or CD25-intact ( ) Thy-1.1 Marilyn CD4 T cells by 
i.v. injection. Next day two groups of mice only were inoculated s.c. with 0.5 x106 MB49 cells. 
Five days after MB49 inoculation, all groups were analysed by staining of dLN and MB49 or pLN 
cells with anti-Vβ6PE, anti-Thy-1.1PerCP and anti-CD4APC. The mean frequency ± SD is presented. * 
CD25-depleted, tdLN vs CD25-depleted pLN; p = <0.01.   
B, C, D) The donor cells in lymph nodes (LN) and MB49 were identified by co-expression of Thy-
1.1 and CD4. In addition, LN samples were also stained with anti-Vβ6PE, anti-Thy-1.1PerCP and anti-
CD44APC. The donor cells were identified by co-expression of Thy-1.1 and Vβ6 and their CFSE 
profiles were presented as CFSE versus CD44. A total of 2 million events (no gate) was acquired 
for each sample (B, C, right hand side of panel). One representative experiment of three is shown. 
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7.3 : MB49 expands Marilyn but not B6 natural Treg cells in vivo.  
 
A small nTreg-cell population has a significant impact on a much larger CD4 T-cell 
population of the same specificity, therefore, it is possible that MB49 can preferentially 
expand nTreg cells. MB49-induced nTreg-cell expansion can be either antigen driven or 
not, or a combination of both, because some tumour cell lines can expand nTreg cells in an 
antigen-independent fashion290. As MB49 variants lacking expression of HY are not 
available, the relative contribution of antigen non-specific expansion cannot be determined. 
To overcome this limitation, we used the alternative strategy of transferring polyclonal 
nTreg cells from Thy1.1+ female C57BL/6 mice to MB49 bearing female B6 Thy-1.2 mice. 
If MB49 can induce nTreg cells to proliferate non-specifically, then expansion of B6 nTreg 
cells from this source would be seen.   
To test antigen dependent expansion of nTreg, CD25 replete Thy1.1+ Marilyn 
nTreg cells were adoptively transferred into two groups of Thy1.2+ C57BL/6 females, one 
group was given MB49 inoculation the next day. As shown in Figure 40A and B, 
following MB49 challenge, Marilyn nTreg cells underwent an eight-fold expansion in the 
dLN when compared to tumour free control (0.0207 ± 0.0111 vs. 0.0026 ± 0.0013% in 
tumour-free control group, p < 0.05). Furthermore, the degree of donor nTreg cells 
expansion was higher when absolute numbers of donor cells recovered from the two 
groups was compared (data not shown). Marilyn nTreg cells also showed a significant loss 
of Foxp3 expression in the dLN of MB49 bearing mice (84.83 ± 0.08% vs. 96.55 ± 3.45% 
in control group) (Figure 40B, top right panel). 
 To test antigen independent expansion of polyclonal B6 nTreg, cells were 
adoptively transferred into two groups of Thy1.2+ C57BL/6 females, one group was given 
MB49 inoculation the next day. There was no expansion of B6 nTreg cells in response to 
MB49 in the tdLN, based on the measurement of both frequency (Figure 40A and B) and 
absolute cell number (data not shown), suggesting that MB49 tumour can‟t non-
specifically expand nTreg cells.  
The frequency of donor Marilyn nTreg cells that had migrated to the tumour was 
higher (0.5821 ± 0.3011%) than that of B6 nTreg (0.0069 ± 0.0069%)(Figure 40C) But 
only one-third of tumour-infiltrated donor Marilyn nTreg cells maintained Foxp3 
expression (33.93 ± 10.49% in MB49 vs. 84.83 ± 0.08% in dLN)(Figure 40D, top right 
panel) 
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Figure 40. MB49 expands Marilyn but not B6 natural regulatory T (nTreg) 
cells in vivo  
Four groups of Thy1.2+ C57BL/6 females (three mice/group) were transferred with 1 x 105 
Thy-1.1 Marilyn nTreg or Thy-1.1 B6 nTreg cells of which two groups of mice were given 
MB49 cells the next day but the other two groups were not. 11 days after MB49 
inoculation, analysis was performed by staining the cells with anti-Vβ6PE or anti-TCRβPE, 
anti-Thy-1.1PerCP and anti-CD4APC, before intracellular staining with anti Foxp3FITC. The 
donor cells were identified by co-expression of Thy-1.1 and CD4 (R2), and their Foxp3 
expression was presented as CD4 versus Foxp3. 
A) The frequency of Marilyn nTreg or B6 Treg in the tumour draining lymph nodes of 
treated mice or peripheral lymph nodes of untreated mice is presented as mean ± SD. * 
Marilyn vs. Marilyn + MB49; p < 0.001. * B6 vs. B6 + MB49; p < 0.001.  
C) The frequency of Marilyn nTreg or B6 nTreg in the tumour mass of treated mice is 
presented as mean ± SD.  
B and D) representative dot plots of nTreg in tdLN and tumour. One representative 
experiment of four is shown. A total of 2 million events was acquired for each sample. For 
the MB49 samples, tumour size is also indicated. 
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7.4 : Characterisation of HY expressing B16 line 
 
Antigen-specific and non-specific nTreg-cell expansion by tumours could be directly 
compared using antigen-positive and antigen-negative variants of the same tumour cell line. 
As an HY-negative, mutant MB49 cell line is not available and a knockout of the HY Dby 
gene from MB49 cells is technically challenging, an HY-expressing variant of an HY-
negative tumour cell line was produced. The widely used melanoma cell line B16178 was 
transfected with the HYDby gene and a stable HY-expressing clone was obtained 
(B16/HY). Although Dby expression by B16/HY was lower than MB49, it was 
significantly higher than B16 (p < 0.05) (Figure 41A). Dby expression by B16/HY was 
maintained following tumour development (Figure 41B), suggesting that the expression of 
the transgene is stable in vivo.  
Adoptively transferred, CFSE-labelled Marilyn conventional CD4 T cells 
proliferated in dLN in response to B16/HY but there was no activation of donor cells in 
B16-bearing mice (Figure 41C), or in tumour-free controls (data not shown). Donor T cells 
were also detectable in B16/HY tumours (Figure 41D). These in vivo T-cell recognition 
assays conclusively demonstrated that transduced Dby genes in B16/HY were functional.  
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Figure 41. Characterization of HY-expressing B16 cell line (B16/HY) 
A) B16, B16/HY and MB49 cells were compared for Dby expression by reverse transcription–
polymerase chain reaction (RT-PCR) with male or female B6 spleen cells used as internal controls. 
One representative experiment of three is shown. Mean Dby expression is presented ±SD. * B16 
vs. B16/HY; p < 0.05  
B) Two groups of B6 females (three mice/group) were inoculated subcutaneously (s.c.) with 5 x105  
B16 or B16/HY cells, respectively. Two weeks later, B16 and B16/HY tumours from individual 
mice were compared for Dby expression by RT-PCR with B16 and MB49 cell lines were used as 
internal controls. One representative experiment of two is shown. 
Three groups of Thy-1.2 B6 females (three mice/group) were adoptively transferred with 3 x 106 
CFSE-labelled Thy-1.1 Marilyn CD4 T cells. Next day the mice in two groups (d, e) were 
inoculated s.c. with 5 x 105 B16 or B16/HY cells, respectively. Thirteen days after tumour 
inoculation, analysis of dLN (C) or tumour (D) was conducted by staining the cells from various 
tissues with anti-Vβ6PE, anti-Thy-1.1PerCP and anti-CD4APC. The donor cells were identified by co-
expression of Thy-1.1 and CD4 (R2). The CFSE dilution by donor cells is presented as CFSE 
versus CD4. One representative experiment of two is shown. A total of 2 million events was 
acquired for each sample. For the B16 and B16/HY samples, tumour size is also indicated. 
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7.5 : Comparison of the relative contribution by non-specific and 
ag-specific nTreg cell expansion 
 
Thy1.1+CD4+Vβ6+CD25+GFP+ cells from (Foxp3/GFP knockin x Marilyn) F1 females 
were sorted by FACS, and adoptively transferred into three groups of Thy1.2+ females, 
then two of the groups were injected s.c. with either B16 or B16/HY cells the next day. 
 The expansion and Foxp3 expression by donor Treg cells was analysed 11 days 
after tumour inoculation. 
 Expansion of Marilyn nTregGFP cells in B16/HY tumour bearing mice was more 
efficient than in mice with the B16 tumour, 3.8-fold more donor cells accumulated in dLN 
of B16/HY than in dLN of B16 (0.0381 ± 0.0092% vs. 0.0101 ± 0.0005%, p < 
0.05)(Figure 42A and B). Furthermore, the absolute donor Treg-cell numbers recovered 
from B16/ HY-bearing mice was significantly higher than those from B16-bearing mice 
(data not shown). However, B16 tumour appeared to be able to expand Marilyn nTreg cells 
non-specifically, as the frequency of donor Treg cells detected in dLN of B16-bearing mice 
was higher than those in pLN of tumour-free control mice (0.0101 ± 0.0005%, Figure 42, 
top left panel vs. 0.0013 ± 0.000, Figure 42A and B). 
 Marilyn nTregGFP cells were present in B16/HY tumours (0.2585 ± 0.066%,  
Figure 42D, bottom left panel) but were absent from B16 tumours (0.000 ± 0.000%, Figure 
42C and D), indicating that the additional step of migration of nTreg cells to the tumour is 
antigen dependent. 
Finally, Foxp3 expression by nTreg cells in vivo appears to be unstable: following 
antigen recognition, expanded Treg cells can lose Foxp3 expression. Loss of Foxp3 by 
tumour-infiltrated Treg cells is greater (77.68 ± 0.02%, Figure 42D, bottom right panel) 
than that by those in dLN (91.37 ± 0.08%, Figure 42B, bottom right panel).  
To increase sensitivity Rag2-/- C57BL/6 females were used as recipients of Marilyn 
Treg cells. To make a proper comparison, we also modified the FACS acquisition strategy 
by collecting the same number of events within a live lymphocyte gate, allowing a more 
precise measurement of the frequencies of donor Treg cells between the samples. 
HY-specific green Treg cells were transferred to two groups of Rag2-/- C57BL/6 females, 
which were inoculated with either B16 or B16/HY cells on the same day. Twelve days 
later, FACS analysis was performed to compare the frequency of donor Treg cells in dLN, 
spleen and tumour tissues of individual mice between two groups. Unlike the low recovery 
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of donor Treg cells in dLN of B16/HY-bearing WT B6 females (0.04%, Figure 42B, 
bottom left panel), a much higher proportion was present in dLN of B16/HY-bearing Rag2-
/-
 B6 females (15%, Figure 42F, bottom left panel). A significant fraction of  activated 
donor Treg cells also accumulated in both spleen (data not shown) and B16/HY tumours 
(2.7%, Figure 42F, bottom right panel). In B16-bearing Rag2-/- B6 females, however, the 
frequency of donor Treg cells was profoundly decreased in the dLN (0.43%, Figure 42F, 
top left panel, 97% reduction) presumably because of the lack of HY antigens. 
Consequently, donor Treg cells were barely detectable in the B16 tumour mass (0.02%, 
Figure 42F, top right panel, 99% reduction). Taken together, these results demonstrate that 
both antigen-specific and non-specific proliferation of Marilyn nTreg cells contributes to 
the expansion by HY-expressing B16 tumours, but the presence of antigen not only 
amplifies the expansion in dLN but is also required for expanded Treg cells to migrate into 
tumour. A fraction of Treg cells were shown to lose Foxp3 following in vivo activation. 
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Figure 42. Comparison of the relative contribution by non-specific and antigen-specific 
natural regulatory T (nTreg) cell expansion.  
Three groups of Thy-1.2 B6 females (three mice/group) were injected i.v. with 1 x 105 Thy-1.1 Marilyn 
nTreg cells co-expressing Foxp3/GFP (Mar-nTregGFP), of two groups of mice were s.c. inoculated with B16 
cells or B16/HY cells (5 x 105) next day. Eleven days later, cells from tdLN or tumour tissues were stained 
with anti-Vβ6PE, anti-Thy-1.1PerCP and anti-CD4APC. Donor cells were identified by co-expression of Thy-1.1 
and Vβ6 (R2) and their Foxp3 expression is presented as Vβ6 versus GFP.  
A) dLN was analysed for donor Mar-nTregGFP and the results are presented as mean ± SD. * B16 vs. 
B16/HY; p = < 0.05. B) representative dot plots are shown.  
C) Tumour was analysed for donor Marilyn nTreg and the results are presented as mean ± SD. 
D) representative dot plots are shown, One representative experiment of two is shown. A total of 2 million 
events was acquired for each sample. For the B16 and B16/HY samples, tumour size is also indicated. 
E and F) Two groups of Rag2-/- B6 females (four mice/group) were transferred with 2 x 104 Thy-1.2 Mar-
nTregGFP and were also inoculated s.c. with either 1 x 105 B16 or B16/HY cells on the same day. After 12 
days, analysis was performed by staining the draining lymph nodes and B16 or B16/HY tumour tissues with 
anti-Vβ6PE, anti-CD4PerCP, and anti-Thy-1.2APC. Donor Treg cells were identified by co-expression of Thy-1.2 
and Vβ6 (R2). FACS dot plots of one representative mouse of each group are shown. An equal number of 
events in the live lymphocyte gate were acquired for the paired samples (2 x 104 for dLN, 5 x 104 for spleen 
and 5 x 103 for B16 and B16/HY). One representative experiment of two is shown. 
E) dLN was analysed for donor Mar-nTregGFP and the results are presented as mean ± SD. * B16 vs. 
B16/HY; p = < 0.05. F) representative dot plots are shown. 
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7.6 : Expansion of Marilyn nTreg cells by MB49 is TGF-β 
dependent.  
 
The MB49 cell line constitutively expresses TGF-β, revealed by intracellular staining 
(Figure 43A). This cytokine may play an essential role in tumour-induced expansion of 
Marilyn nTreg cells. To explore this, Thy1.2+Marilyn nTreg cells co-expressing the 
dominant negative TGF-β receptor II (Mar-nTregDN cells) were transferred to two groups 
of Thy1.1+ C57BL/6 females, one group was inoculated with MB49 cells next day. Twelve 
days after cell transfer, the mice were analysed for the presence of donor cells. There was 
no difference in terms of the proportion of donor cells in pLN of tumour-free control 
(0.0005 ± 0.000%, Figure 43B) and dLN of MB49-bearing mice (0.0002 ± 0.0001%, 
Figure 43C, right panel). Donor cells were barely detectable in ndLN (Figure 43C, middle 
panel) and MB49 (Figure 43C, right panel). The defect in TGF-β signal transduction on 
nTreg cells abrogated their expansion in response to MB49 indicating that nTreg expansion 
by MB49 appears to be TGF-β dependent. It is unclear whether the data shown may result 
from a developmental defect of nTreg cells expressing the dnTGF-βRII, which may 
prevent appropriate activation in response to antigen. 
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Figure 43. Expansion of Marilyn natural regulatory T (nTreg) cells by MB49 is 
dependent on transforming growth factor-β (TGF-β). 
A) MB49 cells were cultured with 10% fetal calf serum RPMI-1640 in the presence of 1 
µg/ml brefeldin A for 4 hr. After fixing and permeabilizing, the cells were stained for anti-
TGF-βPE (filled) or isotype control (open). 
B and C) Two groups of Thy-1.1 B6 females (three mice/group) were transferred with 1 x 
105 Thy-1.2 Marilyn nTreg cells co-expressing dnTGF-βRII (Mar-nTregdn), of which one 
group of mice received MB49 cells next day (C). Eleven days after tumour inoculation, 
analysis was conducted by staining the cells with anti-Vβ6PE, anti-CD4PerCP and anti-Thy-
1.2APC, before intracellular staining with anti-Foxp3FITC. The donor cells were identified by 
co-expression of Thy-1.2 and Vβ6 (R3). A total of 2 million events was acquired for each 
sample. 
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7.7 : Comparison of Marilyn Treg with or without dnTGF-β in vivo 
and in vitro.   
 
To determine the functionality of dnTGFβRII Marilyn Treg cells in vivo, we performed co-
transfer experiments using Rag2-/- C57BL/6 females as recipients. To this end HY-specific 
conventional CD4 T cells alone (CD4+Vβ6+CD25-CD44low sorted from Thy1.1+ Rag2-/- 
Marilyn females), HY-specific Treg cells alone (CD4+ Vβ6+ CD25+ sorted from Thy1.2+ 
Rag2+/- Marilyn females), HY-specific and dnTGFβRII -expressing Treg cells alone (CD4+ 
Vβ6+ CD25+ sorted from Thy-1.2+ dnTGFβRII + Rag2+/- Marilyn females), or a mixture of an 
equal number of conventional and each Treg-cell population were adoptively transferred 
into five groups of Rag2-/- B6 females which were given MB49 inoculation on the same 
day. Analysis was conducted 12 days later. In the absence of donor Treg cells, Marilyn 
CD4 T cells underwent a robust expansion in response to MB49 tumours with a significant 
accumulation of donor cells (Vβ6+ CD4+ Thy-1.1+) in dLN (50%, Figure 44B, top left 
panel) and the MB49 tumour mass (16%, Figure 44B, top left panel) . However, this HY-
derived systemic activation of donor Marilyn responders was inhibited by co-transferred 
Marilyn Treg cells with 50% suppression in dLN (Figure 44B, middle left panel) and 50% 
suppression in MB49 (Figure 44B, middle right panel). Interestingly, dnTGFβRII-
expressing Marilyn Treg cells showed a partial suppression in dLN (20% suppression, 
Figure 44B, bottom right panel), but they failed to inhibit the accumulation of donor 
responders in MB49 tissue (Figure 44B, bottom right panel). For the suppression of 
accumulation of donor responder cells in dLN, both types of Marilyn Treg cells were 
effective regarding the analysis of both frequency (Figure 44A) and absolute cell numbers 
(data not shown), although overall Treg cells without dnTGFβRII are more potent 
inhibitors than their dnTGFβRII-expressing counterparts. In the presence of donor 
responder cells, the frequency of Marilyn Treg cells in dLN was significantly higher than 
that of dnTGFβRII-positive Treg cells (Figure 44C). Moreover, in the absence of responder 
cells, MB49-induced expansion of Marilyn Treg cells (20%) was significantly greater than 
that of dnTGF-βRII-expressing Marilyn Treg cells (4%) (Figure 44D and E). 
We also conducted a standard in vitro co-culture to determine whether dnTGFβRII-
expressing Marilyn Treg cells are functional. Although Marilyn dnTGFβRII+ CD4+ CD25+ 
cells were apparently anergic, they were also less suppressive than WT Marilyn CD4+ 
CD25+ cells, as at a 1 : 10 ratio of Treg cells to responder cells, no inhibition was achieved 
(Figure 45). In contrast, Marilyn CD4+ CD25+ cells can readily induced a complete 
suppression even at 1 : 1 ratio, as shown previously183.  
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Figure 44. Comparison of Marilyn regulatory T (Treg) cells with or without dnTGF-βRII in 
vivo and in vitro  
Five groups of Rag2-/- B6 females (four mice/group) were transferred with 2 x 104 Thy-1.1 Marilyn CD4 T 
cells alone, 2 x 104 Thy-1.2 Marilyn Treg cells alone, 2 x 104 Thy-1.2 Marilyn Treg cells co-expressing 
dnTGF-βRII alone, or Thy-1.1 Marilyn CD4 mixed with either Thy-1.2 Marilyn nTreg cells or Thy-1.2 
Marilyn Treg cells co-expressing dnTGF-βRII. The mice in all groups were also inoculated subcutaneously 
with 1 x 105 MB49 cells on the same day. Twelve days later, analysis was performed by staining dLN, spleen 
and MB49 tissues with anti-Vβ6FITC, anti-CD4PE, anti-Thy-1.1PerCP and anti-Thy-1.2APC. The donor responder 
and donor Treg cells were identified by co-expression of Thy-1.1 and Vβ6 (R4) and Thy-1.2 and CD4 (R6), 
respectively.  
A and B) The representation of donor responder cells in dLN of three groups, responders alone (R alone), 
responders plus Marilyn Treg cells (R+Treg), and responders plus dnTGF-βRII-expressing Marilyn Treg 
cells (R+Tregdn), results are displayed as mean frequency ± SD. 
C) Frequency of donor Treg cells in draining lymph nodes (dLN) of two co-transfer groups responders plus 
Marilyn Treg cells (Treg), and responders plus dnTGF-βRII-expressing Marilyn Treg cells (Tregdn).  
D) The representation of donor Treg cells in dLN of two groups [Marilyn Treg cells alone (Treg), and 
dnTGF-βRII-expressing Marilyn Treg cells alone (Tregdn)]. results are displayed as mean frequency ± SD. 
E) One representative experiment of two is shown. A total of 0.5 million events was acquired for each 
sample. 
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Figure 45. Mar-Treg
DN
 In vitro suppression assay  
Marilyn CD4+ CD25- responder T cells (1 x  104/well) were incubated with either WT 
Marilyn CD4+CD25+ (Treg) or dnTGF-βRII+ Marilyn CD4+CD25+ (TregDN) cells (1 x 
103/well) together with 50nm HYDby peptide in the presence of antigen-presenting cells (5 
x 104/well, T-cell-depleted B6 female spleen cells) in round-bottomed 96-well plates for 3 
days. Thymidine was added to each well for the last 12 hr. One representative experiment 
of two is shown.  
 
 
 
7.8 : Marilyn CD4 T cells co-expressing transgenic dominant 
negative TGFβ receptor II are resistant to the induction of 
Th17 and iTreg cells in vitro.  
 
Marilyn CD4 T cells-expressing transgenic dnTGFRII also endogenously express 
an intact TGF receptor which can respond to TGF. To examine whether endogenous 
TGF-receptors could maintain TGF signalling in the presence of transgenic dnTGFβRII 
in Marilyn CD4 T cells, we have used in vitro peptide culture systems of inducing Th17 
and Treg cells, as the development of both subsets is dependent on TGFβ293, 294.  
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In the model for generating iTreg cells, spleen and LN cells from dnTGFRII-
negative or dnTGFRII -positive Marilyn females were stimulated with cognate HYDby 
peptide plus rhu-IL-2 in the absence or presence of rhu-TGFWe found that up to 28% 
of dnTGFRII-negative Marilyn CD4 T cells were differentiated into Foxp3-expressing 
iTreg cells following TCR, IL-2 and TGF signalling (bottom of Figure 46B). In contrast, 
development of iTreg cells was profoundly inhibited when dnTGFβRII-positive Marilyn 
cells were used (top of Figure 46B). Induction of Foxp3 expression in dnTGFRII-
expressing Marilyn CD4 T cells was not rescued by increasing the concentration of TGFβ 
(Figure 46A).  
In the Th17 model, spleen and LN cells from dn TGFRII-negative or dn TGFRII 
-positive Marilyn females were stimulated with cognate HYDby peptide and IL-6 with or 
without TGF. Up to 13% of dn TGFRII-negative Marilyn CD4 T cells were 
differentiated into IL-17-producing Th17 cells following TCR, IL6 and TGF signalling 
(bottom of Figure 46D). Th17 development was blocked when dnTGFβRII+ Marilyn 
spleen cells were stimulated under the same condition (top of Figure 46D). Th17 
differentiation was not restored in dnTGFβRII-expressing Marilyn CD4 T cells when the 
concentration of TGF was increased to 10 ng/ml (Figure 46C).   
 These results from two independent in vitro culture systems demonstrated that a) 
intact TGF signalling in T cells is needed for Th17 differentiation and iTreg development, 
and b) the expression of endogenous intact TGF receptors is insufficient to restore TGF 
signalling by competing with dnTGFRII which are over-expressed on Marilyn CD4 T 
cells. 
 
 175 
 
Figure 46. Induction of Th17 and iTreg cells from Marilyn CD4 T cells with or 
without dnTGFβRII in vitro. 
A and B).  2 x 105 of dnTGFβRII-positive (DN+, ) or dnTGFβRII-negative (DN-, ) Marilyn 
spleen and LN cells were cultured with 1nM HYDby peptide plus 20 U/ml of IL-2 in the absence 
or presence of TGFβ in 96-well plates. After 6 days culture, the cells were harvested and stained 
with anti-Vβ6FITC and anti-CD4PerCP. Then cells were fixed and stained with anti-FoxP3FITC. Gated 
CD4+Vβ6+ T cells were further analysed for the expression of Foxp3. 
C and D) 2 x 105 dnTGFβRII-positive (DN+, ) or dnTGFβRII-negative (DN-, ) Marilyn 
spleen and LN cells were cultured with 150 nM of HYDby peptide plus 1ng/ml of IL6 in the 
absence or presence of TGFβ in 96 well plates. After 6 days the cells were stimulated with PMA 
(50 ng/ml), Ionomycin (500 ng/ml) and Brefaldin (1 g/ml) for 4hrs, then harvested and stained 
with anti-Vβ6FITC and anti-CD4PerCP. After fixation and permeabilization, the cells were stained 
with anti-IL-17PE and anti-IFNγAPC. Gated CD4+Vβ6+ cells were further analysed for the 
intracellular production of IL-17 and IFNγ. 
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7.9 : Discussion 
 
This chapter establishes an in vivo model to study the fate of tumour antigen specific 
natural Treg (nTreg) cells in response to tumour. There are several unique features to this 
model. Firstly, the surrogate HY can be expressed either endogenously (MB49) or 
exogenously (B16/HY). Importantly, this gene transfer does not necessarily result in over 
expression, indeed the B16/HY line expresses a low level of HY, which is stable both in 
vitro and in vivo (Figure 41). 
Second, unlike other studies in which the detection of transferred nTreg cells in 
tumour-bearing mice relies on a vaccination to viral components291, 292, we were able to 
show the expansion of antigen specific nTreg cells by tumour without vaccination. 
 Third, unlike other investigations in which the detection of nTreg cells is limited to 
spleen291, 292, we were able to detect the progeny of antigen-specific nTreg cells in both 
tumour tissues and tumour draining lymph nodes (tdLN).  
The first observation of this study is that the induction of non-specific nTreg-cell 
expansion is dependent on the tumour cell lines used. This conclusion was based on the 
results from two sets of adoptive transfer experiments. When B16 and MB49 tumours were 
compared for their capacities for inducing non-specific nTreg expansion, we found that 
adoptively transferred polyclonal nTreg cells underwent expansion in dLN of B16-bearing 
mice (data not shown) but they failed to do so in MB49-bearing mice (Figure 40A), 
indicating that B16 but not MB49 tumours are able to expand nTreg cells non-specifically.  
In the second adoptive transfer experiment, we found that the expansion of HY-
specific nTreg cells could be induced by both HY-negative B16 and HY-positive B16 
tumours in vivo (Figure 42), indicating that B16 is capable of expanding nTreg cells non-
specifically. Because MB49 cells constitutively express HY and an HY-negative MB49 
cell line is not available, MB49-induced antigen specific nTreg-cell expansion in the 
presence or absence of HY cannot be assessed. Although we have not used HY-knockout 
MB49 cells, it is highly unlikely that MB49 is able to induce non-specific nTreg-cell 
expansion, as MB49 cannot expand polyclonal nTreg cells in vivo (Figure 40C). The 
conclusion that B16 but not MB49 can expand Treg cells non-specifically helps to explain 
why B16-bearing mice display a significant increase of percentage of nTreg cells in dLN290 
whereas MB49-bearing mice do not (data not shown). However, the weaker expansion of 
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Treg cells in WT female B6 recipients does not represent the most sensitive model system 
to examine antigen non-specific Treg-cell expansion by tumours. To make a conclusive 
demonstration, tumour-bearing Rag2-/- recipients of Treg cells should be used in future 
studies. Whether the capacity of inducing antigen-non-specific nTreg-cell expansion is 
restricted to spontaneous tumour cell lines remains to be determined. In addition, B16 cells 
are less immunogenic than MB49 cells. Whether there is a correlation between 
immunogenicity and capacity of inducing non-specific nTreg-cell expansion also needs to 
be explored further. Interestingly, there was a significant reduction of Foxp3 expression by 
a fraction of donor Treg cells in response to HY antigens from MB49 (Figure 40) and 
B16/HY tumours (Figure 42). Loss of Foxp3 was more marked in tumour-infiltrating 
donor Treg cells than in dLN. In addition, we show that development of Foxp3-negative 
donor cells (called ex-Treg cells) represents differentiation from green Treg cells and is not 
the result of the expansion of contaminating conventional CD4 T cells. The second 
observation is that although both antigen specific and non-specific expansion contribute to 
the overall pool of adoptively transferred nTreg cells with defined antigen specificity, 
nTreg cells expanded through these two pathways display distinct tissue distribution. 
Although several pairs of antigen-negative and antigen positive tumour cell lines are 
available, direct comparison of the contributions from antigen-specific and non-specific 
expansion has not previously been examined. Consequently, there is very limited 
information regarding the behaviour of nTreg cells expanded by these two pathways. Our 
current investigation provides a detailed comparison showing that the expansion of nTreg 
cells with defined antigen specificity in the presence of antigen is more potent than that in 
the absence of antigen. It is not surprising, as the expansion of Marilyn nTreg cells by 
B16/HY results from a combination of two pathways. Importantly, we have shown for the 
first time that nTreg cells undergoing antigen-specific expansion can migrate to tumours 
where nTreg cells undergoing non-specific expansion cannot (Figure 42). Hence, unlike 
expansion, migration of nTreg cells into tumours is strictly dependent on the presence of 
antigen. 
The third observation is that TGFβ produced by MB49 cells is a key factor 
promoting expansion of Marilyn nTreg cells (Figure 43). This conclusion is based on the 
results showing that the presence of intact TGFβ signalling on Marilyn Treg cells appears 
to be essential for their expansion in response to MB49 tumours (Figure 44). A similar 
strategy has been used by Zitvogel and colleagues to dissect the role of TGFβ in the 
induction of expansion of polyclonal nTreg cells by B16 tumours in vivo, but their study 
was restricted to endogenous polyclonal nTreg cells290. In this respect, our study offers an 
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example showing that TGFβ is required for the expansion of tumour-antigen-specific, 
monoclonal nTreg cells (Figure 44). 
A caveat to this conclusion is the potential for a developmental defect of Treg cells 
expressing the dnTGFβRII which may prevent appropriate activation in response to 
antigen. To address this concern, we compared dnTGFβRII-negative and dnTGFβRII-
positive Marilyn Treg cells both in vivo and in vitro. In vitro, dnTGFβRII -expressing 
Marilyn Treg cells are clearly anergic and have weak suppressive activity (Figure 45). 
Moreover, in vivo, dnTGFβRII RII-positive Marilyn Treg cells can inhibit anti-HY T-cell 
responses, although they are less potent compared with Marilyn Treg cells (Figure 44A).  
 Finally, dnTGFβRII-positive Treg cells expand less efficiently than dnTGFβRII-
negative Treg cells in response to HY antigens from MB49 tumours regardless 
of the presence or absence of co-transferred conventional Marilyn CD4 T cells (Figure 
44D). 
Additional in vivo TGFβ neutralization experiments are needed to confirm the 
requirement for TGFβ signalling for in vivo expansion of nTreg cells. Although the 
MB49 cell line can make TGFβ (Figure 43), we have not examined whether growing 
MB49 tumours would produce TGFβ. In this regard, it has been reported that B16 tumours 
induce a subset of DC in dLN to produce active TGFβ, which then expands polyclonal 
nTreg cells290. In addition, tumour-specific Treg cells are also able to induce tumour 
resident immature DC to produce TGFβ295. Apart from TGFβ, indoleamine 2,3-
dioxygenase is another molecule that can directly contribute to Treg-cell expansion296.  
 
I owe a great deal of thanks to Dr. Caroline Addey, Matthew White, Prof. Elizabeth 
Simpson, Prof. Julian Dyson and Dr. Jian-Guo Chai, for their help in the preparation of this 
chapter and the paper that we published together using these results. The paper is published 
under the title „The roles of antigen-specificity, responsiveness to transforming growth 
factor-β and antigen-presenting cell subsets in tumour-induced expansion of regulatory T 
cells‟ in Immunology297. 
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Summary 
 
This work has established the MB49 tumour as a relevant murine model for the study of 
anti-tumour immune responses. MB49 cells create an immunogenic tumour that is rejected 
at low doses in female C57BL/6 mice because it expresses the male minor antigen HY.   
 Cells from MB49 tumours express the inhibitory ligands PD-L1 and PD-L2, and 
down regulate MHC Class I. Both of these features are hallmarks of cancer and its ability 
to evade the immune system108. Further study to examine how these traits affect the 
immunogenicity of MB49 tumours could prove valuable. 
 By using both IL-10KO mice and anti-IL-10R mAb we have demonstrated that the 
growth of the MB49 tumour is inhibited by IL-10 in vivo. This confirms previous reports 
which studied B16 melanoma and murine mammary adenocarcinomas genetically 
engineered to over express IL-10228-230, but in a more physiologically relevant system. 
Future studies need to address the apparent contradictory effect of IL-10 in the context of 
cancer. 
   Anti-GITR therapy is extremely effective at causing tumour rejection; it was the 
only therapy in this study that consistently caused complete tumour rejection. This 
confirms numerous previous murine studies147, 149, 200, 201 demonstrating that anti-GITR 
therapy causes tumour rejection in several different tumours. It is not surprising that Tolerx 
Inc. are currently conducting Phase I trials with TRX518, humanised anti-human GITR298, 
for malignant melanomas. However, the timing of anti-GITR therapy is crucial, and it 
remains to be seen whether it will be effective in patients with late stage melanomas. 
  Tumour antigen specific Marilyn CD4 cells become activated, proliferate 
vigorously and infiltrate MB49 tumours, but despite this they only slow tumour progress 
and do not cause tumour rejection. It is reported that they cause tumour rejection in Rag-/- 
mice178 which suggests that in immuno-competent mice suppression by T regs or 
competition from other T cells inhibits the CD4 anti-tumour response. Pre-conditioning the 
mice by irradiation greatly enhanced the anti-tumour efficacy of adoptively transferred 
Marilyn cells, presumably because of reduction in Treg suppression and T cell competition.  
  Adoptive transfer of tumour antigen specific MataHari CD8 cells was only 
effective when mice were preconditioned by irradiation and donor cells secreted 
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exogenous IL-15. These results suggests that myeloablative pre-conditioning is essential 
before the adoptive transfer of antigen specific anti-tumour T cells. 
The induction of non-specific nTreg-cell expansion is also shown as not 
representing a common rule for all tumour lines. By making a side-by-side comparison of 
antigen-specific and non-specific nTreg  cell expansion, we provide an example where the 
relative contribution by two pathways can be evaluated. Moreover, for the first time, 
distinct nTreg-cell migration patterns are uncovered, depending on whether expansion is 
antigen dependent or independent. These mechanisms that are responsible for nTreg-cell 
expansion by tumours have implications for understanding and manipulating tumour 
immune evasion.  
Lessons like these from murine models are directly relevant to adoptive immunotherapy 
for human cancer and the rapid pace of research in the coming years will drive 
improvements in the survival rates for cancer patients. 
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Abstract In vitro, engagement of GITR on Treg cells by
the agonistic anti-GITR mAb, DTA-1, appears to abrogate
their suppressive function. The consequence of in vivo
engagement of GITR by DTA-1 is, however, less clear. In
this study, we show that Treg cells isolated from DTA-1-
treated mice were as potent as those from untreated mice in
suppressing conventional CD4 T cells in vitro, indicating that
in vivo GITR ligation does not disable Treg cells. Treatment
of Foxp3/GFP knock-in mice with DTA-1 led to a selective
reduction of circulating Treg cells, suggesting that DTA-1 is
a depleting mAb which preferentially targets Treg cells. In
tumour-bearing mice, DTA-1-mediated depletion of Treg
cells was most marked in tumours but not in tumour-draining
lymph node. These features were conWrmed in an adoptive
transfer model using tumour antigen-speciWc Treg cells.
Interestingly, Treg cells detected in tumour tissues expressed
much higher levels of GITR than those in tumour-draining
lymph nodes, indicating that the eYciency of depletion might
be correlated with the level of GITR expression. Finally, in
vivo labelling of GITR in naive or tumour-bearing mice
demonstrated that Treg cells constitutively expressed higher
levels of GITR than conventional T cells, independent of
location and activation state, consistent with the preferential
in vivo depletion of Tregs by DTA-1. Thus, depletion of
Treg cells represents a previously unrecognised in vivo activ-
ity of DTA-1 which has important implications for the appli-
cation of anti-GITR antibodies in cancer immunotherapy.
Keywords Anti-GITR · Regulatory T cells · Depletion · 
HY · Tumour · Therapy
Abbreviations
dLN Tumour-draining lymph node
pLN Peripheral LN
nTreg Natural CD4+CD25+Foxp3+ regulatory T cells
Mar Marilyn mice
PBL Peripheral blood lymphocytes
MFI Mean Xorescence intensity
Foxp3/GFP Foxp3/GFP knock-in mice
Introduction
Glucocorticoid-induced tumour necrosis factor receptor
(GITR), a member of the tumour necrosis factor receptor
(TNFR) family is expressed on T lymphocytes with the pri-
mary function of protection from activation-induced cell death
[1–3]. Under steady state conditions, CD4+CD25+Foxp3+ reg-
ulatory (Treg) cells constitutively express higher levels of
GITR than conventional CD4 and CD8 T cells [4, 5]. The out-
come of GITR signalling on Treg cells appears to be functional
inactivation (i.e, neutralisation of inhibitory function) [4–6],
whereas ligation of GITR on conventional T cells provides a
co-stimulatory signal promoting activation [7–11].
Since ligation of GITR by DTA-1, an agonistic anti-GITR
mAb, disables Treg whilst co-stimulating conventional
T cells [12, 13], DTA-1 is an attractive reagent for enhancing
T cell immunity against tumour cells [14–18]. Although the
eVectiveness of DTA-1 in cancer immunotherapy is well
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cated by following factors. Firstly, the assumption that DTA-
1 disarms Treg cells is based largely, if not exclusively, on in
vitro data [4, 5], however, this conclusion has been chal-
lenged by a subsequent investigation [11]. Using co-cultures
of Treg and conventional CD4 T cells from WT and GITR-
deWcient mice, Shevach and colleagues showed that GITR
engagement on CD25¡ve but not CD25+ve T cells is required
for neutralising suppression, and the action of DTA-1 is to
confer on CD25¡ T cells resistance to CD25+ve Treg-medi-
ated inhibition, rather than by direct inactivation of Treg cells
[11, 12]. Secondly, T cell behaviour in vivo cannot always be
predicated on in vitro analysis, and few studies have
addressed the impact of DTA-1 on Treg cells in vivo [19].
Inactivation [4, 15, 19], expansion [16] and depletion of Treg
cells [20] are three possible outcomes of GITR ligation by
DTA-1 on Treg cells. Although it has been proposed [12]
and indicated [20] that DTA-1 depletes Tregs in vivo, a for-
mal demonstration has not been made. Thirdly, expression of
GITR on Treg has been largely, if not exclusively, investi-
gated in vitro by comparing the pattern of expression before
and after activation [4, 5, 11, 21]. In vivo, there is competi-
tion between target cells to bind injected antibody eVectively
lowering the number of molecules bound, in comparison
with in vitro studies where an excess of conjugated antibody
is used. Evaluation of GITR expression in real time is vital to
understand the in vivo mechanisms of DTA-1 action.
To investigate in vivo GITR expression and determine
whether DTA-1 selectively targets Treg cells for depletion,
several strategies were adopted including the use of Foxp3/
GFP knock-in mice [22] and adoptive transfer of tumour-
antigen speciWc Treg cells [23]. Furthermore, a staining
protocol enabling in vivo evaluation of GITR expression
was developed.
Materials and methods
Mice
Thy1.2 C57BL/6 (B6) and CBA mice were purchased from
Harlan Olac (Bicester, UK), and bred in the Central Biolog-
ical Services Unit at Hammersmith Campus, Imperial College
London. TCR-transgenic Marilyn [23] and Foxp3/GFP
knock-in [22] mice were kindly provided by Dr. O Lantz
and Dr. B Malissen, respectively. Marilyn mice used in this
study were Thy1.1+ and Rag2+/¡.
Tumour cell line, inoculation and measurement 
of tumour growth
MB49 is a chemically induced murine bladder carcinoma
derived from a B6 male mouse [24]. MB49 cells were
maintained in RPMI 1640 Medium (Gibco, UK) supple-
mented with 10% FCS, 10 mM HEPES, penicillin (100 IU/
ml) and streptomycin (100 g/ml), 5 £ 10¡5 M 2-ME and
2 mM L-glutamine. 5 £ 105 MB49 cells were injected sub-
cutaneously on the right Xank of B6 and Foxp3/GFP knock-
in mice. Tumour growth was measured every other day and
recorded as longest dimension £ shortest dimension in
millimetres squared (mm2).
mAbs and treatment
DTA-1 is rat IgG2b mAb speciWc for mouse GITR [4].
GL-113 is rat IgG1 recognising -galactosidase [25], and
PC61 is rat IgG1 against mouse CD25 [26]. mAbs were
partially puriWed from hybridoma culture supernatants by
precipitation in 50% ammonium sulphate, and were further
puriWed using protein G column. mAb treatment was
conducted by intraperitoneal (i.p.) injection.
PuriWcation of Treg and conventional CD4 T cells
To purify HY-speciWc Treg cells, spleen and pooled LN cells
from Rag2+/¡ Marilyn females (Thy1.1) were incubated with
anti-B220- and anti-CD8-Dynalbeads (Invitrogen, UK). After
depletion of B and CD8 cells, the remaining cells were
stained with anti-V6FITC, anti-CD25PE and anti-CD4PE/Cy5
before sorting for CD4+CD25+V6+ cells (HY-speciWc Treg
cells). To isolate polyclonal Treg and conventional CD4
T cells from B6 mice, similar procedure was used except that
anti-V6FITC was omitted. FACS sorted CD4+CD25+ and
CD4+CD25¡ cells were used as polyclonal Treg and conven-
tional CD4 cells, respectively.
In vitro suppression assay
This was conducted as described previously [27]. In brief,
conventional CD4 T cells, alone or mixed with Treg cells at
various ratios, were stimulated with anti-CD3 mAb in the
presence of accessory cells (irradiated T cell-depleted B6
spleen cells) in round-bottomed 96-well plates for 3 days.
Thymidine was added to each well for the last 12 h and pro-
liferation was measured by thymidine uptake.
Adoptive T cell transfer
FACS-sorted Marilyn Treg cells (Thy1.1+) were adoptively
transferred to Thy1.2+ B6 female recipients by intravenous
(i.v.) injection (1 £ 105 /mouse).
FACS analysis
To detect donor cells (Thy1.1 Marilyn Treg) in recipient
mice (Thy1.2 B6), the cells from MB49 and its draining123
Cancer Immunol Immunotherlymph node were stained with anti-V6PE, anti-Thy1.1PercP
and anti-CD4APC. Donor cells were identiWed by co-expres-
sion of Thy1.1 and V6. To measure the percentage of
T cell subsets in MB49, the cells from MB49 tissues were
stained with anti-CD4PercP and anti-CD8APC, or anti-
CD4APC before intracellular anti-Foxp3FITC staining. Treg cells
in Foxp3/GFP mice were identiWed by co-expression of
CD4 and GFP.
In vivo GITR staining
This was conducted by i.v. injection of Foxp3/GFP mice
with 5 g of PE-conjugated DTA-1. GITR expression in
T cell subsets was analysed by FACS after CD4 and CD8
staining, but without a further staining of GITR.
Statistical analysis
This was performed using a two-sided Student’s t test and
GraphPad Prism software (version 3.02).
Results
Rejection of established MB49 tumours by a single dose 
of DTA-1 treatment
Although administration of DTA-1 alone is suYcient to
reject some types of experimental tumours (Meth A and
Colon 26 [15]), such a treatment appears to be less eVective
for other tumours (B16 and RENCA [15, 16]) unless an
additional manipulation such as DNA vaccination [17] is
included, suggesting that eYciency of DTA-1 therapy is
dependent on the characteristics of transplantable tumour.
Thus, the starting point of this investigation was to assess
the susceptibility of MB49 tumours (murine bladder carci-
noma naturally expressing HY) [24] to DTA-1 therapy.
Like other tumour cell lines such as B16 and RENCA [16],
MB49 does not express GITR (not shown). On day 0, a
total of 11 B6 females were subcutaneously inoculated with
5 £ 105 MB49 cells, at day 8, 6 randomly chosen mice
were given 50 g of DTA-1 by i.p. injection and the
remaining 5 mice were not. Growth of MB49 tumours in
the untreated group was very aggressive reaching a volume
>100 mm2 by day 17 (Fig. 1a). In contrast, DTA-1 was
very eVective in treating established MB49 tumours with
100% rejection rate (Fig. 1b). A control rat IgG (GL-113)
Fig. 1 DTA-1 is highly eVective in treating established tumours. a, b
A single injection of DTA-1 results in the regression of established
MB49 tumours. A total of 11 B6 female mice were s.c. inoculated with
5 £ 105 MB49 cells. 8 days later, the mice were randomly divided into
two groups: one group (B, n = 6) was treated with 50 g of DTA-1
mAb by i.p. injection and the other group was not (A, n = 5). The
growth of MB49 tumours was monitored by measuring tumour size
every other day. One representative of three independent experiments
is shown. c–f Regression of MB49 is correlated with increased
accumulation of tumour-inWltrating CD4 and CD8 T cells but
decreased accumulation of Treg cells. Untreated and DTA-1-treated
mice (3 mice/group) were prepared as described in A and B. At day 15,
MB49 tumours isolated from untreated (C and E) and DTA-1-treated
mice (D and F) were stained with anti-CD4PerCP and anti-CD8APC
(C and D), or anti-CD4PerCP followed by intracellular staining with
anti-Foxp3FITC (E and F). Percentage of CD4+, CD8+, or CD4+Foxp3+
cells in MB49 from individual mice in each group is shown as mean §
SEM. One representative of two independent experiments is shown
123
Cancer Immunol Immunother[25] showed no eVect on MB49 growth (not shown). When
the proportion of inWltrating T cell populations (CD4+,
CD8+ and Foxp3+CD4+) within the MB49 tumours of
untreated (Fig. 1c, e) and DTA-1 treated groups (Fig. 1d, f)
was compared, we found that DTA-1 treatment was associ-
ated with an increased accumulation of CD4 and CD8 T
cells but a reduction of Treg cells. Therefore, MB49 can be
added to a list of tumours which can be rejected by DTA-1.
Given, MB49 tumours are very aggressive and resistant to
HY vaccination [28], complete rejection of established
tumours following a single dose of DTA-1 administration is
very encouraging.
Treg cells puriWed from DTA-1-treated mice 
are competent suppressive cells
In vitro, DTA-1-mediated GITR signalling on Treg cells
abrogates their suppressive activities [4, 5]. As T cell
behaviour in vivo cannot be predicated on the in vitro
behaviour of T cell co-cultures, we evaluated the inhibitory
capacities of Treg cells isolated ex vivo from either
untreated or DTA-1-treated mice 1 day after mAb adminis-
tration. In a standard in vitro suppression assay, Treg cells
from DTA-1-treated mice were as potent as those from
untreated mice in inhibiting conventional CD4 T cells
(from untreated mice) in response to anti-CD3 stimulation
(Fig. 2). Likewise, Treg cells from GL-113-treated mice
showed similar suppressive activity to those from untreated
or DTA-1-treated mice (not shown). Thus, in vivo GITR
signalling on Treg cells does not lead to their functional
inactivation. This observation is consistent with another
report [16].
DTA-1 treatment in vivo leads to a partial depletion 
of Treg cells
Although early studies indicated that DTA-1 (rat IgG2b) is
a non-depleting mAb for Treg cells [4, 15, 19], we repeat-
edly observed a signiWcant reduction (up to 40%) of circu-
lating CD4+CD25+ cells in B6 mice following a single
injection of DTA-1, raising the possibility that DTA-1 is a
depleting mAb in vivo. To provide a conclusive demonstra-
tion, we used Foxp3/GFP knock-in mice in which Treg and
non-Treg cells can be reliably distinguished by GFP
expression [22]. 3 days after DTA-1 treatment, the propor-
tion of CD4+GFP+ cells in PBL decreased from 0.89%
(untreated) to 0.63% (representing a 30% reduction,
p < 0.05), whereas that of the CD4+GFP¡ population of
cells remained unchanged (from 15.3 to 15.1%, left and
middle panels of Fig. 3a). However, in the depletion of
Treg cells, DTA-1 was less eYcient than PC61, a widely
used anti-CD25 depleting mAb [26] which resulted in a
52% reduction of circulating Treg cells (right panel of
Fig. 3a). The proportion of Treg and non-Treg in the PBL
of Foxp3/GFP mice did not change following GL-113 treat-
ment (not shown).
Next, we examined whether DTA-1 treatment would
deplete polyclonal Treg cells in tumour-bearing mice. Two
groups of Foxp3/GFP knock-in mice were injected s.c. with
MB49 cells at day ¡8, one group was given DTA-1 at day
0 and the other was not. 3 days after DTA-1 administration,
each MB49 tumour and its draining LN (dLN) were ana-
lysed for the presence of CD4+GFP+ cells. Following i.p.
injection of DTA-1, there was a 44% (reduced from 0.9 to
0.5%, p < 0.05) and 28% (from 3.12 to 2.24%) decrease of
Treg cells in MB49 tumours and dLN, respectively
(Fig. 3b). Treatment of MB49-bearing mice with GL-113
failed to alter the pattern of Treg accumulation in MB49 or
dLN (not shown). Data shown in Fig. 3b indicate that
DTA-1 depletes tumour-resident Treg cells. However,
DTA-1 treatment also increases the proportion of tumour-
inWltrating eVector T cells (Fig. 1c, d), the decrease of Treg
cells might reXect an increase in another cell population.
We therefore compared the absolute number of tumour-
inWltrated Treg cells from untreated and DTA-1-treated
mice. As shown in Fig. 3c, there was a signiWcant reduction
of tumour-resident Treg cells following DTA-1 treatment,
strongly suggesting that DTA-1 can preferentially deplete
tumour-inWltrating Treg cells.
To investigate whether the results obtained from the
measurement of polyclonal Tregs in tumour-bearing mice
Fig. 2 Treg cells isolated from DTA-1 treated mice are competent
suppressive cells in vitro. Two groups of B6 mice (3 mice/group) were
untreated or treated with anti-GITR by i.p. injection of 50 g of DTA-
1. 24 h later, Treg (CD4+CD25+) and conventional CD4 T cells
(CD4+CD25¡) were puriWed from pooled LN and spleen cells of each
group by FACS sorting. Conventional CD4 T cells (1 £ 105/well)
from the untreated group were cultured with anti-CD3 (0.05 g/ml)
and accessory cells (T cell-depleted and irradiated B6 spleen cells,
2 £ 105/well) in the absence (open triangles) or presence of various
numbers (two time serial diluted from 1 £ 105/well to 780 /well) of
nTregs from either untreated (open squares) or DTA-1-treated group
mice (open circles) in 96-round bottomed plates for 3 days. Thymi-
dine (0.5 Ci/well) was added to each well for the last 12 h. One
representative of two independent experiments is shown123
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adoptively transferred HY-speciWc Treg cells
(Thy1.1+CD4+V6+CD25+ cells sorted from Rag2+/¡ Mari-
lyn females) to four groups of Thy1.2 B6 mice which were
injected with MB49 cells (G2 and G4) or not (G1 and G3)
on the same day of Treg cell transfer, and given DTA-1 (G3
and G4) or not (G1 and G2) on day 8 (Fig. 3d). The impact
of DTA-1 treatment on monoclonal Treg cells was deter-
mined by comparing the proportion of donor cells in MB49
and dLN between G2 and G4. DTA-1 treatment led to 95%
reduction in the accumulation of Marilyn Treg cells in the
MB49 tumour (decreased from 0.0957% in G2 to 0.0048%
in G4, p < 0.001) (Fig. 3d), whereas depletion in tumour
dLN was less marked (0.0024 vs. 0.0018%). However, GL-
113 treatment did not inXuence Marilyn Treg cells in
response to MB49 tumours (not shown).
In the same experiment, we also measured the changes
in proportions of host Treg cells (Thy1.1¡CD4+Foxp3+) in
tumour tissues with or without DTA-1 treatment (S-Fig. 1).
Fig. 3 DTA-1 is a depleting mAb in vivo. a A single injection of
DTA-1 mAb leads to a reduction of the percentage of circulating
CD4+Foxp3+ cells. Three groups of Foxp3/GFP knock-in mice (4
mice/group) were untreated or treated with 25 g of DTA-1 or PC61
by i.p. injection. 3 days later, peripheral blood lymphocyte (PBL)
samples were collected from individual mice in each group and stained
with anti-CD4PE. Percentage of CD4+GFP– and CD4+GFP+ cells in
PBL is shown as mean § SEM. One representative of three indepen-
dent experiments is shown. b DTA-1 preferentially depletes tumour-
resident Treg cells. Two groups of Foxp3/GFP knock-in mice (4 mice/
group) were s.c. inoculated with 5 £ 105 MB49 cells on day ¡8. The
mice were untreated or treated with 50 g of DTA-1 by i.p. injection
on day 0. 3 days later, dLN and MB49 tumours from individual mice
in each group were stained with anti-CD4PerCP. Percentage of
GFP+CD4+ cells is shown as mean § SEM. One representative of two
independent experiments is shown. c The number of tumour-resident
Treg cells was profoundly reduced following DTA-1 treatment. Two
groups of Foxp3/GFP knock-in mice (4 mice/group) were s.c. inocu-
lated with 5 £ 105 MB49 cells on day ¡8. The mice were untreated or
treated with 50 g of DTA-1 by i.p. injection on day 0. 3 days later,
MB49 tumours from individual mice in each group were stained with
anti-CD4PerCP. The absolute tumour-inWltrated Treg cell numbers were
determined by total tumour cells £ % of small lymphocyte gate £ %
of CD4+GFP+ cells within gated tumour-inWltrated lymphocyte (TIL).
d Accumulation of adoptively transferred HY-speciWc Treg cells in
MB49 tumours is profoundly impaired following DTA-1 treatment.
HY-speciWc Treg cells (Thy1.1+) were adoptively transferred to four
groups of Thy1.2+ B6 females (4 mice/group) by i.v. injection
(1 £ 105/mouse). On the same day, the mice in G2 and G4 were inoc-
ulated s.c. with MB49 cells (5 £ 105/mouse) and the mice in G1 and
G3 were not. On day 8, the mice in G3 and G4 were treated with 50 g
of DTA-1 by i.p. injection, and the mice in G1 and G2 were not. On
day 11, dLN (pLN for G1 and G3) and MB49 tumours from individual
mice in each group were stained with anti-V6PE, anti-Thy1.1PerCP and
anti-CD4APC followed by intracellular staining of anti-Foxp3FITC.
Percentage of Treg cells of donor origin (Thy1.1+V6+) is shown as
mean § SEM. One representative of two independent experiments is
shown. e Tumour-inWltrating Treg cells express higher levels of GITR
than those in dLN. Foxp3/GFP knock-in mice (n = 4) were s.c. injected
with 5 £ 105 MB49 cells on day 0. 8 days later, MB49 and dLN cells
from individual mice were stained with anti-GITRPE and anti-
CD4PercP. The MFI of GITR by gated GFP+GITR+ cells in dLN and
MB49 is shown as mean § SEM. One representative of four indepen-
dent experiments is shown
123
Cancer Immunol ImmunotherComparing the proportion of host Treg cells within the
MB49 tumours between G2 and G4 revealed that a single
injection of DTA-1 resulted in 38% reduction of recipient
tumour-resident Treg cells (0.993–0.575%, p < 0.05). Thus,
the results shown in Fig. 3b using Foxp3/GFP knock-in
mice were reproducible using WT B6 mice.
Figure 3b–d shows that depletion of polyclonal or mono-
clonal Treg cells by DTA-1 is more extensive in tumours
than in the dLN. We speculated that the environment of a
growing MB49 tumour might preferentially increase GITR
expression on tumour-inWltrating Treg cells, rendering
them more susceptible to depletion. To test this, Foxp3/
GFP mice were inoculated with MB49 cells, and 8 days
later the expression of GITR by Treg cells in the MB49
tumour was compared with those in dLN. As shown in
Fig. 3e, there was a 4.5-fold increase in GITR expression
on MB49-inWltrating Treg cells (MFI 545 § 27 tumour
draining LN, MFI 2475 § 124 tumour; p < 0.05), which is
likely to increase sensitivity to DTA-1-induced depletion.
Treg cells are primary cellular targets of DTA-1 in vivo
In vitro staining of PBL from Foxp3/GFP knock-in mice
with anti-GITRPE, anti-CD4PerCP and anti-CD8APC clearly
demonstrated that Treg cells expressed higher levels of
GITR than conventional CD4 and CD8 cells (top of
Fig. 4a).
Whether GITR expression in vivo is similar to that
seen in vitro is unclear. We therefore performed a pilot
experiment to test the feasibility of “in vivo” staining.
CBA mice were injected i.v. with 20 g of anti-CD4PE,
and PBL samples collected at various time points were
stained with anti-CD3FITC in vitro, before analysing for
CD4+CD3+ cells. Cells co-expressing CD4 and CD3 were
detectable as early as 18 min after injection, and were still
present after 22 h, by which time CD4 molecules were
down-regulated, presumably due to antibody-mediated
internalisation (S-Fig. 2B).
Having veriWed this in vivo staining protocol, we applied
it to determine the cellular targets of DTA-1. Foxp3/GFP
mice were injected i.v. with 5 g of DTA-1PE, and 15 h
later the PBL samples were stained with anti-CD4PercP and
anti-CD8APC to allow identiWcation of Foxp3/GFP positive
from Foxp3/GFP negative cells in each population. MFI of
GITR by Treg cells was threefold higher than that of con-
ventional CD4 and CD8 T cells (bottom panel of Fig. 5a),
indicating that in vivo, DTA-1 antibodies primarily bind to
Treg cells which have abundant surface GITR molecules
compared with non-Treg cells (top panels of Fig. 4a).
Although Treg cells rather than conventional T cells are
the primary targets of DTA-1 under normal conditions, it is
not known whether this would be found in tumour-bearing
mice. To address this question, we injected 5 g of DTA-1PE
into Foxp3/GFP mice inoculated with MB49 cells 8 days
previously. 6 h later, we analysed GITR expression by
CD4+GFP+, CD4+GFP¡ or CD8+GFP¡ subsets in spleen,
dLN and MB49 tumours (Fig. 4b). Several observations
can be made. Firstly, Treg cells within MB49 tumours
displayed a 2.1-fold higher GITR expression than those in
dLN, thus conWrming the in vitro staining results shown in
Fig. 3d. Secondly, like Treg cells, conventional CD4 and
CD8 T cells present in the MB49 tumour also showed
higher MFI of GITR than those in dLN. This observation
indicates that either the tumour microenvironment can
induce and maintain GITR expression on inWltrating T cell
subsets or those T cells with higher GITR expression are
able to preferentially migrate into the tumour. Finally,
GITR expression by Treg cells was consistently higher than
that by conventional CD4 or CD8 T cells, regardless of tis-
sue of origin, suggesting that Treg cells constitutively
express higher levels of GITR in vivo.
As shown in Fig. 4b, splenic Treg cells appear to express
higher GITR than tumour-resident Treg cells (223 vs. 184
of MFI), raising the possibility that splenic Treg might be
the primary target of DTA-1. To explore this, we compared
changes of Treg cells in spleen and tumour after DTA-1
treatment. A moderate decrease of splenic Treg cell number
in MB49-bearing mice was observed following DTA-1
therapy (Fig. 4c), however, the reduction of tumour-resi-
dent Treg cells was more signiWcant in the same experiment
(Fig. 3c). This disparity may be related to the experimental
conditions including antibody dose (5 vs. 50 g) and dura-
tion of treatment (6 vs. 72 h). In addition, we speculate that
i.v. delivered DTA-1PE mAb might reach the spleen before
entering tumour tissue. Moreover, some mAb will be con-
sumed within the spleen by binding to GITR-expressing
cells, thus reducing the amount of mAb available for entry
into other tissues. Thus, the local concentration of mAb in
the spleen is likely to be higher than that in tumour, as a
result, Treg cells in the spleen show higher GITR expres-
sion than those in the tumours.
DTA-1 but not PC61 therapy can control established 
MB49 tumours
If DTA-1 can deplete Treg cells in vivo, it would be of
interest to compare DTA-1 with PC61, a standard anti-
CD25 depleting mAb. A single injection of PC61 was very
eVective in treating MB49 tumours when administered to
B6 females 2 days before MB49 inoculation [Fig. 5a, 100%
(5/5) tumour-free mice]. However, the same treatment pro-
tocol using DTA-1 had limited impact on tumour growth
[Fig. 5B, 20% (1/5) tumour-free mice]. This diVerence
could be explained by our observations showing PC61 was
more potent than DTA-1 in depleting Treg in vivo
(Fig. 3a). On the other hand, DTA-1 treatment was very123
Cancer Immunol ImmunotherFig. 4 Treg cells constitutively 
express higher levels of GITR 
than conventional CD4 T cells in 
vivo. a Treg cells are primary 
targets of DTA-1. Top panels, 
the PBL from a group of Foxp3/
GFP knock-in mice (n = 3) were 
stained with anti-GITRPE, anti-
CD4PerCP and anti-CD8APC. The 
expression of GITR by 
GFP+CD4+, GFP¡CD4+ and 
GFP¡CD8+ T cells from individ-
ual mice was presented as histo-
grams. MFI of GITR is shown as 
mean § SEM. Bottom panels, a 
group of Foxp3/GFP knock-in 
mice were given 5 g of anti-
GITRPE (clone DTA-1) by i.v. 
injection. 15 h later, the PBL 
from individual mice were 
stained with anti-CD4PerCP and 
anti-CD8APC. MFI of GITR by 
GFP+CD4+, GFP¡CD4+ and 
GFP¡CD8+ T cells is presented 
as mean § SEM. One represen-
tative of three independent 
experiments is shown. 
b Tumour-inWltrating Treg, CD4 
and CD8 T cells express higher 
levels of GITR than those in 
dLN. A group of Foxp3/GFP 
knock-in mice (n = 4) were s.c. 
inoculated with MB49 cells 
(5 £ 105/mouse) 8 days previ-
ously. On day 0, the mice were 
i.v. injected with 5 g of 
DTA-1PE. 6 h later, spleen, dLN 
and MB49 tumour cells from 
individual mice were stained 
with anti-CD4PerCP and anti-
CD8APC. MFI of GITR by 
GFP+CD4+, GFP¡CD4+ and 
GFP¡CD8+ T cells is presented 
as mean § SEM. One represen-
tative of two independent exper-
iments is shown. c The number 
of splenic Treg cells was moder-
ately reduced following DTA-1 
treatment. Two groups of Foxp3/
GFP knock-in mice (4 mice/
group) were s.c. inoculated with 
5 £ 105 MB49 cells on day ¡8. 
The mice were untreated or 
treated with 50 g of DTA-1 by 
i.p. injection on day 0. 3 days 
later, MB49 tumours from indi-
vidual mice in each group were 
stained with anti-CD4PerCP. The 
absolute spleen-resident Treg 
cell numbers were determined 
by total spleen cells £ % of lym-
phocyte gate £ % of CD4+GFP+ 
cells within gated lymphocytes123
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5c, 100% (6/6) tumour-free mice] whereas PC61 therapy
had no eVect (Fig. 5d, 0% tumour-free mice). We speculate
that CD25-expressing anti-MB49 eVector T cells were
depleted by PC61 treatment. In support of this, we were
able to show that anti-tumour activity by DTA-1 was com-
pletely lost if PC61 was co-injected with DTA-1 on day 8
(Fig. 5e, 0% tumour-free mice). Since DTA-1 leads to par-
tial Treg depletion and timing of DTA-1 administration is
the key factor determining the outcome of cancer therapy,
we conclude that Treg depletion is one mechanism but
cannot be regarded as the only one responsible for cancer
therapy by DTA-1, other mechanisms such as co-stimula-
tion of T cells might be in operation.
Discussion
CD4+CD25+ cells isolated from mice given DTA-1 24 h
previously were found to be functional Treg cells with
similar suppressive activity as those from untreated mice
(Fig. 2), suggesting that in vivo GITR signalling does not
disable Treg cells. This conclusion is in line with a report
showing that Treg cells puriWed from either rat IgG-treated
or DTA-1-treated mice are equally eYcient in suppressing
allo-MLR [16]. However, only a single ratio of Treg to
responder (1:1) was tested in MLR [16], whereas our assay
covered a wide range of ratio from 1:1 to 1:128. Since
maximum Treg depletion occurred 3 days after DTA-1
administration (Fig. 3a), Tregs were isolated at 24 h after
DTA-1 treatment allowing suYcient time for GITR binding
and signal transduction (Fig. 4).
As injected DTA-1 mAb preferentially binds to Treg
cells (Fig. 4b) but does not inactivate them (Fig. 2), we
consider that depletion of Treg cells is an alternative conse-
quence of GITR binding. In support of this, DTA-1 is
IgG2b, an isotype shared by a large panel of in vivo deplet-
ing mAb with speciWcity for CD4 (GK1.5 and YTS 191),
CD8 (YTS169 and 2.43) and Thy1.2 (30H12). Although
Fig. 5 Comparison of DTA-1 and PC61 for their anti-MB49 activities
in vivo. a, b. Two groups of B6 female mice (5 mice/group) were
treated with 50 g of PC61 (A) or DTA-1 mAb (B) by i.p. injection.
2 days later, all mice were s.c. inoculated with 5 £ 105 MB49 cells.
The growth of MB49 tumours was monitored by measuring tumour
size every other day. c–e A total of 16 B6 female mice were s.c. inoc-
ulated with 5 £ 105 MB49 cells. 8 days later, the mice were randomly
divided into three groups: group one (C, n = 6) was treated with 50 g
of DTA-1 mAb by i.p. injection, group two (D, n = 5) was treated with
50 g of PC61 mAb by i.p. injection, and group three (E, n = 5) was
treated with 50 g of DTA-1 and 50 g of PC61 by i.p. injection. The
growth of MB49 tumours was monitored by measuring tumour size
every other day
123
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deplete GITR expressing-Treg cells in vivo, a formal
demonstration is lacking. In this study we provide evidence
showing that DTA-1 is a depleting mAb causing a moder-
ate but signiWcant reduction of endogenous polyclonal
Tregs in tumour-free (Fig. 3a) and tumour-bearing Foxp3/
GFP knock-in mice (Fig. 3b, c). The most remarkable Treg
depletion following DTA-1 treatment is illustrated in adop-
tive transfer experiments using HY-speciWc Treg cells
(Fig. 3d). Importantly, the reduction of donor Treg cells is
more complete in MB49 tissue than dLN (Fig. 3d) and
correlates with the level of GITR expression by Treg cells
in these two tissues (Fig. 3e).
Discrepancies between our data and other studies [15]
regarding the depleting potential of DTA-1 may reXect
diVerences between mouse strains (BALB/c vs. B6) and the
cells used for analysis (spleen cells vs. PBL) and the use of
diVerent markers (CD25 vs. Foxp3) to identify Treg cells. It
becomes increasingly clear that not all CD25+ are Treg
cells and not all Treg cells are necessarily CD25+ [29].
Why DTA-1 can only induce a partial Treg depletion in
B6 mice is unclear. One reason is likely to be the nature of
this particular clone. In this respect, it would be of interest
to compare DTA-1 with other anti-GITR clones of IgG2b
isotype for eYciency of Treg depletion. In addition, the
current treatment regime might be suboptimal, given a sin-
gle i.p. injection with 50 g of mAb. Furthermore, Treg
cells are composed of distinct subsets which might display
diVerent sensitivity to DTA-1-triggered depletion.
Another key element determining eYciency of depletion
is the level of expression of the target molecule on the cell
surface. There is a clear link between the degree of deple-
tion and the level of GITR expression. Firstly, Treg cells
constitutively express higher levels of GITR than conven-
tional CD4 T cells under steady-state conditions (Fig. 4a).
Thus DTA-1 seems to selectively target Treg but spare the
conventional CD4 T cells (Fig. 3a). The degree of Treg
depletion following DTA-1 treatment is moderate in naïve
mice, which is perhaps due to relatively low target mole-
cule expression. Secondly, GITR expression on Treg cells
is itself variable with the highest level observed on tumour-
resident Tregs and lower levels seen on Treg cells from
tumour-draining LN (Fig. 3e). Thus, Treg cells in tumour
but not those in the dLN are likely to be depleted in the
presence of DTA-1 in vivo (Fig. 3b, c). These observations
could explain why the percentage of tumour-resident Treg
cells but not those within dLN were signiWcantly reduced
following DTA-1 administration, as reported [15] and
shown in Fig. 1. Finally, timing of DTA-1 treatment deter-
mining the eYciency of cancer therapy (Fig. 5) [15, 17], as
mAb given on day 8 after tumour inoculation is more eVec-
tive than that on day 1. A potential interpretation for this
observation is that Treg cells in the tumour reach the peak
of GITR expression on day 8 (Figs. 3e, 4b), perhaps mak-
ing them optimally sensitive to DTA-1-mediated depletion
(Fig. 3c, d). Like GITR, other Treg-related molecules
including CD103, ICOS, PDL1 and OX40 were found to be
up-regulated preferentially by Treg cells detected in MB49
mass, compared with those in dLN (data not shown). These
results are consistent with two recent reports showing that
vast majority of tumour-inWltrating Treg cells are OX40high
[30] and GITRhigh [31]. However, this comparison was
made with splenic Treg cells from tumour-free naive mice
[30] rather than Treg cells from dLN of tumour-bearing
mice. In this respect, our data are more informative as
GITR expression was assessed on both MB49 tumour-inWl-
trating Treg cells and those in the tumour dLN.
An alternative interpretation for the reduction of Treg
cells (95% reduction, from 0.48 to 0.02%) in tumour tissue
following DTA-1 treatment is altered Treg migration. If
this hypothesis is correct, one would expect that reduced
Treg representation in tumour mass should correlate with
increased Treg accumulation in other lymphoid tissues such
as dLN and ndLN. However, we observed that the
decreased proportion of adoptively transferred Marilyn
Treg cells was also evident, but to a less extent, in dLN
(64% reduction, from 0.28 to 0.10%) and ndLN (40%
reduction, from 0.15 to 0.09%) (S-Fig. 3A), making this
explanation unlikely. In addition, the reduction of donor
Treg cells in dLN was also evident when absolute cell num-
ber was compared between untreated and DTA-1-treated
groups (S-Fig. 3B). Nevertheless, LN and tumour tissues
are diVerent microenvironments with distinct structures and
capacity to recruit Treg cells. The contributions of deple-
tion and altered migration to the reduced accumulation of
Tregs in tumour tissues following DTA-1 therapy needs
further investigation.
Treg cells promote tumour progression by suppressing
anti-tumour immunity via diVerent mechanisms [32, 33].
Treg cells are recruited into the tumour mass because they
not only recognise tumour-associated antigens but also nor-
mal self-antigens released from the tumour [34]. In addi-
tion, tumours are able to induce a subset of DC to produce
TGF [35] or IDO [36], which trigger endogenous Treg
cell expansion and activation. Although the initiation of
Treg activation requires TCR engagement, once activated,
Treg cells can inhibit T cell responses non-speciWcally via
bystander suppression, thus the action of Treg cells can be
both antigen speciWc and non-speciWc [37]. In vivo Treg
cells can target various populations such as CD8 T cells,
APC and innate immune cells including NKT and NK cells
via cell-to-cell contact (using CTLA-4 or membrane bound
TGF) or production of inhibitory cytokines such as TGF
and IL10 [37]. Treg cells prevent CD8 T cells from
diVerentiation into cytolytic eVector cells in vivo without
aVecting their proliferation or IFN production [38, 39].123
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tumour microenvironment. For example, tumour-inWltrat-
ing Treg cells can kill anti-tumour eVector cells such as
CD8 and NK cells locally by releasing granzyme B and
perforin [40].
We have not explored the mechanisms of Treg depletion
by DTA-1 in great detail. Both expression of FcR and com-
plement by the host appear to be required for optimal Ab-
mediated depletion. It has been diYcult to determine the
relative contributions of T cell costimulation and Treg
depetion by DTA-1. In this regard, it would be of interest to
compare between DTA-1 and the soluble GITR-L for their
eVects, as the latter can only deliver co-stimulatory signals
without the involvement of Treg depletion. Also, 2F8 [41],
is another agonist anti-GITR mAb which is unable to
deplete or disable Treg cells in vivo, presumably because of
the isotype (rat IgG2a). It has been demonstrated recently
that 2F8 treatment signiWcantly accelerates the onset of dia-
betes in NOD mice by promoting T cell activation without
aVecting Treg cells [41].
It has been well documented that T cell costimulation by
DTA-1 is another key mechanism for cancer immunother-
apy [7–11]. We observed that in vivo, GITR signalling
enhanced allo-recognition by conventional CD4 T cells,
and ampliWed anti-MB49 responses by adoptively trans-
ferred Marilyn CD4 T cells (manuscript in preparation). In
this study, we also veriWed whether successful cancer
immunotherapy using DTA-1 could be extended to the
aggressive HY+H2b+ MB49 tumour. Given HY vaccination
fails to control MB49 growth [28], a complete regression of
established MB49 tumours following a single DTA-1
administration is very impressive. As reported [15] and
shown in Fig. 1, the proportion of Treg cells in rejecting
tumour tissues is dramatically reduced, which appears to be
a direct consequence of depletion. Intra-tumour injection of
DTA-1 [15] or depleting anti-CD4 mAb [42] results in
regression of established tumours, highlighting the impact
of local removal of Treg cells on therapeutic outcome.
The current study has two implications. Firstly, the con-
sequence of an in vivo therapeutic antibody treatment can
be down-regulation (7D4, anti-CD25), blockade or func-
tional inactivation (YTS 177, non-depleting anti-CD4), co-
stimulation (37.51, anti-CD28) or depletion of the target T
cell population. Apart from antibody speciWcity and iso-
type, outcome depends on cellular targets, expression level
of targeted molecules, tissue distribution and modulation
under physiological or pathological circumstances. The
results of antibody therapy need to be carefully interpreted,
as for example, a putative blocking antibody (MR1, anti-
CD40L) shown in earlier studies [43], was found to be
depleting by a subsequent investigation [44]. Secondly, for
the identiWcation of the cellular targets of an antibody and
investigation of their expression pattern under diVerent
conditions, “in vivo” staining by injection of conjugated
antibodies has the advantage of allowing expression to be
monitored in real time.
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The roles of antigen-speciﬁcity, responsiveness to transforming
growth factor-b and antigen-presenting cell subsets in
tumour-induced expansion of regulatory T cells
Introduction
The primary function of natural CD4+ CD25+ Foxp3+
regulatory T (nTreg) cells is to control self-reactive
peripheral T cells that escape thymic deletion, as sug-
gested by early studies using neonatal thymectomy or
depletion using anti-CD25 antibodies,1,2 and verified by
recent investigations using Foxp3DTR mice.3 As many
tumour-associated antigens are aberrantly expressed nor-
mal self-proteins,4 the activity of self-reactive nTreg cells
is also proposed to mediate an inhibitory influence over
tumour-specific T-cell responses. Indeed, in vivo depletion
of nTreg cells improves tumour immunosurveillance and
enhances the efficiency of therapeutic cancer vaccines.5,6
Expansion of nTreg cells is often correlated with
tumour growth,7,8 but several key questions regarding
tumour-driven nTreg expansion remain unanswered.
First, many tumour antigens are altered self-proteins and
nTreg cells are highly self-reactive, it is possible that
tumours can activate endogenous polyclonal nTreg cells.
Furthermore, tumour-derived transforming growth fac-
tor-b (TGF-b) can further expand activated Treg cells in
an antigen-independent manner.9 Moreover, activated
nTreg cells can suppress anti-tumour immunity non-spe-
cifically in vivo. Hence, polyclonal nTreg cells non-specifi-
cally expanded by tumour could make a significant
impact on tumour progression. Although several sponta-
neous tumour lines can induce endogenous polyclonal
nTreg cells to proliferate in tumour-draining lymph node
(dLN),9 it is unclear whether non-specific expansion of
nTreg would also be mediated by carcinogen-induced
tumour lines. Second, the responses of tumour-antigen-
specific nTreg cells in vivo have only been examined
following viral vaccination,10,11 and little is known about
nTreg expansion solely in response to the tumour.
Tumour-specific nTreg cells are able to proliferate in
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Summary
In this study we investigated the impact of several factors on the expan-
sion of natural regulatory T (nTreg) cells by tumours, including antigen
specificity, transforming growth factor-b (TGF-b) signalling and the anti-
gen-presenting cell subsets responsible for expansion. We found that anti-
gen non-specific expansion of nTreg cells is tumour cell line-dependent.
Although both antigen-specific and non-specific pathways can contribute
to expansion, the migration of activated nTreg cells to tumour tissues is
strictly antigen-dependent. Intact TGF-b signalling on nTreg cells is also
essential for tumour-induced expansion. Finally, for stimulation of resting
antigen-specific CD4 T cells, CD11c+ cells purified from tumour-draining
lymph nodes were more potent than CD11b+ cells, suggesting that den-
dritic cells are the key antigen-presenting cell subset involved in cross-pre-
sentation of tumour antigens. This study not only provides an in vivo
system in which cross-talk between nTreg cells and tumours can be
explored but also reveals novel aspects of tumour immune evasion.
Keywords: adoptive transfer; Foxp3; immune evasion; regulatory T cells;
tumour
Abbreviations: dLN, draining lymph node; dnTGFbRII, dominant negative TGF-b receptor type II; Mar, Marilyn; nTreg, natural
CD4+ CD25+ Foxp3+ regulatory T cells; Mar-nTreg, nTreg purified from Rag2+/) Marilyn mice; Mar-nTregdn, nTreg purified
from (dnTGFbRII · Marilyn) F1 mice; Mar-nTregGFP, nTreg purified from (Foxp3/GFP knockin · Marilyn) F1 mice; ndLN,
non-draining lymph node; pLN, peripheral lymph node; TGF-b, transforming growth factor-b.
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response to a growing tumour, the relative contributions
of antigen-specific and non-specific expansion to the
overall pool of nTreg cells has not been investigated. In
addition, the in vivo migration of nTreg cells expanded
by these two distinct pathways has not been explored.
Third, although non-immunogenic B16 tumours expand
polyclonal nTreg cells via a TGF-b-dependent mecha-
nism,9 whether this mechanism applies to other immuno-
genic tumours and to tumour-specific nTreg cells has not
been evaluated. Finally, although it has been suggested
that cross-presentation of tumour antigens operates con-
tinuously in dLN,12 the precise antigen-presenting cell
subset(s) involved has not been identified.
To address these issues, we have employed adoptive
transfer experiments in which nTreg cells (polyclonal or
tumour-specific monoclonal) were injected intravenously
(i.v.) into tumour-bearing wild-type (WT) B6 mice. The
male-specific minor histocompatibility antigen, HY13 is
used as a surrogate tumour antigen. HY is naturally
expressed by the chemically induced B6 male bladder
MB49 carcinoma, an immunogenic but nevertheless
aggressive tumour.14 The HY-negative B16 melanoma cell
line was transfected with the Dby gene to produce an
HY-positive variant (B16/HY). Hence, the relative contri-
butions of non-specific and HY-specific nTreg-cell expan-
sion by tumours can be investigated. Tumour-specific
nTreg cells for adoptive transfer are purified from female
Rag2+/) HY TCR-transgenic Marilyn mice.15 The availabil-
ity of Marilyn mice has facilitated analysis of HY-specific
CD4 responses and immunoregulation.16–18 Recently, the
HY system has been employed to explore T-cell responses
against tumours.19,20 For example, B6 recipients of Rag2)/)
Marilyn CD4 T cells and murine fibrosarcoma cells trans-
fected with HY Dby complementary DNA (cDNA) have
been used to analyse intra-tumour CD4 T-cell accumula-
tion.19 However, the responses of HY-specific nTreg cells
in tumour-bearing mice have not been explored.
In this study, we aimed to address the following ques-
tions. Whether the induction of non-specific nTreg-cell
expansion is tumour cell line dependent. What are the
relative contributions of antigen-specific versus non-spe-
cific expansion of nTreg cells by tumours. Is expansion of
tumour-antigen-specific nTreg cells by tumours also
dependent on TGF-b? Which subset(s) of antigen-pre-
senting cells in tumour-draining LN is involved in cross-
presentation of tumour antigen?
Materials and methods
Tumour cell lines
MB49 is a chemically induced B6 bladder carcinoma14
that constitutively expresses the endogenous HY genes.
B16 is a murine melanoma cell line that does not express
HY.20 Both lines were maintained in 10% RPMI-1640
supplemented with fetal calf serum (10%), antibiotics,
HEPES, glutamine and 2-mercaptoethanol.
Generation of B16/HY cell line
B16 cells were plated out at 2 · 105 cells/well in six-well
plates and after 24 hr were transfected using Lipofectamine
2000 (Invitrogen, Paisley, UK) and 2 mg pcDNA3.1/Zeo-
Dby following the manufacturer’s guidelines. After 48 hr,
cells were diluted 1 : 10 into selection medium containing
1 mg/ml Zeocin. Resistant colonies were picked at
2–3 weeks, expanded and Dby expression was measured by
quantitative reverse transcription–polymerase chain reac-
tion (RT-PCR).
Mice
Thy-1.2 B6, and Thy-1.1 B6 mice were purchased from
Harlan Laboratories (Bicester, UK) and the Jackson Labo-
ratory (Bar Harbor, ME), respectively. Marilyn mice15
obtained from Dr O. Lantz (Institut Curie, Paris, France)
were originally on Rag2)/) Thy-1.2+ background. Thy-
1.2+, Thy-1.1+ and Thy-1.1+ Thy-1.2+ Marilyn mice on
either Rag2+/) or Rag2)/) background were subsequently
produced after crossing with Thy-1.1 B6 mice. Either
dnTGFbRII-transgenic21 or Foxp3/green fluorescent pro-
tein (GFP) knock-in 22 mice on B6 background, kindly
provided by Dr R Flavell (Yale University School of Med-
icine, New Haven, CT) and Dr B Malissen (Centre
d’Immunologie de Marseille-Luminy, Marseille, France),
respectively, were mated with Rag2)/) Marilyn mice to
produce F1 mice, from which double-transgenic nTreg
cells (Mar-nTregdn or Mar-nTregGFP) were purified.
Although WT B6 females were used as recipients in a
majority of experiments, Rag2)/) B6 mice were used as
recipients in some adoptive transfer experiments.
Purification of nTreg and conventional CD4 T cells
This was conducted as described previously.16 In brief,
enriched CD25+ cells were obtained by magnetic anti-
body cell sorting (MACS) positive selection (anti-
CD25PE or anti-CD25APC followed by anti-phycoerythrin
(PE) or anti-allophycocyanin (APC) -microbeads), and
then were sorted on a BD FACS Aria after staining. We
sorted CD4+ CD25+ cells for polyclonal nTreg cells,
CD4+ Vb6+ CD25+ cells for Marilyn nTreg cells (Mar-
nTreg or Mar-nTregdn), and CD4+ Vb6+ CD25+ GFP+
cells for green Marilyn nTreg cells (Mar-nTregGFP). The
combination of MACS enrichment and fluorescence-acti-
vated cell sorting (FACS) sorting is efficient for obtain-
ing nTreg cells with a high purity and a good yield.
Conventional CD4 T cells were purified by MACS posi-
tive selection. CD25-depleted CD4 T cells were prepared
by MACS positive selection after depletion of
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CD25-expressing cells (anti-CD25PE staining followed by
anti-PE-microbeads).
Adoptive cell transfer and tumour inoculation
Most adoptive transfer experiments were conducted by
i.v. injection of Thy-1.1+ conventional CD4 [carboxyfluo-
rescein succinimidyl ester (CFSE) -labelled, CD25-intact
or depleted] or Thy-1.1+ nTreg cells (monoclonal or
polyclonal) into Thy-1.2 B6 females. CFSE labelling was
conducted as described previously.16,23 Tumour cells
(MB49, B16 or B16/HY) were inoculated subcutaneously
(s.c.; 5 · 105) 1 day after T-cell transfer.
Analysis of expansion and accumulation of donor T cells
in various tissues
Single-cell suspensions from dLN, ndLN and tumour
tissues were stained with anti-Vb6PE or anti-TCRPE, anti-
Thy-1.1PercP or anti-CD4PercP and anti-CD4APC or anti-
CD44APC. Donor cells were identified by gating of
Thy-1.1+ CD4+, Thy-1.1+ Vb6+ or CD4+ Thy-1.2+ before
further analysis of CFSE/CD44 profiles or Foxp3 expres-
sion. To produce a physiologically relevant model, WT
(rather than Rag-deficient) mice were used as recipients
and relatively small populations (105) of donor nTreg
cells were transferred. To obtain a reliable representation
of the small cohorts of donor nTreg cells, two million
events were acquired, except for Rag2)/) B6 recipients
where 05 million events were acquired because donor
cells undergo homeostatic expansion). Acquisition of the
same number of events for each sample enables reliable
comparison of the percentages of donor Treg cells
between the samples. Analysis of gated lymphocytes was
performed using CELLQUEST software (version 3.3, Becton
Dickinson UK Ltd, Oxford, UK).
Quantitative RT-PCR
RNA (DNase I treated) and first-strand cDNA were pre-
pared using the RNAqueous-4PCR and High Capacity
cDNA synthesis kits (Applied Biosystems, Warrington,
UK). Relative concentrations of 18S ribosomal RNA and
Dby transcripts were determined using Power SYBR PCR
master mix (Applied Biosystems), and performing the
reactions on the 7900HT Fast Real-Time PCR system
(Applied Biosystems). Primer pairs were assessed by gel
electrophoresis and melting curve analysis, to ensure
that only specific products were generated. No product
was obtained when female cDNA was tested with Dby-
specific primers. The primer sequences were as follows:
18S forward, 50-CCGCAGCTAGGAATAATGGAAT-30;
18S reverse, 50-CGAACCTCCGACTTTCGTTCT-30; Dby
forward, 50-GAAAGTAGTATGGGTTGAAAGAAC-30; Dby
reverse, 50-CTCCTCTCGATCTTTCTGTGAT-30.
Test samples (cell lines, tumour tissues and spleen cells)
were assayed in triplicate. Expression values were deter-
mined from standard curves generated using dilutions of
male cDNA and plotting cycle threshold values against log
quantity. Normalized Dby expression was calculated by
dividing Dby quantity by the corresponding 18S quantity.
Purification of antigen-presenting cell subsets from
LN cells
Pooled LN were chopped into small pieces and incubated
in a mixture containing collagenase XI and DNase. After
digestion, cell suspensions were prepared from which
CD11c+ cells were isolated by MACS after incubating with
anti-CD11c microbeads. The CD11c-negative fractions
were subsequently incubated with anti-CD11b microbeads
to isolate CD11b+ cells. Finally, B220+ cells were positively
selected from the CD11b-negative fractions.
Proliferation assay
This was conducted as described previously.16,23
Statistical analysis
Data are presented as means ± SEM. Group comparisons
were conducted using the two-tailed Student’s t-test or a
two-tailed non-parametric Mann–Whitney U-test, depend-
ing on the number of samples. P-values of < 005 are
considered statistically significant.
Results
CD25-depleted but not CD25-intact Marilyn CD4
T cells are potent responders in vivo
To compare in vivo anti-HY responses by Marilyn CD4 T
cells with or without nTreg cells, CD4 cells purified from
Rag 2+/) Thy-1.1+ Marilyn females were either depleted
CD25-expressing cells or not. After CFSE labelling, these
two donor cell populations were adoptively transferred
into a total of four groups of Thy-1.2 females. Next day
MB49 cells were injected subcutaneously into the right
flank of two groups of recipients of each donor popula-
tion. Five days after tumour inoculation, we analysed the
representation of donor cells in various tissues of the
individual mice in all four groups.
As shown in Fig. 1(a), the donor cells in the group
which received both CD25-depleted CD4 and MB49 cells,
mounted a robust response with an eight-fold expansion
in the dLN (0545 ± 001% versus 0065 ± 002% in the
tumour-free control group, P < 001), and a significant
accumulation in the tumour (355 ± 027%). In addition,
proliferating donor cells (Thy-1.1+ Vb6+) in dLN signifi-
cantly increased CD44 expression following progression
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of cell division whereas those in peripheral LN (inguinal,
pLN) of the tumour-free control group did not
(867 ± 03% versus 598 ± 16%, P < 001).
In contrast, the donor cells in the group given both
CD25-intact CD4 T cells and MB49 cells (Fig. 1c),
underwent a poor response with a limited accumulation
in the dLN (001 ± 001% versus 0055 ± 001% in
tumour-free control group, P > 005) and tumour
(006 ± 001%), which could be the result of either fail-
ure of activation or accelerated activation-induced cell
death in the presence of CD25+ nTreg cells. As > 90%
of CD25-intact donor cells lost CFSE but up-regulated
CD44 (Fig. 1c), it is likely that all donor cells were
recruited into the anti-MB49 response but most of them
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Figure 1. Comparison of anti-MB49 responses
by CD25-depleted and CD25-intact Marilyn
CD4 T cells. Four groups of Thy-1.2 B6 females
(three or four mice/group) were adoptively
transferred with 1.5 · 106 CFSE-labelled CD25-
depleted- (a, b) or CD25-intact Thy-1.1 Marilyn
CD4 T cells (c, d) by intravenous injection.
Next day two groups of mice only were inocu-
lated subcutaneously with 0.5 · 106 MB49 cells
(a, c). Five days after MB49 inoculation, all
groups were analysed by staining of dLN and
MB49 (a, c) or pLN (b, d) cells with anti-Vb6PE,
anti-Thy-1.1PerCP and anti-CD4APC. The donor
cells in lymph nodes (LN) and MB49 were
identified by co-expression of Thy-1.1 and CD4.
In addition, LN samples were also stained
with anti-Vb6PE, anti-Thy-1.1PerCP and anti-
CD44APC. The donor cells were identified by
co-expression of Thy-1.1 and Vb6 and their
CFSE profiles were presented as CFSE versus
CD44. A total of 2 million events (no gate) was
acquired for each sample. For MB49 samples,
tumour size is also indicated. One representa-
tive experiment of three is shown.
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were eventually eliminated during the course of the
response.
Taken together, these results clearly indicate that
CD25+ nTreg cells have a huge impact on determining
whether a CD4 response would be successful, because a
minor population of Marilyn nTreg cells co-transferred
with a majority of conventional Marilyn CD4 T cells is
associated with a substantially reduced response to MB49.
To provide direct evidence that HY-specific nTreg cells
can impact the progress of MB49 tumours, we compared
tumour growth in B6 female mice with or without adop-
tively transferred Marilyn Treg cells (1 · 105/mouse). As
shown in Fig. S1(b), the presence of adoptively transferred
HY-specific nTreg cells not only led to an accelerated MB49
growth, but also to increased mortality (25%, 2/8). In con-
trast, inoculated MB49 cells with an optimal dose
(5 · 105 cells/mouse) into the right flank of B6 females in
the absence of transferred Marilyn Treg cells develop into
tumours within 12 days, which usually do not kill the hosts
(i.e. 0% mortality) (Fig. S1a). These results were repro-
duced in a second Treg transfer and MB49 challenge experi-
ment in which the data are presented as survival of
tumour-bearing mice (Fig. S1c). The impact of the trans-
ferred HY-specific nTreg cells on tumour progress is there-
fore of biological significance. To further explore this, we
repeated the above experiment in the second tumour model
using HY/Dby-transduced B16 cells. Injection of B6 female
mice with a suboptimal dose of B16/HY cells (2 · 105) led
to a slow tumour growth (Fig. S2a), which was significantly
enhanced in the presence of transferred Marilyn Treg cells
(Fig. S2b). Similar results were also observed when the per-
centage of survival was used as readout (Fig. S2c). Collec-
tively, these experiments indicate that in this adoptive
transfer model, tumour-antigen-specific Treg cells are capa-
ble of suppressing anti-tumour T-cell responses in vivo.
MB49 tumour expands HY-specific but not polyclonal
nTreg cells
How might the small nTreg-cell population have such a
striking impact on a major CD4 T-cell population of the
same specificity? We hypothesized that MB49 could pref-
erentially expand nTreg cells. To test this, Thy-1.1 Mari-
lyn nTreg cells were adoptively transferred into two
groups of Thy-1.2 B6 females, of which one group was
given MB49 inoculation next day.
As shown in Fig. 2(b), following MB49 challenge, donor
nTreg cells underwent an eight-fold expansion in dLN
(00207 ± 00111 versus 00026 ± 00013% in tumour-free
control group, P < 005). Interestingly, expanded donor
Treg cells also showed a significant loss of Foxp3 expres-
sion (8483 ± 008% versus 9655 ± 345% in control
group). Furthermore, the degree of donor nTreg cells
expansion was much more marked when absolute numbers
of donor cells recovered from two groups were compared
(Fig. 2c). Activated donor nTreg cells also migrated to the
tumour (05821 ± 03011%), but only one-third of
tumour-infiltrated donor nTreg cells still expressed Foxp3
expression (3393 ± 1049% in MB49 versus 8483 ±
008% in dLN).
MB49-induced nTreg-cell expansion seen in Fig. 2(b)
can be either antigen driven or not or a combination of
both because some tumour cell lines can expand nTreg
cells in an antigen-independent fashion.9 As MB49 vari-
ants lacking expression of HY are not available, the rela-
tive contribution of antigen non-specific expansion
cannot be determined. To overcome this limitation, we
used the alternative strategy of transferring polyclonal
nTreg cells from Thy-1.1 WT B6 mice to MB49-beraing
B6 Thy-1.2 mice (Fig. 2e). If MB49 could induce nTreg
cells to proliferate non-specifically, the expansion of B6
nTreg cells should be seen. Instead, we found no expan-
sion of B6 nTreg cells in response to MB49 in all three
tissues tested (Fig. 2e), based on measurement of both
frequency (Fig. 2e) and absolute cell number (Fig. 2f).
These results do not support the hypothesis that MB49
tumour can non-specifically expand nTreg cells.
Generation and characterization of HY-expressing
B16 cell line
Antigen-specific and non-specific nTreg-cell expansion by
tumours could be directly compared using antigen-positive
and antigen-negative variants of the same tumour cell line.
As an HY-negative, mutant MB49 cell line is not available
and a knockout of the HY Dby gene from MB49 cells is
technically challenging, an HY-expressing variant of an
HY-negative tumour cell line was produced. The widely
used melanoma cell line B1620 was transfected with the HY
Dby gene and a stable HY-expressing clone was obtained
(B16/HY). Although Dby expression by B16/HY was lower
than MB49, it was significantly higher than B16 (P < 005)
(Fig. 3a). More importantly, Dby expression by B16/HY
remained following tumour development (Fig. 3b), sug-
gesting that the expression of transgene is stable in vivo.
Finally, adoptively transferred, CFSE-labelled Marilyn con-
ventional CD4 T cells proliferated in dLN in response to
B16/HY (Fig. 3e). They were also detectable in B16/HY
tumours. In sharp contrast, the activation of donor cells
was not evident in B16-beraing mice (Fig. 3d), or in
tumour-free controls (Fig. 3c), as expected. These in vivo
T-cell recognition assays conclusively demonstrated that
transduced Dby genes in B16/HY were functional.
Marilyn nTreg cells undergoing antigen-specific
expansion, but not those expanded non-specifically,
migrate to tumours
Next, we sorted CD4+ Vb6+ CD25+ GFP+ cells from
(Foxp3/GFP knockin · Marilyn) F1 females, and adoptively
 2010 Blackwell Publishing Ltd, Immunology 5
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transferred these green nTreg cells (Thy-1.1+) into three
groups of Thy-1.2 females, of which two groups were
injected s.c. with either B16 or B16/HY cells next day.
The expansion and Foxp3 expression by donor Treg cells
were analysed 11 days after tumour inoculation.
We made the following observations regarding the abil-
ity of B16 and B16/HY tumours to expand donor Treg
cells in vivo. First, for expansion of Marilyn nTregGFP cells,
B16/HY tumour was more efficient than B16 tumour, as
38-fold more donor cells accumulated in dLN of B16/HY
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Figure 2. MB49 expands Marilyn but not B6 natural regulatory T (nTreg) cells in vivo. Four groups of Thy-1.2 B6 females (three mice/group)
were transferred with 105 Thy-1.1 Marilyn nTreg (a, b) or Thy-1.1 B6 nTreg cells (c, d), of which two groups of mice were given MB49 cells the
next day (b, e) but the other two groups were not (a, d). 11 days after MB49 inoculation, analysis was performed by staining the cells with anti-
Vb6PE or anti-TCR-bPE, anti-Thy-1.1PerCP and anti-CD4APC, before intracellular staining with anti-Foxp3FITC. The donor cells were identified by
co-expression of Thy-1.1 and CD4 (R2), and their Foxp3 expression was presented as CD4 versus Foxp3. The absolute numbers of donor cells in
various tissues [peripheral (pLN), draining (dLN) and non-draining (ndLN) lymph nodes] were calculated by total cell number · % of gated
lymphocytes (R1) · % of donor cells (R2)(c, f). One representative experiment of four is shown. A total of 2 million events was acquired for
each sample. For the MB49 samples, tumour size is also indicated.
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(Fig. 4i) than in dLN of B16 (Fig. 4c) (00381 ± 00092%
versus 00101 ± 00005%, P < 005). Furthermore, the
absolute donor Treg-cell numbers recovered from B16/
HY-bearing mice was significantly higher than those from
B16-bearing mice (data not shown). Second, Marilyn
nTregGFP cells were present in B16/HY tumours
(02585 ± 0066%, Fig. 4m) but were completely absent in
B16 tumours (0000 ± 0000%, Fig. 4g), indicating that
migration of nTreg cells to the tumour is strictly antigen-
dependent. Third, B16 tumour appeared to be able to
expand Marilyn nTreg cells non-specifically, as the fre-
quency of donor Treg cells detected in dLN of B16-bearing
mice was higher than those in pLN of tumour-free control
mice (00101 ± 00005%, Fig. 4c versus 00013 ± 0000,
Fig. 4a). Finally, Foxp3 expression by nTreg cells in vivo
appears to be unstable, following antigen recognition,
expanded Treg cells can lose Foxp3. In addition, it seems
that loss of Foxp3 by tumour-infiltrated Treg cells is
greater (7768 ± 002%, Fig. 4n) than that by those in
dLN (9137 ± 008%, Fig. 4j).
B16/HY tumours appear to be less potent than MB49
in recruiting donor Marilyn Treg cells in the tumour
mass (Fig. 2b versus Fig. 4m). This raises concerns of
whether comparing donor Treg-cell recruitment between
B16 and B16/HY tumour tissues is feasible, given the few
cells detectable (Fig. 4g versus Fig. 4m). To increase sensi-
tivity, we used Rag2)/) B6 females as recipients of Mari-
lyn Treg cells. To make a proper comparison, we also
modified the FACS acquisition strategy by collecting the
same number of events within a live lymphocyte gate,
allowing a more precise measurement of the frequencies
of donor Treg cells between the samples.
HY-specific green Treg cells were transferred to two
groups of Rag2)/) B6 females, which were inoculated with
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Figure 3. Characterization of HY-expressing B16 cell line (B16/HY).
(a) B16, B16/HY and MB49 cells were compared for Dby expression
by reverse transcription–polymerase chain reaction (RT-PCR) with
male or female B6 spleen cells were used as internal controls. One
representative experiment of three is shown. (b) Two groups of B6
females (three mice/group) were inoculated subcutaneously (s.c.)
with 5 · 105 B16 or B16/HY cells, respectively. Two weeks later, B16
and B16/HY tumours from individual mice were compared for Dby
expression by RT-PCR with B16 and MB49 cell lines were used as
internal controls. One representative experiment of two is shown.
(c–e) Three groups of Thy-1.2 B6 females (three mice/group) were
adoptively transferred with 3 · 106 CFSE-labelled Thy-1.1 Marilyn
CD4 T cells. Next day the mice in two groups (d, e) were inoculated
s.c. with 5 · 105 B16 or B16/HY cells, respectively. Thirteen days
after tumour inoculation, analysis was conducted by staining the
cells from various tissues with anti-Vb6PE, anti-Thy-1.1PerCP and
anti-CD4APC. The donor cells were identified by co-expression of
Thy-1.1 and CD4 (R2). The CFSE dilution by donor cells is pre-
sented as CFSE versus CD4. One representative experiment of two is
shown. A total of 2 million events was acquired for each sample. For
the B16 and B16/HY samples, tumour size is also indicated.
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Figure 4. Comparison of the relative contribution by non-specific and antigen-specific natural regulatory T (nTreg) cell expansion. (a–n) Three
groups of Thy-1.2 B6 females (three mice/group) were adoptively transferred with 105 Thy-1.1 Marilyn nTreg cells co-expressing Foxp3/GFP
(Mar-nTregGFP) by intravenous injection, of which two groups of mice were subcutaneously (s.c.) inoculated with B16 cells (c–h) or B16/HY cells
(i–n) (5 · 105) next day. Eleven days after tumour inoculation, analysis was performed by staining of the cells from various tissues with anti-
Vb6PE, anti-Thy-1.1PerCP and anti-CD4APC. The donor cells were identified by co-expression of Thy-1.1 and Vb6 (R2) and their Foxp3 expression
was presented as Vb6 versus GFP. One representative experiment of two is shown. A total of 2 million events was acquired for each sample. For
the B16 and B16/HY samples, tumour size is also indicated. (o–t) Two groups of Rag2)/) B6 females (four mice/group) were transferred with
2 · 104 Thy-1.2 Marilyn green Treg cells and were also inoculated s.c. with either 1 · 105 B16 (o–q) or B16/HY cells (r–t) on the same day. After
12 days, analysis was performed by staining the draining lymph nodes (dLN; o, r), spleen (p, s) and B16 or B16/HY tumour tissues (q, t) with
anti-Vb6PE, anti-CD4PerCP, and anti-Thy-1.2APC. Donor Treg cells were identified by co-expression of Thy-1.2 and Vb6 (R2). Fluorescence-acti-
vated cell sorter dot plots of one representative mouse of each group are shown. An equal number of events in the live lymphocyte gate were
acquired for the paired samples (2 · 104 for dLN, 5 · 104 for spleen and 5 · 103 for B16 and B16/HY). One representative experiment of two is
shown. (u–w) Quantitative comparison of donor Treg frequency in dLN (u), spleen (v) and tumour mass (w) between two groups.
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either B16 or B16/HY cells on the same day. Twelve days
later, FACS analysis was performed by comparing the fre-
quency of donor Treg cells in dLN, spleen and tumour
tissues of individual mice between two groups. Unlike the
low recovery of donor Treg cells in dLN of B16/HY-bear-
ing WT B6 females (004%, Fig. 4i), a much higher
proportion was present in dLN of B16/HY-bearing Rag2)/)
B6 females (15%, Fig. 4r). A significant fraction of acti-
vated donor Treg cells also accumulated in both spleen
(11%, Fig. 4s) and B16/HY tumours (27%, Fig. 4t). In
B16-bearing Rag2)/) B6 females, however, the frequency
of donor Treg cells was profoundly decreased in both
dLN (043%, Fig. 4o, 97% reduction) and spleen (011%,
Fig. 4p, 90% reduction) because of the lack of HY anti-
gens. Consequently, donor Treg cells were barely detect-
able in B16 mass (002%, Fig. 4q, 99% reduction). These
results were confirmed by quantitative analysis showing
that the frequency of donor Marilyn Treg cells in the
presence of HY was significantly higher than that in the
absence of HY (Fig. 4u–w), which was also validated by
counting absolute donor cell numbers (not shown).
Taken together, these data demonstrate that (i) both
antigen-specific and non-specific proliferation of Marilyn
nTreg cells contribute to expansion by HY-expressing B16
tumours, (ii) the presence of antigen not only amplifies
the expansion in dLN but also is required for expanded
Treg cells to migrate into tumour, and (iii) a fraction of
Treg cells can lose Foxp3 following in vivo activation.
The involvement of TGF-b in the expansion of
Marilyn nTreg cells by MB49 tumours
The MB49 cell line constitutively expresses TGF-b,
revealed by intracellular staining (Fig. 5a). We hypothe-
sized that this cytokine may play an essential role in
tumour-induced expansion of Marilyn nTreg cells. To
explore this possibility, Thy-1.2+ Marilyn nTreg cells
co-expressing the dominant negative TGF-b receptor II
(Mar-nTregdn cells) were transferred to two groups of
Thy-1.1 B6 females, of which one group was inoculated
with MB49 cells next day. Twelve days after cell transfer,
the mice were analysed for the presence of donor cells
between these two groups. There was no difference in
terms of the proportion of donor cells in pLN of
tumour-free control (00005 ± 0000%, Fig 5b) and dLN
of MB49-bearing mice (00002 ± 00001%, Fig. 5c).
Donor cells were barely detectable in ndLN (Fig. 5d) and
MB49 (Fig. 5e). The defect in TGF-b signal transduction
on nTreg cells abrogated their expansion in response to
MB49, indicating that nTreg expansion by MB49 appears
to be TGF-b dependent.
Characterization of Marilyn Treg cells co-expressing
dnTGFbRII
It is unclear whether the data shown in Fig. 5 may result
from a developmental defect of nTreg cells expressing the
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Figure 5. Expansion of Marilyn natural regulatory T (nTreg) cells by MB49 is dependent on transforming growth factor-b (TGF-b). (a) MB49
cells were cultured with 10% fetal calf serum RPMI-1640 in the presence of 1 lg/ml brefeldin A for 4 hr. After fixing and permeabilizing, the
cells were stained for anti-TGF-bPE (filled) or isotype control (open). (b–e) Two groups of Thy-1.1 B6 females (three mice/group) were trans-
ferred with 105 Thy-1.2 Marilyn nTreg cells co-expressing dnTGFbRII (Mar-nTregdn), of which one group of mice received MB49 cells next day
(c–e). Eleven days after tumour inoculation, analysis was conducted by staining the cells with anti-Vb6PE, anti-CD4PerCP and anti-Thy-1.2APC,
before intracellular staining with anti-Foxp3FITC. The donor cells were identified by co-expression of Thy-1.2 and Vb6 (R3). A total of 2 million
events was acquired for each sample.
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dnTGFbRII, which may prevent appropriate activation in
response to antigen.
To determine the functionality of dnTGFbRII Marilyn
Treg cells in vivo, we performed co-transfer experiments
using Rag2)/) B6 females as recipients. Unlike polyclonal
CD4 populations from WT B6 mice, conventional and
Treg cells from Marilyn mice failed to repopulate the
lymphopenic host, presumably as a result of the lack of
cognate HY antigens (manuscript under preparation,
C. Addey and J.-G. Chai). In addition, we have previously
shown that the efficiency of positive selection of trans-
genic thymocytes on a Rag-sufficient background is very
high, resulting in > 96% CD4 and > 99% CD8 T cells
expressing Vb6.16
To this end HY-specific conventional CD4 T cells alone
(CD4+ Vb6+ CD25) CD44low sorted from Thy-1.1+ Rag2)/
) Marilyn females), HY-specific Treg cells alone
(CD4+ Vb6+ CD25+ sorted from Thy-1.2+ Rag2+/) Mari-
lyn females), HY-specific and dnTGFbRII-expressing Treg
cells alone (CD4+ Vb6+ CD25+ sorted from Thy-
1.2+ dnTGFbRII+ Rag2+/) Marilyn females), or a mixture
of an equal number of conventional and each Treg-cell
population were adoptively transferred into five groups of
Rag2)/) B6 females which were given MB49 inoculation on
the same day. Analysis was conducted 12 days later.
In the absence of donor Treg cells, Marilyn CD4 T cells
underwent a robust expansion in response to MB49
tumours with a significant accumulation of donor cells
(Vb6+ CD4+ Thy-1.1+) in dLN (50%), spleen (10%) and
MB49 mass (16%, Fig. 6a–c). However, this HY-derived
systemic activation of donor Marilyn responders was
inhibited by co-transferred Marilyn Treg cells with a
range of 30–50% suppression in all three tissues tested
(Fig. 5d–f). Interestingly, dnTGFbRII-expressing Marilyn
Treg cells showed a partial suppression in dLN (20% sup-
pression, Fig. 5g), but they failed to inhibit the accumula-
tion of donor responders in spleen and MB49 tissue
(Fig. 6h–i). For the suppression of accumulation of donor
responder cells in dLN, both types of Marilyn Treg cells
were effective regarding the analysis of both frequency
(Fig. 6j) and absolute cell numbers (Fig. 6k), although
overall Treg cells without dnTGFbRII are more potent
inhibitors than their dnTGFbRII-expressing counterparts.
In the presence of donor responder cells, the frequency of
Marilyn Treg cells in dLN was significantly higher than
that of dnTGFbRII-positive Treg cells (Fig. 6l). Moreover,
in the absence of co-transferred donor responder cells,
MB49-induced expansion of Marilyn Treg cells (20%)
was significantly greater than that of dnTGFbRII-express-
ing Marilyn Treg cells (4%), Fig. 6m–o).
We also conducted a standard in vitro co-culture to deter-
mine whether dnTGFbRII-expressing Marilyn Treg cells
are functional. Although Marilyn dnTGFbRII+ CD4+ CD25+
cells were apparently anergic, they were also clearly less
suppressive, as even at a 10 : 1 ratio of Treg cells to
responder cells, only partial inhibition was achieved
(Fig. 6p). In contrast, Marilyn CD4+ CD25+ cells can
readily induce a complete suppression even at 1 : 1 ratio,
as shown previously.16,23
CD11c+ cells in dLN of MB49 tumours display major
histocompatibility complex–peptide complexes
Having established that MB49-induced expansion of Mar-
ilyn nTreg cells is antigen-dependent, we wish to deter-
mine which antigen-presenting cell subset in dLN is
involved in this process by identifying antigen-presenting
cells displaying major histocompatibility complex–HY
peptide complexes. Three groups of tumour-bearing mice
were prepared by s.c. inoculation of MB49 cells on day –
21 (G1), day – 14 (G2) and day -– 7 (G3). On day 0, the
average tumour sizes in these groups were 90 (G1), 70
(G2) and 30 mm2 (G3). A group of naive B6 mice (G4)
was used as tumour-free controls. On day 0, dendritic
cells (DC), macrophages and B cells isolated from dLN of
three groups of MB49-bearing B6 females (G1, G2 and
G3) or pLN of naive B6 females (G4), were compared for
their ability to prime resting Marilyn CD4 T cells (Fig. 7).
CD11c+ cells from G1, G2 and G3 induced proliferation
whereas those from G4 did not (top panel of Fig. 7),
demonstrating that MB49-derived HY antigens were
expressed by DC in dLN as early as 7 days after MB49
inoculation, reached the peak expression level at day 14,
and sustained this until at least day 21. Responses to
CD11b+ cells were lower, peaking at day 7 and declining
thereafter (middle of Fig. 7), whereas B cells did not stim-
ulate a response (bottom of Fig. 7). When Marilyn CD4
T cells were replaced by WT CD4 T cells in the above
assays, no proliferation was induced (not shown), indicat-
ing that the responses observed were HY-specific.
Discussion
Our study establishes an in vivo model by which the fate
of tumour-antigen-specific nTreg cells in response to a
growing tumour can be followed. There are several unique
features in this model. First, the surrogate tumour antigen,
HY, can be expressed either endogenously (MB49) or
exogenously (B16/HY). Importantly, gene transfer does
not necessarily result in an over-expression, indeed the
B16/HY line expresses a low level of HY, which is stable
both in vitro (Fig. 3a) and in vivo (Fig. 3b). Second, unlike
other studies in which the detection of transferred nTreg
cells in tumour-bearing mice relies on a viral vaccina-
tion,10,11 we were able to show the expansion of antigen-
specific nTreg cells by tumour without any boost. Third,
unlike other investigations in which the detection of nTreg
cells is limited to spleen,10,11 we were able to detect the
progeny of antigen-specific nTreg cells in both tumour tis-
sues and tumour-dLN. Finally, the application of this
10  2010 Blackwell Publishing Ltd, Immunology
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model can be extended, for example, MB49 and B16/HY
can be injected either s.c. or i.v.24 In addition, a compari-
son of nTreg behaviour in response to normal (male skin
grafts) and tumour tissues can be made.
The first observation of the current study is that the
ability of inducing non-specific nTreg-cell expansion is
dependent on the tumour cell lines used. This conclusion
was based on the results from two sets of adoptive trans-
fer experiments. When B16 and MB49 tumours were
compared for their capacities for inducing non-specific
nTreg expansion, we found that adoptively transferred
polyclonal nTreg cells underwent expansion in dLN of
B16-bearing mice (data not shown) but they failed to do
so in MB49-bearing mice (Fig. 2d–f), indicating that B16
but not MB49 tumours are able to expand nTreg cells
non-specifically. In the second adoptive experiment, we
found that the expansion of HY-specific nTreg cells could
be induced by both HY-negative B16 and HY-positive
B16 tumours in vivo (Fig. 4), indicating that B16 is capa-
ble of expanding nTreg cells non-specifically. Because
MB49 cells constitutively express HY and an HY-negative
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Figure 6. Comparison of Marilyn regulatory T (Treg) cells with or
without dnTGFbRII in vivo and in vitro. Five groups of Rag2)/) B6
females (four mice/group) were transferred with 2 · 104 Thy-1.1
Marilyn CD4 T cells alone (a–c), 2 · 104 Thy-1.2 Marilyn Treg cells
alone (m), 2 · 104 Thy-1.2 Marilyn Treg cells co-expressing dnTGF-
bRII alone (n), or Thy-1.1 Marilyn CD4 mixed with either Thy-1.2
Marilyn nTreg cells (d to f) or Thy-1.2 Marilyn Treg cells
co-expressing dnTGFbRII (g–i). The mice in all groups were also
inoculated subcutaneously with 1 · 105 MB49 cells on the same day.
Twelve days later, analysis was performed by staining dLN, spleen
and MB49 tissues with anti-Vb6FITC, anti-CD4PE, anti-Thy-1.1PerCP
and anti-Thy-1.2APC. The donor responder and donor Treg cells
were identified by co-expression of Thy-1.1 and Vb6 (R4, a–i) and
Thy-1.2 and CD4 (R6, m–n), respectively. The representation of
donor responder cells in dLN of three groups [responders alone (R
alone), responders plus Marilyn Treg cells (R+Treg), and responders
plus dnTGFbRII-expressing Marilyn Treg cells (R+Tregdn)] was dis-
played as frequency (j) or absolute cell numbers (k). (l) Frequency
of donor Treg cells in draining lymph nodes (dLN) of two co-trans-
fer groups [responders plus Marilyn Treg cells (Treg), and respond-
ers plus dnTGFbRII-expressing Marilyn Treg cells (Tregdn)]. The
representation of donor Treg cells in dLN of two groups [Marilyn
Treg cells alone (Treg), and dnTGFbRII-expressing Marilyn Treg
cells alone (Tregdn)] is shown in (m, n), (o) shows the comparison
of the frequency of donor Treg cells in dLN of these two groups.
One representative experiment of two is shown. A total of 0.5 mil-
lion events was acquired for each sample. (p) In vitro suppression
assay. Marilyn CD4+ CD25) T cells alone (1 · 104/well), Marilyn
CD4+ CD25+ dnTGFbRII+ cells alone (1 · 105/well), or both popu-
lations were incubated with 50 nm HY/Dby peptide in the presence
of antigen-presenting cells (5 · 104/well, T-cell-depleted B6 female
spleen cells) in round-bottomed 96-well plates for 3 days. Thymidine
was added to each well for the last 12 hr. One representative experi-
ment of two is shown.
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MB49 cell line is not available, MB49-induced antigen-
specific nTreg-cell expansion in the presence or absence
of HY cannot be assessed. Although we have not used
HY-knockout MB49 cells, it is highly unlikely that MB49
is able to induce non-specific nTreg-cell expansion, as
MB49 cannot expand polyclonal nTreg cells in vivo
(Fig. 2d–f). The conclusion that B16 but not MB49 can
expand Treg cells non-specifically helps to explain why
B16-bearing mice display a significant increase of percent-
age of nTreg cells in dLN9 whereas MB49-beraing mice
do not (data not shown). However, the weaker expansion
of Treg cells in WT female B6 recipients does not repre-
sent the most sensitive model system to examine antigen
non-specific Treg-cell expansion by tumours. To make a
conclusive demonstration, tumour-bearing Rag2)/) recipi-
ents of Treg cells should be used in future studies.
Whether the capacity of inducing antigen-non-specific
nTreg-cell expansion is restricted to spontaneous tumour
cell lines remains to be determined. In addition, B16 cells
are less immunogenic than MB49 cells. Whether there is
a correlation between immunogenicity and capacity of
inducing non-specific nTreg-cell expansion also needs to
be explored further.
Interestingly, there was a significant reduction of Foxp3
expression by a fraction of donor Treg cells in response
to HY antigens from MB49 (Fig. 2b) and B16/HY
tumours (Fig. 4i–n). Loss of Foxp3 was more marked in
tumour-infiltrating donor Treg cells than in dLN. In
addition, we show that development of Foxp3-negative
donor cells (called ex-Treg cells) represents differentiation
from green Treg cells and is not the result of the expan-
sion of contaminating conventional CD4 T cells. More-
over, Treg cells are converted to Th1-like responder cells
after losing Foxp3 (manuscript under preparation,
C. Addey and J.-G. Chai).
The second observation is that although both antigen-
specific and non-specific expansion contribute to the
overall pool of adoptively transferred nTreg cells with
defined antigen specificity, nTreg cells expanded through
these two pathways display distinct tissue distribution.
Although several pairs of antigen-negative and antigen-
positive tumour cell lines are available, direct comparison
of the contributions from antigen-specific and non-spe-
cific expansion has not been examined. Consequently,
there is very limited information regarding the behaviour
of nTreg cells expanded by these two pathways. Our cur-
rent investigation provides a detailed comparison showing
that the expansion of nTreg cells with defined antigen
specificity in the presence of antigen is more potent than
that in the absence of antigen. It is not surprising, as the
expansion of Marilyn nTreg cells by B16/HY results from
a combination of two pathways. Importantly, we have
shown for the first time that nTreg cells undergoing anti-
gen-specific expansion can migrate to tumours where
nTreg cells undergoing non-specific expansion cannot
(Fig. 4). Hence, unlike expansion, migration of nTreg
cells into tumours is strictly dependent on the presence of
antigen.
The third observation is that TGF-b produced by
MB49 cells (Fig. 5a) is a key factor promoting expansion
of Marilyn nTreg cells (Fig. 5c–e). This conclusion is
based on the results showing that the presence of intact
TGF-b signalling on Marilyn Treg cells appears to be
essential for their expansion in response to MB49
tumours (Fig. 6). A similar strategy has been used by
Zitvogel and colleagues to dissect the role of TGF-b in
the induction of expansion of polyclonal nTreg cells by
B16 tumours in vivo,9 but their study was restricted to
endogenous polyclonal nTreg cells. In this respect, our
study offers an example showing that TGF-b is required
for the expansion of tumour-antigen-specific, monoclonal
nTreg cells (Fig. 6). A caveat to this conclusion is the
potential for a developmental defect of nTreg cells
expressing the dnTGFbRII which may prevent appropriate
activation in response to antigen. To address this concern,
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Figure 7. CD11c+ cells in draining lymph nodes (dLN) of MB49
tumour display HY antigens. Three groups of B6 females (two mice/
group) were inoculated with MB49 cells at day – 21 (G1), day – 14
(G2) or day – 7 (G3) whereas mice in G4 were not. At day 0, pooled
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round-bottomed plates for 3 days.
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we compared dnTGFbRII-negative and dnTGFbRII-posi-
tive Marilyn Treg cells both in vivo and in vitro. In vitro,
dnTGFbRII-expressing Marilyn Treg cells are clearly aner-
gic and have weak suppressive activity (Fig. 6p). More-
over, in vivo, dnTGFbRII-positive Marilyn Treg cells can
inhibit anti-HY T-cell responses (Fig. 6g–i), although they
are less potent compared with Marilyn Treg cells
(Fig. 6d–f). Finally, dnTGFbRII-positive Treg cells expand
less efficiently than dnTGFbRII-negative Treg cells in
response to HY antigens from MB49 tumours regardless
of the presence or absence of co-transferred conventional
Marilyn CD4 T cells (Fig. 6l–o).
Additional in vivo TGF-b neutralization experiments
are needed to confirm the requirement for TGF-b signal-
ling for in vivo expansion of nTreg cells. Although the
MB49 cell line can make TGF-b (Fig. 5a), we have not
examined whether growing MB49 tumours would pro-
duce TGF-b. In this regard, it has been reported that B16
tumours induce a subset of DC in dLN to produce active
TGF-b, which then expands polyclonal nTreg cells.9 In
addition, tumour-specific Treg cells are also able to
induce tumour resident immature DC to produce TGF-
b.27 Apart from TGF-b, indoleamine 2,3-dioxygenase is
another molecule that can directly contribute to Treg-cell
expansion.25,26
The final observation is that CD11c+ cells in dLN dis-
play major histocompatibility complex/HY peptide com-
plexes (Fig. 7) and therefore are likely to be the major
APC subset involving in antigen-derived expansion of
Marilyn nTreg cells. Although tumour antigens persist in
the dLN of tumour-bearing mice,12 it has not been inves-
tigated which population of APC are involved in antigen
presentation. In this aspect, our study provides the first
direct evidence for the role of CD11c+ cells. Although the
MB49 cell line does not express H2Ab in vitro, it has been
suggested that freshly isolated MB49 tumour cells do.20
This raises the possibility of direct antigen presentation
by tumour cells to CD4 T cells. We have not investigated
whether freshly isolated MB49 tumour cells would be able
to stimulate Marilyn CD4 T cells in the presence of inter-
leukin-2 in vitro.
In summary, using this HY system, which is composed
of HY-expressing tumour cell lines and HY-specific nTreg
cells, we have revealed novel aspects of the dynamic
behaviour of tumour-antigen-specific nTreg cells for the
first time. We demonstrate that the induction of non-spe-
cific nTreg-cell expansion does not represent a common
rule for all tumour lines. By making a side-by-side com-
parison between antigen-specific and non-specific nTreg-
cell expansion, we provide an example where the relative
contribution by two pathways can be evaluated. More-
over, for the first time, we uncover distinct nTreg-cell
migration patterns depending on whether expansion is
antigen dependent or independent. These findings explore
mechanisms responsible for nTreg-cell expansion by
tumours and have implications for understanding and
manipulating tumour immune evasion.
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